QUERI

Comparative Effectiveness of Home-based Kidney Dialysis versus In-center or Other Outpatient Kidney Dialysis Locations – A Systematic Review

April 2015

Prepared for:
Department of Veterans Affairs
Veterans Health Administration
Quality Enhancement Research Initiative
Health Services Research & Development Service
Washington, DC 20420

Prepared by:
Evidence-based Synthesis Program (ESP) Center
Minneapolis VA Medical Center
Minneapolis, MN
Timothy J. Wilt, MD, MPH, Director

Investigators:
Principal Investigator:
Areef Ishani, MD, MS
Yelena Slinin, MD

Co-Investigators:
Nancy Greer, PhD
Timothy J. Wilt, MD, MPH

Research Associates:
Roderick MacDonald, MS
Joseph Messana, MD
Indulis Rutks, BS

VA HEALTH CARE Defining EXCELLENCE in the 21st Century

PREFACE

Quality Enhancement Research Initiative's (QUERI) Evidence-based Synthesis Program (ESP) was established to provide timely and accurate syntheses of targeted healthcare topics of particular importance to Veterans Affairs (VA) clinicians, managers and policymakers as they work to improve the health and healthcare of Veterans. The ESP disseminates these reports throughout the VA, and some evidence syntheses inform the clinical guidelines of large professional organizations.

QUERI provides funding for four ESP Centers and each Center has an active university affiliation. The ESP Centers generate evidence syntheses on important clinical practice topics, and these reports help:

- develop clinical policies informed by evidence;
- guide the implementation of effective services to improve patient outcomes and to support VA clinical practice guidelines and performance measures; and
- set the direction for future research to address gaps in clinical knowledge.

In 2009, the ESP Coordinating Center was created to expand the capacity of HSR&D Central Office and the four ESP sites by developing and maintaining program processes. In addition, the Center established a Steering Committee comprised of QUERI field-based investigators, VA Patient Care Services, Office of Quality and Performance, and Veterans Integrated Service Networks (VISN) Clinical Management Officers. The Steering Committee provides program oversight, guides strategic planning, coordinates dissemination activities, and develops collaborations with VA leadership to identify new ESP topics of importance to Veterans and the VA healthcare system.

Comments on this evidence report are welcome and can be sent to Nicole Floyd, ESP Coordinating Center Program Manager, at Nicole.Floyd@va.gov.

Recommended citation: Ishani A, Slinin Y, Greer N, MacDonald R, Messana J, Rutks I, Wilt TJ. Comparative Effectiveness of Home-based Kidney Dialysis versus In-center or Other Outpatient Kidney Dialysis Locations - A Systematic Review. VA ESP Project #09-009; 2015.

This report is based on research conducted by the Evidence-based Synthesis Program (ESP) Center located at the Minneapolis VA Medical Center, Minneapolis, MN, funded by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Quality Enhancement Research Initiative. The findings and conclusions in this document are those of the author(s) who are responsible for its contents; the findings and conclusions do not necessarily represent the views of the Department of Veterans Affairs or the United States government. Therefore, no statement in this article should be construed as an official position of the Department of Veterans Affairs. No investigators have any affiliations or financial involvement (*eg*, employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties) that conflict with material presented in the report.

TABLE OF CONTENTS

EXECUTIVE SUMMARY

INTRODUCTION

Home-based dialysis (defined for this review as in-home hemodialysis [HHD] or peritoneal dialysis [PD] outside of a dialysis facility) may offer advantages over in-center hemodialysis (HD), including patient convenience, expanded capacity for VA to deliver fully integrated care to Veterans with end-stage renal disease (ESRD), a reduction in fee-basis costs associated with dialysis, and potentially improved patient quality of life and blood pressure control with greater survival and fewer hospitalizations. As the number of patients requiring renal replacement therapy (RRT) increases, there is need for a current review of the benefits and harms of home-based dialysis (HHD or PD) versus in-center HD, the benefits and harms of different home-based dialysis modalities, and the predictors of successful home-based dialysis to allow VA to better serve patient needs. We reviewed the evidence from studies of adults with chronic kidney disease requiring dialysis and comparing home-based and in-center HD. Due to between-country differences in health care systems, we focused our review on studies most relevant to the VA, *ie*, those from North America, Europe, or Australia/New Zealand.

We addressed the following key questions:

Key Question 1. What are the benefits and harms (*ie*, all-cause mortality, cardiovascular events, hospitalizations, depression, cognitive impairment, quality of life, conversion to a different type of dialysis, complications related to vascular access, complications of dialysis) of *in-home compared to in-center hemodialysis*?

1a. What are the benefits and harms (*ie*, all-cause mortality, cardiovascular events, hospitalizations, depression, cognitive impairment, quality of life, conversion to a different type of dialysis, complications related to vascular access, complications of dialysis) of the various modalities of in-home hemodialysis (*ie*, short daily, nocturnal) compared to conventional hemodialysis?

Key Question 2. What are the benefits and harms (*ie*, all-cause mortality, cardiovascular events, hospitalizations, depression, cognitive impairment, quality of life, conversion to a different type of dialysis, complications related to vascular access, complications of dialysis) of *peritoneal dialysis compared to in-home hemodialysis or in-center hemodialysis*?

2a. Do results differ depending on whether peritoneal dialysis was the initial therapy or the therapy used following failed in-center dialysis?

Key Question 3. What are the a) health care system, b) provider, and c) patient factors associated with selection of and technique survival for home-based dialysis (including peritoneal dialysis)?

Key Question 4. In the published literature, what are the costs of home hemodialysis or peritoneal dialysis compared to in-center hemodialysis?

METHODS

Data Sources and Searches

MEDLINE and the Cochrane Library were searched from 1995 to December 2014 for randomized controlled trials (RCTs), controlled clinical trials (CCTs), and observational studies. The search strategy included MeSH terms and keywords for hemodialysis and peritoneal dialysis.

We included studies of adults with chronic kidney disease receiving dialysis (in-center, in-home, or peritoneal) as outpatients. We excluded studies that did not report our outcomes of interest: all-cause mortality (primary outcome); health system, provider, or patient factors associated with selection of and technique survival for home-based dialysis; costs; cardiovascular events; hospitalizations; clinically diagnosed depression or cognitive impairment; clinically meaningful difference in quality of life scale scores; conversion to a different type of dialysis; quality of life scale scores; depressive symptoms; cognitive function; total and mental- and physical-health subscale scores; or harms.

Study Selection

We included all RCTs or CCTs that met eligibility criteria. For Key Questions 1, 2, and 4, eligible studies provided comparison data for 2 or more dialysis modalities. For Key Questions 1 and 2, we required registry studies to enroll at least 1,000 patients and have a mean or median follow-up of at least one year if they reported outcomes of mortality, cardiovascular events, technique failure, or transplantation. For all other outcomes and for Key Question 3, a minimum enrollment of 100 and a mean or median follow-up of at least one year was required. Additionally, for Key Question 3, we included studies of dialysis modality selection only if they followed patients to determine the dialysis modality the patient received.

Data Abstraction, Quality Assessment, and Strength of Evidence

From registry studies we extracted study characteristics, patient characteristics, data analysis technique, length of follow-up, and outcomes. If reported, we also extracted data on interactions between mortality and age, gender, race, body mass index (BMI), diabetes, cardiovascular disease, and duration of ESRD therapy.

For mortality outcomes, most of the registry studies presented more than one analysis approach (different statistical model, different adjustment factors, *etc*). We extracted the most-adjusted model. Many studies reported outcomes at multiple time points during the follow-up period. We focused on data at one year, 2 years, and at maximum follow-up time, if provided.

For included RCTs and CCTs, trained research methodologists rated the risk of bias of individual studies as low, moderate, or high risk. Risk of bias ratings were based the following criteria: allocation sequence generation, allocation concealment, blinding, incomplete outcome data, and selective outcome reporting – a modification of the Cochrane approach to determining risk of bias.

For observational studies, we assessed risk of bias based on selection bias, masking of the outcome assessment, use of intention-to-treat principles, attrition bias, and selective reporting of

prespecified outcomes. Studies were considered high risk of bias unless all 5 criteria were addressed. Studies addressing all 5 criteria were considered moderate or low risk of bias depending on the completeness of addressing the criteria.

We assessed strength of evidence based on study risk of bias as well as the consistency, directness, and precision of our main outcome (mortality) as reported in the registry studies for the comparisons of HHD to HD and PD to HD.

Data Synthesis and Analysis

Due to differences in study methodology, data could not be pooled. For Key Questions 1 and 2, we summarized the results by outcome. For Key Question 3, we summarized findings for health care system, provider, and patient factors. For Key Question 4, we summarized costs of HHD versus in-center HD and PD versus in-center HD.

RESULTS

Results of Literature Search

We identified 130 articles (3 of which were systematic reviews) meeting inclusion criteria. For Key Questions 1 and 2, we included data from 32 registry studies, 3 RCTS, 3 CCTs, and 4 reports from 2 clinical cohort studies. Sixteen of the registry studies, 1 of the CCTs, and 1 of the clinical cohort studies were completed in the US. To further address hospitalization, quality of life, and cognitive, depression, and adverse event outcomes, we included 3 systematic reviews, 1 CCT, and 17 other articles reporting on observational studies (4 from the US). For Key Question 3, we included 29 articles reporting on 28 studies (8 from the US, 1 from the US and Canada, and 1 multinational, including North America) addressing factors associated with selection of a dialysis modality, 5 articles (none from the US) reporting factors associated with HHD technique survival, and 15 articles (8 from the US) reporting factors associated with PD technique survival. We identified 15 articles (2 from the US) that reported cost outcomes (Key Question 4) comparing either PD to HD or HHD to HD.

Summary of Results for Key Questions

Key Question 1. What are the benefits and harms (ie, all-cause mortality, cardiovascular events, hospitalizations, depression, cognitive impairment, quality of life, conversion to a different type of dialysis, complications related to vascular access, complications of dialysis) of in-home compared to in-center hemodialysis?

Evidence regarding the comparative effectiveness of HHD versus in-center HD should be interpreted with caution because it is generally of high risk of bias and limited clinical applicability. Specifically, we found few randomized or controlled clinical trials, or prospective clinical cohort studies, comparing in HHD and in-center HD. Available clinical trials were small in size and had short follow-up durations. Most of the data on mortality is from registry studies. Results from these studies should be viewed cautiously due to likely residual confounding and selection bias. Of 7 registry studies reporting mortality, 5 suggest that HHD is associated with improved overall survival compared to in-center HD. One registry study found a benefit for individuals receiving in-center HD over HHD while another found no difference. Two small RCTs of short follow-up duration reported no difference in mortality between in-center versus in-home modalities. A multinational CCT with 415 patients and 1006 patient-years of follow-up

reported a mortality benefit for HHD compared to in-center HD while 2 smaller, shorter duration CCTs found no difference. Two registry studies reported no difference in cardiovascular mortality.

Strength of evidence for mortality was low, based on high risk of bias associated with the registry studies (Executive Summary Table).

Limited data are available for secondary outcomes. One registry study reported no difference in all-cause hospitalization but reduced hospitalization for cardiovascular causes in the HHD group. Results from 2 registry studies suggest that HHD patients may be more likely than in-center HD patients to switch dialysis modalities at some point during their treatment but no differences in rate of transplant or all-cause hospitalizations were observed. Results for quality of life and adverse events were mixed with some studies showing benefits of HHD and others showing no difference. No studies suggested HHD was associated with harms.

Executive Summary Table. Strength of Evidence for Mortality Outcome Based on Registry Studies

Outcome (studies reporting)	Results	Risk of Bias	Consistency	Directness	Precision	Strength of Evidence
Overall Mortality HHD vs HD (7 registry studies)	5 of 7 studies reported decreased overall mortality with HHD	high	consistent	direct	precise	low
Overall Mortality PD vs HD (22 registry studies)	4 studies reported decreased mortality with PD; 6 studies reported increased mortality with PD; 12 studies reported no difference in mortality	high	inconsistent	direct	imprecise	low

HHD = home hemodialysis; HD = in-center hemodialysis; PD = peritoneal dialysis

Key Question 1a. What are the benefits and harms (ie, all-cause mortality, cardiovascular events, hospitalizations, depression, cognitive impairment, quality of life, conversion to a different type of dialysis, complications related to vascular access, complications of dialysis) of the various modalities of in-home hemodialysis (ie, short daily, nocturnal) compared to conventional hemodialysis?

Based on evidence from generally low-quality studies we were unable to detect differences between various modalities of HHD compared to conventional HD. Of 6 studies reporting, 3 registry studies found reduced mortality with more frequent and longer HHD compared to conventional HD while 3 trials (2 RCTs and one CCT) found no difference in mortality between more frequent and/or extended HHD and conventional HD. Cardiovascular mortality, all-cause hospitalization, and catheter-related sepsis or catheter life (each reported in one or 2 studies) did not differ between the modalities.

Key Question 2. What are the benefits and harms (ie, all-cause mortality, cardiovascular events, hospitalizations, depression, cognitive impairment, quality of life, conversion to a different type of dialysis, complications related to vascular access, complications of dialysis) of peritoneal dialysis compared to in-home hemodialysis or in-center hemodialysis?

Peritoneal versus In-center HD

Evidence is inconsistent whether mortality differs between patients treated with PD compared to in-center HD. Twenty-seven registry studies, one RCT, and 2 clinical cohort studies provided evidence for the comparison of PD to in-center HD. Of 22 registry studies reporting mortality for the total sample, 12 (2 from the US, 3 from Canada, 1 from Australia/New Zealand, and 6 from Europe/UK) found no difference in mortality between PD and in-center HD. Four studies (2 from the US, one from Canada, and one from Europe/UK) found a mortality benefit for PD while 6 studies (3 from the US, 2 from Australia/New Zealand, and one from Europe/UK) found a mortality benefit for in-center HD. It is difficult to assess if results vary by time of publication due to differences in study populations, length of follow-up reported, and methods of data analysis, but publication dates suggest that a trend may exist. Studies showing increased mortality with PD compared to in-center HD were generally published before 2003 while studies showing no difference or reduced mortality with PD were generally published after 2003.

A small RCT from the Netherlands found no difference in mortality between PD and in-center HD. This study was terminated due to low enrollment. A prospective, clinical cohort study from the United States with 1,041 patients and a follow-up of up to 7 years found no difference in mortality. Data from a prospective cohort study from the Netherlands showed no difference in 2-year mortality.

Analyses of interactions between dialysis modality and age (10 studies), gender (4 studies), race (5 studies), BMI (5 studies), diabetes (12 studies), cardiovascular disease (6 studies), and duration of ESRD (3 studies) yielded mixed results.

Of 5 registry studies reporting cardiovascular disease risk, only one reported a significantly higher percentage of deaths due to cardiovascular disease in the PD group; the 4 others suggested no difference. Hospitalizations were significantly higher in the HD groups in 3 of 5 studies reporting hospitalizations. Mixed results were reported for quality of life outcomes including mental and physical health components, quality of life utilities, and life participation activities. Changes in treatment modality were generally more likely for patients receiving PD while rates kidney transplantation results were mixed. Few studies reported adverse events. Findings were based on evidence from studies of generally low quality.

Peritoneal versus In-home HD

There is limited evidence for the comparison of PD and HHD. In 2 registry studies, results were mixed with a study from the United States finding no difference in mortality and a study from the United Kingdom finding a mortality benefit for HHD. Other outcomes were not reported.

Key Question 2a. Do results differ depending on whether peritoneal dialysis was the initial therapy or the therapy used following failed in-center dialysis?

Two studies reported higher mortality among patients who initiated ESRD treatment with HD and then switched to PD compared to patients who initiated PD as their first modality. A third study reported no difference in mortality. Overall duration of ESRD was likely longer in the patients who initiated with HD.

Key Question 3. What are the a) health care system, b) provider, and c) patient factors associated with selection of and technique survival for home-based dialysis (including peritoneal dialysis)?

Peritoneal Dialysis – Selection

Twenty-two papers reporting data from 21 studies, including 8 from the US, provided information on factors associated with selection of PD.

- *Health Care System Factors:* One US cross-sectional study reported that provision of home-based dialysis (including PD) was more likely in larger dialysis facilities (defined as 62 patients or more) with more years of facility Medicare certification and facilities with a higher population of employed 18- to 54-year-old patients. Home-based dialysis was less likely at facilities in more rural areas, facilities offering evening care, and facilities with higher treatment capacity (based on number of patients, number of HD stations, and availability of a late shift).

- *Provider Factors:* Several studies found that provision of patient education about dialysis modalities and a determination of medical (including comorbid conditions and decreased strength, manual dexterity, vision, or hearing) and psychosocial suitability (including fear of self-cannulation, anxiety, decreased cognition, psychiatric conditions, or history of non-compliance) for PD were associated with greater selection of PD. No studies reported on provider factors such as provider age, training, knowledge about PD, etcetera.

- *Patient Factors:* Autonomy, ability to travel, and compatibility with employment were identified as positive features of PD. Conversely, lack of understanding, living alone, lack of space in the home, inability to perform PD in the place of residence, fear of social isolation, fear of inability to perform PD, and preference for medical supervision were patient barriers to selection of PD.

In-Home Hemodialysis – Selection

We identified 5 reports (2 from the US or US and Canada) of factors associated with selection of HHD.

- *Health Care System Factors:* As noted above, dialysis facility size, geographic location, and years of certification were all factors in provision of any home-based dialysis.

- *Provider Factors:* From a provider perspective, patients with medical contraindications, psychosocial contraindications, unsuitable living conditions (including HHD not permitted, overcrowding, dampness/mold growth), lack of support in the home, and

unplanned start or shorter pre-dialysis care by a nephrologist were less likely to be suitable for HHD. Providers with greater numbers of HHD patients reported having a dedicated education team.

- *Patient Factors:* Patient-reported barriers to and advantages of HHD were similar to those noted above for PD.

Peritoneal Dialysis – Technique Survival

Fifteen studies (8 from the US), with sample sizes ranging from 118 to 41,197, evaluated factors associated with technique failure (the inverse of technique survival – a switch from PD to in-center HD). Data were mostly obtained from large registry studies.

- *Health Care System Factors:* Patients from larger clinics had lower technique failure.

- *Provider Factors:* No studies reported on provider factors associated with PD technique survival.

- *Patient Factors:* African-American or indigenous race, increased BMI or obesity, elevated systolic blood pressure, use of HD before switching to PD, and peritoneal dialysis catheter problems were associated with higher rates of technique failure but each factor was reported in 4 or fewer of the 14 included studies. Mixed results were found for presence of diabetes, age, gender, distance from clinic/nephrologist, and need for assisted PD.

In-Home HD – Technique Survival

Five studies (4 from Canada and one from the UK) reported factors associated with HHD technique failure.

- *Health Care System Factors:* No studies reported on health care system factors associated with HHD technique survival.

- *Provider Factors:* No studies reported on provider factors associated with HHD technique survival.

- *Patient Factors:* Interference with home life, lack of carer support, caregiver anxiety, inability to perform cannulation, medical issues (including diabetes and access problems), and increased age were associated with increased technique failure in 4 studies; one identified no significant predictors of technique failure. Another study reported no difference in a composite outcome of time to all-cause hospitalization, technique failure, or death in patients categorized as dependent on or independent of assistance with nocturnal HHD.

Key Question 4. In the published literature, what are the costs of home hemodialysis or peritoneal dialysis compared to in-center hemodialysis?

We identified 15 studies (2 from the US) reporting cost outcomes. Cost analyses have typically reported lower costs for HHD and PD compared to in-center HD. However, the cost categories (*eg*, direct costs, indirect costs) considered in the analyses and factors that can influence costs (*eg*, failure rates, patient age, and comorbidity) vary across studies. Both US studies reported lower expenditures for PD compared to HD as an initial dialysis modality. In one study, with 50 matched pairs, the difference in costs was largely related to increased hospitalizations and emergency department visits among the HD patients. The other study found that switching from PD to HD within one year of starting PD resulted in no economic benefit of the initial start on PD while switching after more than one year on PD maintained the economic benefit of the initial start on PD.

DISCUSSION

Key Findings and Strength of Evidence

- We found few randomized or controlled clinical trials, or prospective clinical cohort studies, comparing home-based and in-center kidney dialysis. Available clinical trials were small in size and had short follow-up durations.

- Most of the data on mortality is from registry studies. Results from these studies should be interpreted with caution due to likely residual confounding and selection bias.

- Home hemodialysis (HHD) versus in-center HD:

    - We found low strength of evidence (findings from registry studies) that HHD is associated with improved overall survival compared to in-center HD. There were few studies of variations of HHD (including longer duration or more frequent sessions).

    - There is evidence from generally low-quality studies to suggest no difference in cardiovascular mortality, no difference or improved quality of life with HHD, no difference in access survival, no difference in transplantation rate, and no difference in all-cause hospitalization rate. In 2 studies reporting, a higher percentage of HHD patients switched dialysis modalities over follow-up periods of up to 4 years.

- Peritoneal dialysis (PD) versus in-center HD:

    - We found low strength of evidence (findings from registry studies) that there is no difference in overall mortality between PD to in-center HD. However, most studies reporting outcomes over time noted an early survival advantage for PD patients with no difference after 2 to 3 years of treatment.

    - There were inconsistent findings for quality of life outcomes with studies reporting no differences or higher scores on some elements of quality of life in PD or in-center HD patients. With limited reporting, results were mixed for cardiovascular outcomes, adverse events, transplantation, and hospitalization. Over follow-up periods of 2 to 7 years, higher percentages of PD patients switched dialysis modalities.

- Only 2 studies compared HHD and PD with mixed results for mortality. Other outcomes were not reported.

- Factors associated with increased selection of home-based dialysis:

    - Facility factors: larger facility, more years of Medicare certification, providing care for more employed patients or patients in the 18 to 54 year age range, earlier initiation of pre-dialysis care, increased patient/family education ;

    - Patient factors: well-informed about choices, patient preference (more autonomy, more flexible schedule, and less travel to dialysis), family/caregiver support;

    - Provider factors: team approach (physician, nurse, social worker) to determining patient eligibility (medical and psychosocial).

- Factors associated with decreased selection of home-based dialysis:

    - Facility factors: location in more rural area, location in high-density zip code area, availability of an evening shift, higher percentage of black patients;

    - Patient factors: lack of knowledge, living alone, lack of space in the home, inability to perform PD in the place of residence, fear of social isolation, fear of inability to perform PD, and preference for medical supervision.

- Factors associated with technique failure:

    - Facility factors: lower technique failure if receiving care from larger dialysis facilities;

    - Patient factors: higher technique failure if lack of caregiver support, caregiver anxiety, medical issues (including diabetes or psychosocial problems), treatment interferes with home life, African-American race (vs white), HD before PD;

    - Provider factors: none identified.

- Costs are lower with HHD and PD compared to in-center HD but costs considered in the analyses and factors that can influence costs (failure rates, patient comorbidity) varied across studies.

This evidence report summarizes literature on the comparative effectiveness and harms of home-based versus in-center dialysis. Home-based dialysis is a potentially effective option of considerable interest to Veterans and could permit VA to expand internal dialysis capacity. However, it is not well known if this is feasible within the Veteran population, due to in part to a greater prevalence of patients of older age and a greater number of comorbidities in the VA system. None of the included studies were conducted at VA medical centers.

Data on clinical outcomes come predominately from large registry studies, not randomized controlled trials. While authors attempted to control for confounding, significant residual confounding from both measured and unmeasured variables likely exists. Patients who undergo

home dialysis are generally different than those who undergo in-center dialysis. In the United States patients undergoing home dialysis are generally younger and healthier than those treated with in-center hemodialysis. Also, patients without insurance and those without pre-dialysis care who present emergently requiring dialysis are much more likely to be initiated on in-center hemodialysis. These differences in patient characteristics can be inferred by the greater rate of transplantation among patients undergoing peritoneal dialysis compared to those undergoing in-center hemodialysis which may then result in artificially increased death rates in PD groups in later periods of follow-up. Given these stark differences between patient populations it is difficult to compare outcomes across these populations, irrespective of the type of statistical technique employed. Our findings are in agreement with earlier reviews and guidelines. A 2009 guideline from Caring for Australians with Renal Impairment (CARI) offered clinical care suggestions based on Level III or Level IV evidence (low or very low quality) including that PD may provide equivalent or better survival in the first few years, that HD may offer better long-term survival, and that timely transfer from PD to HD may improve survival. Based on opinion, it was suggested that survival be considered in the context of life quality as perceived by the patient when selecting a dialysis modality.

Other reviews have identified health care system, provider, and patient factors that are important in selecting a dialysis modality. Patient education, physician training, nurse training, and staff support for patients and caregivers are essential. In addition to prolonging life with kidney dialysis, patients want to maintain a good quality of life, autonomy, and sense of self. For facilities, the creation of centralized training program and the use of continuous quality improvement cycles to monitor and modify treatment protocols have been suggested. One reviewer urged recognition that treatment modalities may be complementary rather than competing in providing optimal outcomes.

There are limited data on caregiver burden associated with dialysis and whether HHD is more stressful for caregivers. One study from Italy reported that both patients and caregivers thought HHD would be an “overwhelming responsibility” for a caregiver. Caregiving would require “significant personal sacrifices” that would impact work and social lives. Caregivers were concerned about seeing the patient “suffer” while undergoing dialysis, about their ability to assist the patient with treatment and technical problems or complications that might arise, and about their ability to manage “medical responsibilities.” Caregivers also reported that they perceived patients were content with their in-center care and that they benefited from peer support.

Applicability

Twenty of the 32 registry studies were completed in the United States or Canada. Across all registry studies, mean ages ranged from 47 to 75 years and between 50% and 67% of included patients were male. There were few exclusion criteria, suggesting that the patients were representative of the ESRD population. However, the cohort years for all but 7 of the registry studies were prior to 2008.

We found no compelling evidence that HHD and PD differ from in-center HD in survival, quality of life, hospitalizations, or costs. Differences, where they exist, could be due to unmeasured differences in patient populations and strong selection biases (by patients, caregivers, or providers). However, HHD and PD are commonly used as the dialysis method of

choice in other countries. We also found some evidence that caregiver support was an important factor in identifying candidates likely suitable for HHD or PD.

Research Gaps/Future Research

Despite the large number of studies included in this report considerable gaps exist. The comparative effectiveness of HHD or PD to in-center HD (including outcomes of mortality, hospitalizations, quality of life, patient satisfaction, and adverse events) and whether treatment choice and technique success vary by modality, patient, provider, or facility factors remains relatively unknown. This is predominately because considerable differences likely exist among individuals selected for (or selecting) different treatment modalities. While difficult to undertake, a large randomized trial comparing different modalities would be useful. Other research needs would be to evaluate methods to understand barriers to and improve implementation of HHD or PD and provide individuals with sufficient skill building and caregiver support in attempts to maximize benefits. Of note, HHD and PD are widely used as treatment options of choice in other developed countries.

Conclusions

Low-strength evidence suggests that home-based dialysis may provide similar health outcomes and at similar or lower costs for many patients compared to in-center hemodialysis. Therefore, home-based dialysis may be an acceptable and sometimes preferred alternative to in-center hemodialysis. Information is limited on factors important in addressing selection of and barriers to home-based dialysis and remains an area of important research and health policy.

ABBREVIATIONS TABLE

APD	Automated peritoneal dialysis
CAPD	Continuous ambulatory peritoneal dialysis
CCPD	Continuous cycling peritoneal dialysis
CCT	Controlled, clinical trial
CKD	Chronic kidney disease
eGFR	Estimated glomerular filtration rate
ESRD	End-stage renal disease
HD	Hemodialysis (in-center)
HHD	In-home hemodialysis
PD	Peritoneal dialysis
RCT	Randomized, controlled trial
RRT	Renal replacement therapy
VA	Veterans Affairs

EVIDENCE REPORT

INTRODUCTION

Home-based dialysis (defined for this review as in-home hemodialysis [HHD] or peritoneal dialysis [PD]) may offer advantages over in-center hemodialysis (HD) including patient convenience, expanded capacity for VA to deliver fully integrated care to Veterans with end-stage renal disease (ESRD), a reduction in fee-basis costs associated with dialysis, and potentially improved patient quality of life and blood pressure control with greater survival and fewer hospitalizations. Home-based dialysis may also increase ability to care for patients living distant from existing medical centers.[1] Home-based dialysis may also allow for more frequent or longer dialysis sessions than conventional (3 times per week for 3 to 4 hours) hemodialysis.[2] Disadvantages include the need for a relative or friend to assist (especially with HHD) and the strain that may put on relationships.[2]

In the United States Renal Data System (USRDS) 2014 Annual Report, it was reported that on December 31, 2012, 402,514 patients (65%) with ESRD were receiving HD, 40,605 (7%) were being treated with PD, and 175,978 (28%) had a functioning graft.[3] Renal replacement therapy was received at home by 49,000 patients with 16% receiving HHD and 84% receiving PD. It was noted that 5 times more patients were using HHD in 2012 (N=7,923) than in 2002 (N=1,563).

A 2003 systematic review included RCTs (k=1; reporting only on blood pressure control), comparative observational studies (k=22), or systematic reviews (k=4) of HHD versus in-center HD (hospital-based or satellite unit) published through 2001.[2] Fourteen studies were conducted in the US. HHD was limited to home hemodialysis using similar equipment and consumables as in-center HD. Sixteen studies (3 systematic reviews and 13 comparative observational studies) reported on quality of life. Although different measures of quality of life were reported, the overall finding was higher quality of life in HHD patients. Of 4 studies that assessed social aspects related to quality of life, 3 found HHD more disruptive for families or that the spouse was less satisfied with the location of the HD compared to in-center HD. The 2003 review also included mortality data from 9 studies – a systematic review published in 1995 and 8 comparative observational studies published from 1978 to 1999. In the 7 studies comparing HHD with in-center HD, survival was generally greater in the HHD groups although some differences were noted depending on the length of follow-up or age at start of RRT. Results were mixed for the 2 studies comparing HHD to HD in free-standing dialysis units; one study reported no difference in survival and the other reported greater survival in the HHD group. The authors noted that HHD patients typically had fewer comorbidities than in-center HD patients. Only one study reported technique survival (the time a person remains on a particular form of RRT) with longer median technique survival in-center HD patients compared to HHD patients.

As the number of Veterans requiring RRT increases, there is a need to expand the Veteran Administration's ability to provide these services by either outsourcing them to the community, expanding in-center dialysis program, or increasing home dialysis (PD or HHD) modalities use among Veterans with ESRD. In order to inform the ESRD program development, the VA commissioned an up-to-date review of the benefits and harms of home-based HD (HHD and PD) versus in-center HD, the benefits and harms of different home-based dialysis modalities, and the predictors of successful home-based dialysis. We focused our review on studies of adults with

chronic kidney disease requiring dialysis and comparing home-based and in-center HD. Due to differences in healthcare systems, we further limited the review to studies from North America, Europe, or Australia/New Zealand. We address the following key questions developed with input from topic nominators and a technical expert panel (TEP):

Key Question 1. What are the benefits and harms (*ie,* all-cause mortality, cardiovascular events, hospitalizations, depression, cognitive impairment, quality of life, conversion to a different type of dialysis, complications related to vascular access, complications of dialysis) of *in-home compared to in-center hemodialysis*?

> **1a.** What are the benefits and harms (*ie*, all-cause mortality, cardiovascular events, hospitalizations, depression, cognitive impairment, quality of life, conversion to a different type of dialysis, complications related to vascular access, complications of dialysis) of the various modalities of in-home hemodialysis (*ie*, short daily, nocturnal) compared to conventional hemodialysis?

Key Question 2. What are the benefits and harms (*ie,* all-cause mortality, cardiovascular events, hospitalizations, depression, cognitive impairment, quality of life, conversion to a different type of dialysis, complications related to vascular access, complications of dialysis) of *peritoneal dialysis compared to in-home hemodialysis or in-center hemodialysis*?

> **2a.** Do results differ depending on whether peritoneal dialysis was the initial therapy or the therapy used following failed in-center dialysis?

Key Question 3. What are the a) health care system, b) provider, and c) patient factors associated with selection of and technique survival for home-based dialysis (including peritoneal dialysis)?

Key Question 4. In the published literature, what are the costs of home hemodialysis or peritoneal dialysis compared to in-center hemodialysis?

METHODS

TOPIC DEVELOPMENT

This topic was nominated by Susan Crowley, MD, VHA National Program Director for Kidney Disease and Dialysis and Rudolph Rodriguez, MD, Chair, VA Renal Field Advisory Committee. Key questions and outcomes were developed with input from a Technical Expert Panel.

SEARCH STRATEGY

MEDLINE and the Cochrane Library were searched from 1995 to December 2013 for randomized controlled trials (RCTs), controlled clinical trials (CCTs), and observational studies. The search strategy included MeSH terms and keywords for HD and peritoneal dialysis (Appendix A).

STUDY SELECTION

We included studies of adults with chronic kidney disease receiving dialysis (in-center HD, HHD, or PD) as outpatients. We excluded studies that did not report our outcomes of interest.

Primary Outcomes:

KQ1, KQ2 – All-cause mortality

KQ3 – Health system organizational factors, provider knowledge, patient factors (age, race, gender, caregiver support, social support, comorbidities, cognitive function, physical abilities, rural vs urban [distance from dialysis center], home vs assisted living or skilled care facility)

KQ4 – Costs (from literature)

Secondary Outcomes:

KQ1, KQ2 – Cardiovascular events (MI, stroke, cardiovascular death); hospitalizations; clinically diagnosed depression or cognitive impairment; clinically meaningful difference in quality of life scale scores; conversion to a different type of dialysis (*eg,* from peritoneal to in-center hemodialysis)

Intermediate Outcomes:

KQ1, KQ2 – Quality of life (EuroQolEQ, Kidney Disease QOL) scale scores; depressive symptoms; cognitive function; total and mental- and physical-health subscale scores

Harms:

KQ1, KQ2 – Complications related to vascular access including button hole technique (access failure, infection requiring procedure, thrombectomy, angioplasty, fibrin striping of catheters, replacement of catheters); complications of dialysis (fluid and electrolyte disorders requiring hospitalization, additional dialysis, or both, symptomatic hypotension)

We included all RCTs or CCTs that met eligibility criteria. For Key Questions 1 and 2, we required registry studies to enroll at least 1,000 patients and have a mean or median follow-up of

at least one year if they reported outcomes of mortality, cardiovascular events, technique failure, or transplantation. For all other outcomes and for Key Question 3, a minimum enrollment of 100 and a mean or median follow-up of at least one year was required. Additionally, for Key Question 3, we included studies of dialysis modality selection only if they followed patients to determine the dialysis modality the patient received.

DATA ABSTRACTION

From registry studies we extracted study characteristics (dialysis modalities, study purpose, cohort years, country, sample size, and patient inclusion criteria), patient characteristics (age, gender, and race), data analysis technique (factors adjusted for, modeling technique, analysis approach), length of follow-up, and outcomes. If reported, we also extracted data on interactions between mortality and age, gender, race, body mass index (BMI), diabetes, cardiovascular disease, and duration of ESRD therapy.

For mortality outcomes, most of the registry studies presented more than one analysis approach (different statistical model, different adjustment factors, *etc*). We extracted the most-adjusted model. Many studies reported outcomes at multiple time points during the follow-up period. We focused on data at one year, 2 years, and at maximum follow-up time, if provided.

QUALITY ASSESSMENT

For included RCTs and CCTs, trained research methodologists rated the risk of bias of individual studies as low, moderate, or high risk. Risk of bias ratings were based the following criteria: allocation sequence generation, allocation concealment, blinding, incomplete outcome data, and selective outcome reporting – a modification of the Cochrane approach to determining risk of bias.[4]

For observational studies, trained methodologists assessed risk of bias using criteria suggested in the AHRQ Methods Guide: selection bias (use of appropriately comparable control group, design/analysis accounted for important confounding and modifying variables); masking of the outcome assessment (outcome assessor); use of intention-to-treat principles (*ie,* inclusion of all comparison group participants in outcomes analyses); attrition bias (if overall or differential dropout/loss to follow-up or exclusions a concern, missing data appropriately handled); and selective reporting of prespecified outcomes.[5] Observational studies were considered high risk of bias unless all 5 criteria were addressed by the study authors. Studies that addressed all 5 criteria were considered moderate or low risk of bias depending on how completely the criteria were addressed.

Quality of existing systematic reviews was assessed using the Assessment of Multiple Systematic Reviews (AMSTAR) criteria.[6]

DATA SYNTHESIS

Due to differences in study methodology, data could not be pooled. For Key Questions 1 and 2, we summarize the results by outcome. For Key Question 3, we summarize findings for health care system, provider, and patient factors. For Key Question 4, we summarize costs of HHD versus in-center HD and PD versus in-center HD.

RATING THE BODY OF EVIDENCE

We rated strength of evidence for our main outcome (mortality) as reported in the registry studies for the comparisons of HHD to HD and PD to HD. The rating is based on risk of bias of individual studies and consistency, precision, and directness of the overall evidence as described by Owens et al.[7]

PEER REVIEW

A draft version of this report was reviewed by clinical content experts as well as clinical leadership. Their comments and our responses are presented in Appendix B and the report was modified as needed.

RESULTS

The majority of studies identified compared in-center hemodialysis (HD) to peritoneal dialysis (PD). Relatively few studies compared in-home hemodialysis (HHD) to HD or PD.

LITERATURE FLOW

Details of the literature search and study selection process are presented in Figure 1. For Key Questions 1 and 2, we identified 32 registry studies (16 from the US, 4 from Canada, 3 from Australia/New Zealand, 7 from Europe or the UK, and 2 multi-national) that compared PD to HD. Seven registry studies (4 from the US, 2 from Australia/New Zealand, one from the UK, and one multinational study) provided data for the comparison of HHD to HD. Two registry studies (one from the US and one from the UK) also compared HHD to PD.

We also identified 3 RCTS. One study from Canada and one from New Zealand compared HHD to HD; one study from the Netherlands compared PD to HD. We identified 3 CCTs (one from the US, one from Canada and one multinational study) that compared HHD to HD and 2 clinical cohort studies (one from the US and one from the Netherlands) that compared PD to HD.

To further address other Key Question 1 and 2 outcomes (hospitalization, quality of life, cognitive, depression, and adverse events) we report findings from systematic reviews, RCTs, CCTs, longitudinal studies, and cross-sectional studies. There were 15 articles from Europe or the UK, 5 from the US, 4 from Canada, and one from Australia/New Zealand; the systematic reviews were multinational.

For Key Question 3, we included 49 articles, 16 from the US, 17 from Canada, one from the US and Canada, 12 from Europe/UK, 2 from Australia/New Zealand, and one multinational. Most of the studies addressed either patient factors associated with selection of a dialysis modality or factors associated with technique survival for PD.

We identified 15 studies that reported cost outcomes (Key Question 4) comparing either PD to HD or HHD to HD. There were 2 studies from the US, 6 from Canada, 6 from Europe/UK, and one from Australia/New Zealand.

Figure 1. Literature Flow Chart



KEY QUESTION 1. What are the benefits and harms (*ie,* all-cause mortality, cardiovascular events, hospitalizations, depression, cognitive impairment, quality of life, conversion to a different type of dialysis, complications related to vascular access, complications of dialysis) of *in-home compared to in-center hemodialysis*?

Summary of Findings

- Evidence is generally of high risk of bias regarding the comparative effectiveness of HHD versus in-center HD. We found few randomized or controlled clinical trials or prospective clinical cohort studies comparing in HHD and in-center HD. Available clinical trials were small in size, had short follow-up durations, and focused on intermediate outcomes rather than mortality outcomes.

- Strength of evidence for mortality was low based on high risk of bias associated with the registry studies. Results from registry studies should be interpreted with caution due to likely residual confounding.

- Of 7 registry studies included, 5 suggest that HHD is associated with improved overall survival compared to in-center HD. One registry study found a benefit for individuals receiving in-center HD over HHD while another found no difference. Two small RCTs of short follow-up duration reported no difference in mortality between in-center versus in-home modalities. A multinational CCT with 415 patients and 1006 patient-years of follow-up reported a mortality benefit for HHD compared to in-center HD while a small, short-duration CCT found no difference.

- Two registry studies reported no difference in cardiovascular mortality.

- Limited data suggest that HHD patients may be more likely than in-center HD patients to switch dialysis modalities at some point during their treatment but no differences in rate of transplant or all-cause hospitalizations were observed. Results for quality of life and adverse events were mixed with some studies showing benefits of HHD and others showing no difference.

- No studies suggested HHD was associated with harms.

In-Home Hemodialysis (HHD) Compared to In-Center Hemodialysis (HD)

Study Characteristics

Seven registry studies,[8-14] 2 RCTs,[15,16] and 3 CCTs[17-19] reported mortality data for HHD and in-center HD programs. Another registry study reported hospitalization data.[20] Among the registry studies, 4 were from the US Renal Data System (USRDS),[8-10,20] two were from the Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry,[11,12] one was from the UK (England and Wales),[14] and one was completed in 3 countries – the US, Canada, and France, with the majority of patients from Canada.[13] Across the studies, registry enrollment occurred between 1986 and 2011; follow-up periods were up to 15 years. Sample sizes ranged from 1,726[13] to 458,329[9] with all but one study[13] enrolling only incident HHD patients. Three studies

included matched prevalent HD patients.[8,13,20] HHD patients tended to be younger.[9-13] Three studies reported a higher percentage of males in the HHD group,[11-13] one reported the HHD patients were more likely non-white,[9] and 2 reported the HHD patients were more likely white or other race.[12,14] Additional information about patients included in the registries is presented in Appendix C, Table 1.

Methods used for data analysis were similar in 4 of the studies – a Cox proportional hazards model and an intent-to-treat analysis with adjustment for patient demographics, and, in most studies, comorbid conditions and laboratory variables.[8-10,13] One used a Cox proportional hazards model with an "as-treated" approach[11] while another study used a marginal structural modeling (MSM) technique with an "as-treated" analysis.[12] Appendix C, Table 1 provides further details on the analysis approach used in each study.

We also included data from 2 RCTs, one from Canada[15] and one from New Zealand[16] (Appendix C, Table 2). The study from Canada randomized patients to either 3 dialysis sessions per week (52% of the patients received in-center HD) or 5 to 6 dialysis sessions per week at home. The total sample size was 61 patients and follow-up was 6 months.[15] The study from New Zealand was a cross-over RCT with 9 patients and 8 weeks per intervention period.[16] The interventions were in-center HD for 3.5 to 4.5 hours per day, 3 times per week and HHD for 6 to 8 hours, 3 times per week.

One CCT was a multinational study (US, Italy, France, and the UK),[18] one was from the US,[17] and one was from Canada.[19,21] The multi-national study enrolled 415 patients and both HD and HHD followed short, daily protocols. A total of 1,006 patient years of follow-up was reported.[18] The US study enrolled 63 nocturnal (5 to 6 times per week) HHD patients and 121 matched conventional (3 times per week) HD patients. Patients were followed for up to 20 months.[17] The study from Canada included a conventional in-center HD group (3.5 to 4.5 hours, 3 times per week), a nocturnal HHD group (6 to 8 hours, 5 to 6 times per week), and a daily HHD group (1.5 to 2.5 hours, 5 to 6 times per week).[19] Follow-up was 18 months. Additional study data are reported in Appendix C, Table 2.

Mortality

A summary of mortality outcomes is presented in Table 1. Five of 7 registry studies reported lower mortality overall in HHD patients with hazard ratios ranging from 0.48 to 0.88.[8,10-13] In 2 studies, the benefit was also observed at follow-up intervals of one, 2, or more than 3 years.[11,12] One study reporting a benefit included only NxStage System One users.[8] The HHD group in this study completed 5 to 6 dialysis sessions per week. Although there was an overall benefit of HHD, the benefit was not observed at the 2 year follow-up assessment.[8] In another study, the HHD was "intensive" – sessions of at least 5.5 hours, 3 to 7 times per week.[13] One study reported a higher mortality in the HHD group (HR 1.10 [95% CI 1.04, 1.17])[9] and one study reported no difference (HR 1.06 [95% CI 0.55, 2.04]).[14] Data are presented in Appendix C, Table 1.

The 2 RCTs and 2 of the CCTs reported no difference in mortality between HD and HH (Appendix C, Table 2).[15-17,19] The other CCT reported higher mortality in the HD group (HR 2.42 [95% CI 1.54, 2.79]).[18] Findings from the RCTs and CCTs should be interpreted with caution given the small sample sizes and short follow-up periods.

Three of the registry studies looked at the interaction of age and modality on mortality outcomes (Table 1 and Appendix C, Table 3). A study from Australia/New Zealand reported a significant interaction by age at dialysis inception (P = .03). The decrease in mortality risk associated with HHD was less for patients in the older age group (greater than 74 years).[12] A more recent report from this group reported that the effect of modality on mortality risk was not modified within subcategories of age.[11] The multinational study also reported no significant interaction with age.[13]

One Australia/New Zealand study reported a significant interaction by ethnicity (P < .001) finding that the decrease in relative mortality risk associated with HHD was less for non-whites and non-Asians.[12] The authors also reported no difference in risk between patients with and without diabetes. The more recent report found no differences in risk based on ethnicity, BMI, presence of cardiovascular disease, or duration of ESRD therapy.[11] The multi-national study reported non-significant interactions between mortality and duration of ESRD.[13]

Other Outcomes

Cardiovascular Events (Appendix C, Table 1)

One US registry study reported cardiovascular mortality.[8] The overall (maximum follow-up of 4 years) cardiovascular mortality did not differ between HHD and HD (HR 0.92 [95% CI 0.78, 1.09]). From an Australia/New Zealand registry study, the percentages of cardiovascular deaths by dialysis modality were 65% for HHD and 47% for HD.[12] Follow-up in this study was a maximum of 11 years and 9 months.

Hospitalization (Appendix C, Table 4)

One registry study reported hospitalizations.[20] There were no significant differences between HHD and matched HD patient groups for all-cause hospitalization or hospitalization for vascular access dysfunction. There was a significantly greater risk of hospitalization for infection (RR 1.32 [95% CI 1.24, 1.40]) and decreased hospitalization for cardiovascular causes (RR 0.83 [95% CI 0.78, 0.88]) in the HHD group. One of the RCTs reported no difference in all-cause hospitalization with rates of 0.62 (HHD) and 0.84 (HD) per patient over the 6 month follow-up period.[15] A CCT, also from Canada, found no difference in hospitalization between conventional HD and either nocturnal HHD or daily HHD patients.[19]

Table 1. Mortality – In-center Hemodialysis (HD) vs Home Hemodialysis Dialysis (HHD) – Registry and Trial Data

Country/ Region: Number of Reports	Study Years	Patients: Number of Reports or Sample Size	Overall Mortality: Number of Reports			Number of Studies Reporting Effects by:						
			No difference	Favor HHD	Favor HD	Age	Gender	Race	BMI	DM	CVD	ESRD Duration
REGISTRY STUDIES												
USA: 3	1986-2008	Incident: 3 (1 with matched prevalent HD)		2[a]	1							
Australia/ New Zealand: 2	1996-2011	Incident		2[b]		2		2	1	1	1	1
UK: 1	1997-2005	Incident	1									
International : 1	2000-2010	Incident and prevalent HHD, matched HD		1[c]		1						1
RANDOMIZED CONTROLLED TRIALS												
Canada: 1	2004-2006	N=61	1									
New Zealand: 1	NR	N=9 (cross-over RCT)	1									
CONTROLLED CLINICAL TRIALS												
USA: 1	1997-2010	N=184	1									
International : 1	1982-2005	N=415		1								
Canada: 1	1998-2001	N=46	1									

[a] One study reported no difference after 2 or more years
[b] Overall, at 1 year, 2 years, and >3 years
[c] HHD was intensive (>5.5 hours per session, 3-7 sessions per week)

Quality of Life, Cognition, Depression (Appendix C, Table 4)

Quality of life, cognition, and depression outcomes were not reported in the registry studies. In the Canadian RCT, no difference was noted between HHD and HD patients in change in EuroQol-5D scores over 6 months.[15] There were significantly greater improvements in two elements of the KDQOL instrument, Effects of Kidney Disease (difference (HHD-HD) in change over 6 months: 8.6; P = .01) and Burden of Kidney Disease (difference (HHD-HD) in change over 6 months: 9.4; P = .02) in the HHD group compared to the HD group. The cross-over RCT from New Zealand also reported quality of life, finding that HHD interfered more with social activities (P < .05), tended to be to be more of a burden on families (P = .07), and was associated with less physical suffering (P < .005).[16] The CCT from Canada found no difference between HHD and either daily or nocturnal HD in the SF-36 physical or mental component scores at 18 months.[21]

A cross-sectional study from the UK included 145 patients receiving HD, HHD, or PD.[22] The study found a significant difference across modalities in scores on the Treatment Effects Questionnaire but subsequent analyses found that the difference was only between modalities of

PD. Using a Beck Depression Inventory cut-off score of 16 or higher as an indication of depression, 42% of the HD group was classified as having depression compared to 8% of the HHD group but the difference was not statistically significant. Similarly, with a cut-off score of 10 or higher on the Cognitive Depression Index, 31% of the HD and 12% of the HHD group were classified as having depression but the difference was not statistically significant. It was noted that the duration of treatment was significantly longer in the HHD group (88 months) than the HD group (39 months).

An earlier study from the UK with 192 patients receiving HD, HHD, or PD reported scores on components of the SF-36.[23] There were significant differences across modalities (with HHD patients having higher scores) for Physical Functioning (HD 28, HHD 47), Role Physical (HD 17, HHD 41), Social Functioning (HD 49, HHD 63), and Role Emotional (HD 30, HHD 65). The study reported the percentage of patients receiving treatment for 9 months or less: 85% of the HD group and 62% of the HHD group.

A Canadian study enrolled 119 patients receiving HD, HHD, or PD.[24] The duration of treatment was 44 months for the HD group and 38 months for the HHD group. No significant difference was noted between HD and HHD patients on the Self-Anchoring Striving Scale. On the Index of Well-Being and the Health State Utility/Time Trade-off, scores for HHD patients were significantly higher than HD patients.

Change in Dialysis Modality (Appendix C, Table 1)

One US registry study reported a significantly greater risk of changing dialysis modalities in the HHD patients compared to the HD patients (HR 10.4 [95% CI 8.9, 12.3]).[8] Over the follow-up of up to 4 years, 26% of the HHD patients changed modality (97% to HD, 3% to PD) compared to 3% of the HD patients. The multi-national study reported that over a maximum follow-up of 4 years (median of 1.8 years), 14% of the HHD patients switched modalities (all to HD) compared to 0% of the HD patients.[13] The study from the UK reported that median technique survival for HHD was 18 months (IQR 9 to 33 months).[14] Of 130 patients with known reasons for stopping HHD, 30 (23%) switched to HD (hospital or satellite) and 1 (0.8%) to PD. The remaining patients either underwent kidney transplant (n=77) or died (n=22). The recent CCT from the US reported no significant difference in percentage of either HHD or HD patients who transferred to PD.[17]

Transplantation (Appendix C, Table 1)

A US registry study found no difference in the percentage of patients receiving a transplant (HHD 10.2%, HD 10.8%, HR 1.05 [95% CI 0.89, 1.25]).[8] The multinational study also reported no difference in transplantation between HHD and HD (9.5 and 8.8/100 person-years, respectively).[13] The maximum follow-up was 4 years in both studies; the multinational study reported a median follow-up of 1.8 years.

Adverse Events (Appendix C, Table 4)

The Canadian RCT, a 6 month study, found no difference in adverse events between HHD and HD.[15] Specifically, there were no significant differences in the number of patients with one or more cases of infection requiring a procedure or the number of patients with one or more vascular access surgical interventions. For adverse event reporting, the Canadian CCT combined

data from the daily and nocturnal HHD groups.[19] The annual rates of access complications and access interventions did not differ between the HHD groups and the HD group.

Another CCT, from Italy, including 148 patients on either conventional HD (mostly in-center) or daily HD (70% at home), reported a significant difference in the rate of access closures (9.8 per 100 patient-years in the HD group, 2.2 per 100 patient-years in the HHD group; rate difference 7.6 [95% CI 3.4, 11.9], P < .01).[25] There was also a significant difference in the 3-year probability of access survival (70% HD, 92% HHD; P < .05).

Catheter-related events were reported in the recent CCT from the US.[17] Considering only the first catheter, there was no difference between groups in the rate of sepsis (16% HHD, 12% HD; P = .21) or time to sepsis (P = .98). Median catheter duration was 5.6 months in the HHD group and 4.6 months in the HD group (P = .64).

KEY QUESTION 1A. What are the benefits and harms (*ie*, all-cause mortality, cardiovascular events, hospitalizations, depression, cognitive impairment, quality of life, conversion to a different type of dialysis, complications related to vascular access, complications of dialysis) of the various modalities of in-home hemodialysis (*ie*, short daily, nocturnal) compared to conventional hemodialysis?

Different In-Home Modalities Compared to In-Center Hemodialysis

Few studies included different HHD modalities. The registry study from Australia/New Zealand included patients receiving more frequent or extended (including nocturnal and short daily regimens) HD and HHD.[12] Over a follow-up period of up to 11 years and 9 months, there was reduced mortality with more frequent or extended HHD compared to HD (HR 0.53 [95% CI 0.41, 0.68]), a finding similar to the reduction in mortality with any HHD compared to HD. The percentages of deaths due to cardiovascular causes were 65% for the HHD group and 73% for the more frequent or extended HHD group.[12] As noted above, in 3 other registry studies the HHD was longer and/or more frequent than the conventional HD. Two reported reduced mortality overall (maximum follow-up of 4 years) in the HHD group.[8,13] In one study reporting cardiovascular mortality, there was no difference between HHD and HD.[8] A more recent study reported no difference in all-cause hospitalizations although, as noted above, there were differences between groups for different causes of hospitalization.[20]

In 4 of the RCTs and CCTs cited above, the HHD regimens were different in frequency and/or duration than the HD regimens.[15-17,19] None of the studies reported a mortality difference between HHD and HD. Additionally, the recent CCT reported no differences between more frequent and extended HHD and conventional HD in catheter-related sepsis, median catheter life, or transfer to PD.[17] Another CCT reported no difference in hospitalizations.[19] Follow-up periods ranged from 8 weeks[16] to 20 months.[17]

Risk of Bias for Key Question 1

We did not assess the risk of bias of individual registry studies. Registry studies are typically considered high risk of bias due to issues with selection bias and inability to assess and include all potential confounders in analyses. There were 2 RCTs that addressed Key Question 1, one

moderate risk of bias and one high risk of bias. The 3 CCTs were rated as moderate (k=1) and high (k=2) risk of bias. Three cross-sectional studies were all rated as high risk of bias. Additional information is presented in Appendix C, Table 2.

KEY QUESTION 2. What are the benefits and harms (*ie,* all-cause mortality, cardiovascular events, hospitalizations, depression, cognitive impairment, quality of life, conversion to a different type of dialysis, complications related to vascular access, complications of dialysis) of *peritoneal dialysis compared to in-home hemodialysis or in-center hemodialysis*?

Summary of Findings

- Evidence is inconsistent whether mortality differs between patients treated with PD compared to in-center HD.

- Strength of evidence for mortality was low based on high risk of bias associated with the registry studies. Results from registry studies should be interpreted with caution due to likely residual confounding.

- Twenty-seven registry studies, one RCT, and 2 clinical cohort studies provided evidence for the comparison of PD to in-center HD. Of 22 registry studies reporting mortality for the total sample, 12 (2 from the US, 3 from Canada, 1 from Australia/New Zealand, and 6 from Europe/UK) found no difference in mortality between PD and in-center HD. Four studies (2 from the US, one from Canada, and one from Europe/UK) found a mortality benefit for PD while 6 studies (3 from the US, 2 from Australia/New Zealand, and one from Europe/UK) found a mortality benefit for in-center HD. It is difficult to assess if results vary by time of publication due to differences in study populations, length of follow-up reported, and methods of data analysis, but publication dates suggest that a trend may exist. Studies showing increased mortality with PD compared to in-center HD were generally published before 2003 while studies showing no difference or reduced mortality with PD were generally published after 2003.

- A small RCT from the Netherlands found no difference in mortality between PD and in-center HD. This study was terminated due to low enrollment. A prospective, clinical cohort study from the United States with 1,041 patients and a follow-up of up to 7 years found no difference in mortality. Data from a prospective cohort study from the Netherlands showed no difference in 2-year mortality.

- Analyses of interactions between dialysis modality and age (10 studies), gender (4 studies), race (5 studies), BMI (5 studies), diabetes (12 studies), cardiovascular disease (6 studies), and duration of ESRD (3 studies) yielded mixed results.

- Of 5 registry studies reporting cardiovascular disease risk, one reported a significantly higher percentage of deaths due to cardiovascular disease in the PD group. In 3 of 5 studies reporting, hospitalizations were higher in the HD groups. Mixed results were reported for quality of life outcomes including mental and physical health components, quality of life utilities, and life participation activities. Changes in treatment modality and kidney transplantation were generally more likely for patients receiving PD.

- Few studies reported adverse events.

- There is limited evidence for the comparison of PD and HHD. In 2 registry studies, results were mixed with a study from the United States finding no difference in mortality and a study from the United Kingdom finding a mortality benefit for HHD. Other outcomes were not reported.

- Two studies reported higher mortality among patients who initiated ESRD treatment with HD and then switched to PD compared to patients who initiated PD as their first modality. Overall duration of ESRD was likely longer in the patients who initiated with HD.

Peritoneal Dialysis (PD) Compared to In-Center Hemodialysis (HD)

Study Characteristics

Twenty-seven registry studies reported mortality outcomes for patients receiving HD or PD. There were 11 reports of Centers for Medicare and Medicaid (CMS) data[26-36] representing patient data from 1987 to 2006. Maximum follow-up ranged from one to 6 years. Sample sizes ranged from 3,337 to 684,426 and all but one[35] reported data from incident patients. In 7 of the 11 studies, the PD patients were younger and in all of the studies, PD patients were less likely to be African-American. Two studies reported that PD patients were more likely male.[30,33]

All studies used an intent-to-treat approach. Three used a Poisson regression model,[30,32,36] 5 used Cox proportional hazards models,[29,31,33,34] one used a MSM approach,[28] 2 used both Cox and MSM models,[26,35] and one did not specify.[27] Two studies included matched-pair data.[27,29] Additional patient characteristics and details about the analyses are presented in Appendix C, Table 1.

One additional study reported US data.[37] This analysis included 17,926 patients either receiving dialysis on January 1, 1992 or starting dialysis during 1992. PD patients were younger and more likely white. An intent-to-treat approach was used with a Cox proportional hazards model. Additional information is provided in Appendix C, Table 1.

There were 3 reports from ANZDATA[11,12,38] including 2 cited above because they also included an HHD group.[11,12] The study dates ranged from 1991 to 2011 with maximum follow-ups of 15 years. Two of the studies included approximately 25,000 incident patients[12,38] while the third included 6,419 patients.[11] Two studies reported that PD patients were older and less likely male.[11,38] As noted for the HHD/HD comparison above, one study use an "as-treated" approach with a MSM model[12] and another used an "as-treated" approach with a Cox proportional hazards model.[11] The third study used an intent-to-treat approach with Cox regression models.[38] Appendix C, Table 1 provides more information about these studies.

Four of the registry studies were from Canada – 3 from the Canadian Organ Replacement Register (CORR)[39-41] and one from the Institute for Clinical Evaluative Sciences (ICES).[42] The studies enrolled patients between 1990 and 2006 with maximum follow-up periods ranging from 5 years[41] to 17 years.[39] Sample sizes ranged from 6,573[42] to 46,839[39] incident patients. One study reported that the HD patients were older than the PD patients[41] and another reported that there was a higher percentage of HD patients in the age 65 and older category while more PD patients were in the age 35 to 64 year category.[39] All of the studies used an intent-to-treat approach with Cox models (Appendix C, Table 1).

The remaining 8 registry reports were from Europe or the UK. Included were reports from the Dutch End-Stage Renal Disease Registry (RENINE),[43] the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA),[44] the Finnish Registry for Kidney Diseases,[45] the French Renal Epidemiology and Information Network (REIN),[46] the Lombardy Dialysis and Transplant Registry,[47] the Romanian Renal Registry,[48] the Scottish Renal Registry,[49] and the United Kingdom Renal Registry (UKRR).[14] The studies included incident patient data from 1987 to 2011 with follow-up periods ranging from a mean of 2.4 years[43] to a maximum of 25 years.[49] Sample sizes ranged from 2,475[14] to 16,643.[43] Three studies reported that PD patients were younger[43-45] while another reported that PD patients were older.[46] Three studies reported that PD patients were less likely male[46,48,49] while a third reported that PD patients were more likely male.[43] One study reported that a higher percentage of PD patients were on the transplant wait list.[45] All of the studies used an intent-to-treat approach with Cox models. Additional information about the studies is reported in Appendix C, Table 1.

One RCT and 2 clinical cohort studies also compared HD and PD. The RCT, completed in the Netherlands, enrolled 38 patients new to dialysis and randomized them to HD or PD.[50] Patients were followed for a maximum of 5 years. The trial was stopped because of low enrollment, failing to reach the goal of 100 patients. Despite randomization, the HD patients were older.

The clinical cohort studies included the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) study completed in the US[51] and the Netherlands Cooperative Study on Adequacy of Dialysis (NECOSAD).[52] The CHOICE study enrolled 1,041 incident patients between 1995 and 1998 and followed them for a maximum of 7 years.[51] The PD patients in this study were younger and more likely white. The NECOSAD cohort enrolled 1,222 incident patients and followed them for a maximum of 4 years.[53] PD patients were younger and more likely male. Both studies used an intent-to-treat approach with Cox proportional hazards models.

Mortality

Mortality outcomes are summarized in Table 2 with more detailed reporting in Appendix C, Tables 1 and 2. Of the 27 registry studies, 22 reported overall mortality with 12 finding no significant difference in mortality between HD and PD, 4 finding a more favorable outcome for PD, and 6 finding a more favorable outcome for HD.

Of the 11 CMS/USRDS studies, one reported overall mortality (maximum follow-up of 4 years) finding no difference (HR 1.05 [95% CI 0.96, 1.16]).[29] By year of follow-up, the difference was not significant during the first year but there was a difference, favoring HD, at 2 years (HR 1.19 [95% CI 1.02, 1.38]).[29] Another study with over 23,000 patients reported results at one year and 2 years (but no overall results).[26] In that study, there was significantly reduced mortality at both one (HR 0.59 [95% CI 0.44, 0.78]) and 2 years (HR 0.52 [95% CI 0.34, 0.80]) for the PD group. Another study reported reduced overall mortality (maximum follow-up of 6 years) for PD (HR 0.88 [95% CI 0.81, 0.95]).[27] Two older studies[33,36] found increased mortality in the PD group. Follow-up periods were 2 years[33] and one year.[36] One study found no difference in mortality over a maximum follow-up of 5 years between PD and HD (HR 1.03 [95% CI 0.99, 1.06]).[28] The remaining study did not report overall mortality results.[31]

The other US study reported an overall increased risk of death over one year follow-up with PD (RR 1.32, P = .005).[37]

Two of the ANZDATA studies favored HD. One reported an increased overall mortality risk (maximum follow-up of 11 years and 9 month) in the PD group (HR 1.10 [95% CI 1.06, 1.16]).[12] The other reported an increased risk in the PD group at one or more years follow-up (HR 1.32 [95% CI 1.26, 1.38]).[38] The third study, focused on patients from New Zealand, found no difference between PD and HD in overall mortality although mortality was lower in the PD group during the first 3 years and greater in the PD group at greater than 3 years.[11]

Among the 4 studies from Canada, 3 found no difference in overall mortality between HD and PD.[39,41,42] Follow-up periods ranged from maximums of 5[41] to 17[39] years. One reported reduced overall mortality (maximum follow-up of 6 years) with PD (mortality rate ratio 0.93 [95% CI 0.87, 0.99]).[40] All but one of the studies[42] reported an early survival advantage for PD patients with no difference after 2 to 3 years of treatment.

Of the 8 studies from Europe or the UK, 6 reported no difference in mortality between HD and PD.[14,43,45,47-49] Follow-up periods were up to 25 years. These studies enrolled patients from 1982 to 2011. In one of the studies, all of the patients were on a renal transplant list at some point after the start of dialysis indicating comparable baseline characteristics.[49] One study reported reduced mortality (mean follow-up of 1.6 years) in the PD group (HR [PD vs HD] 0.82 [95% CI 0.75, 0.90])[44] and one reported reduced morality (maximum follow-up of 7 years) in the HD group (HR [PD vs HD] 1.48 [95% CI 1.33, 1.65]).[46]

Although it is difficult to assess temporal trends due to differences in study populations, length of follow-up reported, and methods of data analysis, publication dates would suggest that a trend may exist. All but 2 studies showing increased mortality with PD compared to in-center HD were published before 2003 while all but 3 studies showing no difference or reduced mortality with PD were published after 2003.

The RCT reported no difference in mortality (HD vs PD) with a maximum follow-up of 5 years.[50] The adjusted hazard ratio was 3.6 (95% CI 0.08, 15.4, P = .09) with higher mortality in the HD group.

In the CHOICE study, the relative hazard of death (PD vs HD) was 1.61 (95% CI 1.13, 2.30) using a multivariate model and adjusting for demographic characteristics, clinical/treatment factors, and laboratory values.[51] By year of treatment, the relative hazard was 1.39 (95% CI 0.64, 3.06) in the first year and 2.34 (95% CI 1.19, 4.59) in the second year indicating that the risk of death did not differ significantly between PD and HD in the first year of treatment but during the second year, the risk of death for PD patients was significantly higher than for HD patients.

In the NECOSAD study, the one year mortality risk ratio (HD vs PD) was 1.32 (0.80, 2.18).[53] There was no difference in mortality for the first 2 years of dialysis. After 2 years, the adjusted risk ratio decreased and favored HD. The authors concluded that long-term use of PD was associated with increased mortality.

Table 2. Mortality – In-center Hemodialysis (HD) vs Peritoneal Dialysis (PD) – Registry and Trial Data

Country/ Region: Number of Reports	Study Years	Patients: Number of Reports or Sample Size	Overall Mortality: Number of Reports			Number of Studies Reporting Effects by:						
			No difference	Favor PD	Favor HD	Age	Gender	Race	BMI	DM	CVD	ESRD Duration
REGISTRY STUDIES												
USA: 12[a]	1987-2006	Incident: 11 Prevalent: 1 (Matched: 2)	2	2[b]	3	4	2	3	3	5[e]	3	
Australia/ New Zealand: 3	1991-2007	Incident: 2	1		2[c]	3		2	2	2	1	2
Canada: 4	1990-2006	Incident: 4	3	1						1		
Europe/ UK: 8	1987-2011	Incident: 8 (Matched: 1)	6	1	1	3	2			2	1	
RANDOMIZED CONTROLLED TRIALS												
Netherlands: 1	1997-2000	N=38	1									
CLINICAL COHORT STUDIES												
USA: 1	1995-1998	Incident, N=1041			1							
Netherlands: 1	1997-2002	Incident, N=1222	1[d]									

[a] 5 studies reported mortality in subgroups but no overall mortality
[b] One study favored PD at 1 year and at 2 or more years (no overall results reported)
[c] After 1st year for 1 of the 2 studies
[d] Favored HD after 2 years
[e] 5 datasets (reported in 7 publications)

Interactions (Appendix C, Table 3)

Age. Ten registry studies assessed interactions between dialysis modality (HD, PD) and age. Significant interactions were reported for 5 studies.[12,29,32,36,43] In one of the US studies, which demonstrated an overall increase in the risk of death with PD, the risk of death was significantly higher for PD patients than for HD for patients older than 55 years but not for those younger than 55 years.[36] Two other US studies evaluated risk above or below age 65 years with a significant interaction favoring HD for patients age 65 and older.[29,32] A study from Australia/New Zealand reported a significant interaction by age at dialysis inception.[12] A study from the Netherlands reported an age by modality interaction with the survival benefit of PD decreasing with age.[43] Five other studies reported either non-significant interactions[11,26,45,46] or a significant interaction in the first year of dialysis but not after one year.[38]

Gender. Four studies assessed interactions between modality and gender. One reported that the mortality risk was significantly higher for PD compared to HD for both males and females but the risk was accentuated for females (RR 1.30 for females vs RR 1.11 for males).[36] One reported an interaction between dialysis modality and gender for patients with ischemic heart disease or peripheral vascular disease with the survival benefit of PD only observed for male patients.[44] Two studies reported that the interaction was not significant.[32,45]

Race. Interactions of modality and race were assessed in 5 studies.[11,32,36,38,54] Two reported no effect of race.[36,38] Another reported a mortality benefit for PD in white patients with BMI greater than 30 but not non-white patients.[54] The significance was not reported. One study reported an interaction effect that was significant for Asian and other categories (relative to white)[32] while the fifth study reported different patterns of risk over time (less than 3 years from inception of dialysis vs more than 3 years) for different ethnicity groups.[11]

BMI. Five studies assessed interactions with BMI.[11,31,32,38,54] The most recent study reported no significant interaction with between modality and BMI.[11] One study found that a BMI of 30 or higher was associated with improved survival for HD patients (HR 0.89) but not PD patients (HR 0.99).[31] Another study found significantly increased mortality risk for PD in the 3 highest BMI groups (BMI of 23.5 or higher) in patients with diabetes, while for patients with no diabetes the mortality risk was significantly higher only in the highest BMI group (BMI greater than 30).[54] One study reported a non-significant interaction of BMI and mortality between 90 and 365 days of treatment but a significant interaction after 365 days.[38] The effect sizes were clinically similar across all BMI categories, however. The fourth study found significant interactions between treatment modality and overweight (BMI 25.1 to 30) and obese (BMI greater than 30) but not underweight (BMI less than 18.5).[32]

Diabetes. Interactions between modality and diabetes were assessed in 12 reports from 10 datasets.[12,26,29,32,33,36,38,42,43,45,54,55] The interaction was not significant in 4 studies[26,38,42,45] while 5 studies reported higher mortality risk (PD vs HD) in patients with diabetes.[12,29,32,36,43] Another study reported that across levels of BMI, patients with diabetes tended to have increased risk of mortality with PD compared to patients without diabetes.[54] Additional analyses of this data focused on patients with coronary artery disease[55] or congestive heart failure.[33] Patients with CAD or CHF and diabetes had higher mortality with PD compared to patients without diabetes.

Cardiovascular Disease. Six reports (2 from the same dataset) reported on interactions between cardiovascular disease and modality.[11,29,32,33,46,55] As noted above, 2 analyses from one study[54] focused on coronary artery disease (CAD)[55] and congestive heart failure (CHF).[33] For patients with diabetes, the mortality risk was greater for PD regardless of CAD status[55] or CHF status.[33] For patients without diabetes, mortality was elevated in the CAD group but not the no-CAD group[55] and in the CHF group but not the no-CHF group.[33] Significant interactions with cardiovascular disease were reported in 2 other US studies[29,32] while a French study and a New Zealand study reported non-significant interactions.[11,46]

Duration of ESRD Therapy. One study reported on duration of ESRD therapy finding a significant statistical interaction between ESRD vintage and mortality risk. It was noted that there was little clinical significance.[38] Another study reported a non-significant interaction.[11]

Other Outcomes

Cardiovascular Events (Appendix C, Table 1)

Five registry studies reported on cardiovascular events.[12,35,46-48] One study from Italy focused on the development of *de novo* cardiovascular disease.[47] At baseline, there were no significant differences between the HD and PD groups in the percentages of patients with a history of coronary heart disease, myocardial infarction, or chronic heart failure. During the study period (maximum follow-up of 4 years), 11.4% of the deaths in the PD group and 21.1% of the deaths

in the HD group were due to cardiac causes although it was noted that these numbers did not take into consideration patients who switched dialysis modalities. The relative risk of developing *de novo* cardiovascular disease (PD vs HD) was 1.06 [95% CI 0.79, 1.43]). Similar risks were reported for ischemic heart disease and congestive heart failure.

Three studies, one from Australia/New Zealand,[12] one from Romania,[48] and one from France,[46] reported cardiovascular mortality. In the first study, 54% of deaths in the PD group and 47% of deaths in the HD group were due to cardiovascular causes (significance not reported).[12] In the second study, the difference in cardiovascular mortality was not statistically significant (PD 47%, HD 49%, P = .70)[48] while in the third study, a significant difference was reported (PD 40%, HD 35%, P = .04).[46]

A study from the US reported risk of cardiovascular mortality (PD vs HD) for patients age 55 and older.[35] In patients with diabetes, both males and females receiving PD had a reduced risk of cardiac death (RR 0.90 for both) relative to males age 55 and older receiving in-center HD. In patients without diabetes, the pattern of results was similar with relative risk of 0.70.

Hospitalization (Appendix C, Table 4)

None of the registry studies reported hospitalization. A NECOSAD publication reported that 46% of PD patients and 58% of HD patients were hospitalized at least once over a follow-up period that ranged from 5 months to 7.8 years.[52] A longitudinal study from the US with 181 incident patients (119 HD, 62 PD) reported higher total admissions per year at risk in the HD group (2.4) compared to the PD group (1.4) (P < .0001).[56] Admissions for infection per year at risk were higher for PD patients (0.42) than HD patients (0.29) (P = .02).[56] A second US study with 177 patients also reported more hospitalizations (1.5 vs 0.4, P < .01) and more hospital days (12.2 vs 2.4, P < .05) over follow-up of up to 15 months in HD patients compared to PD patients.[57] In a UK study of patients who started dialysis at age 70 years or older, hospitalization did not differ between HD (2.0 events/1 patient-year) and PD (1.9 events/1 patient-year) ($RR_{PD\ vs\ HD}$ 0.97 [95% CI 0.77, 1.22]).[58] A cross-sectional study from Canada reported no difference in mean hospitalizations in the past year for HD (1.68) and PD (1.43) patients.[24]

Quality of Life, Cognition, Depression (Table 3, Appendix C, Table 4)

None of the registry studies reported quality of life or related outcomes. We identified a 2011 systematic review that included published and grey literature studies (English language only) through July 2010, enrolling adults on either in-center HD or PD, and using a validated tool to assess and compare quality of life for HD and PD patients.[59] Outcomes for both generic (*ie*, broad aspects of quality of life, suitable for different locations and different cultures such as the SF-36) and disease-specific quality of life tools were reported.

Twenty-six studies from the US, Europe/UK, and the Asia/Pacific region were included. Twenty were cross-sectional studies, 4 were cohort studies, and 2 were retrospective analyses. Of the 12 studies that used the SF-36, only 4 reported physical and mental health component summary scores. A significant difference, with better health in the PD group, was observed for both scores in one cross-sectional study from Turkey enrolling 115 patients. This study also reported significant differences, favoring PD, for the 8 individual dimensions of the SF-36. One other study, a cross-sectional study from China with 1,062 participants, reported significant differences, favoring PD, for 6 of the 8 individual dimensions (bodily pain, general health

perception, vitality, social functioning, role limitations due to emotional functioning, and mental health). Two additional cross-sectional studies, one from the Netherlands with 1,553 participants and one from Taiwan with 244 participants, reported significant differences favoring PD for the bodily pain and role limitations due to emotional functioning dimensions. Of 5 studies reporting kidney disease-specific quality of life with the 11-item KDQOL instrument, significant differences favoring PD were found for 4 of 11 dimensions in a cross-sectional study from Denmark (N=130), 4 of 9 dimensions assessed in a cohort study from France (N=387), and 3 of 3 dimensions assessed in a cross-sectional study from the US (N=226). Other quality of life tools were used in only one or 2 studies and generally no differences were observed between HD and PD patients.

This review was of average quality based on the AMSTAR criteria.[6] Although it was reported that study quality was assessed, the quality ratings were not provided nor used in developing the conclusions for the review. Eleven studies were excluded from the analysis because of either weak design or irrelevance to the topic but no additional information was provided. Little information was provided about the study populations of the included studies and the timing of the quality of life assessment was not reported. Results were provided for only some of the studies reported to have used a particular quality of life assessment tool and little information was provided about tools other than the SF-36 and KDQOL.

We supplemented the information from the Boateng and East review[59] with more complete data from the 3 US studies included in the review (Table 3) and with data from studies identified in our search of MEDLINE and other sources but not included in the review (Appendix C, Table 4). The 3 US studies, all rated as high risk of bias, found few differences between HD and PD patients in overall measures of physical or mental function with mixed results for individual dimensions (Table 3).[60-62]

Among the studies not included in the review, the small RCT (n=38) from the Netherlands found no significant difference in the quality adjusted life year scores for the PD and HD groups (54 vs 59; adjusted difference 3.1 [95% CI -9.9, 16.1], P = .63).[50]

Among 949 patients from the CHOICE study, higher overall functional support (assessed with the Medical Outcomes Study Social Support Survey) was higher for the PD patients (81 vs 76, P = .002).[63] Higher scores were reported for the emotional support, tangible support, and positive social interaction domains but not for the affectionate support domain. Social support in the highest tertile was significantly associated with the chance of receiving PD (P = .02).[63]

Several reports with subsets of the NECOSAD cohort addressed quality of life outcomes. One (n=161) reported no difference between HD and PD in illness consequences or whether treatment controls the illness (both measured with the Brief Illness Perception Questionnaire).[64] Based on responses to the Treatment Effects Questionnaire, HD patients perceived more consequences of treatment than PD patients (P = .01).[64] Another study (n=528) reported that the effect of social support on mortality was similar for HD and PD patients.[65] A third study (n=228) reported a significant adjusted mean difference over time in physical quality of life (SF-36) favoring HD (1.6 [95% CI 0.04, 3.20], P = .04) but no difference in mental quality of life.[66]

Several longitudinal or cross-sectional studies, not included in the existing reviews, also provided quality of life outcomes. A longitudinal study from the UK reported no significant differences in SF-36 Physical Component, SF-36 Mental Component, or KDQOL Symptom scores at 6 or 12 months follow-up between HD and PD patients who were 70 years of age or

older at the start of dialysis.[58] One cross-sectional study from the UK reported scores for the Treatment Effects Questionnaire, Beck Depression Index, and Cognitive Depression Index.[22] No differences were noted between in-center HD and PD. A 2002 study from the UK found mixed results for different quality of life instruments.[67] On the EuroQol EQ-5D, differences between in-center HD and PD patients were not significant. Using the Kidney Disease Quality of Life instrument, patients receiving PD scored significantly higher on effects of kidney disease, burden of kidney disease, and cognitive function but lower for sexual function. On the SF-36, PD patients had higher scores for the mental component summary but not the physical component summary. A 1999 study from the UK (cited above in the in-center HD vs HHD analysis) reported scores on components of the SF-36.[23] Differences across groups (HHD, in-center HD, and PD) were noted for Physical Functioning, Role Physical, Social Functioning, and Role Emotional. The Canadian study (also cited above in the in-center HD vs HHD analysis) reported a non-significant difference between HD and PD in scores on the Self-Anchoring Striving Scale but significantly lower scores for HD vs PD on the Index of Well-Being and the Health State Utility/Time Trade-off assessment.[24] A study from the US reported that the risk of moderate to severe cognitive impairment for patients receiving either PD or in-center PD was significantly higher than that for patients age 55 and older without CKD.[68]

A second average-quality systematic review presented quality of life utilities.[69] Utilities represent the strength of a patient's preference for specified health-related outcomes with values ranging from 0 (death) to one (full health). Some studies included in the review assessed utilities directly. For others, utilities were derived from SF-36 scores. The review included patients ranging from pre-treatment CKD to kidney transplant; 69% of the utilities evaluated in the review were from studies of dialysis. The mean utility estimate for HD (including both in-center HD and HHD) was 0.69 (95% CI 0.59, 0.80) while the estimate for PD was 0.72 (95% CI 0.62, 0.83). Although 0.03 is considered to be the minimum clinically important difference for utility scores, the test for interaction was not significant (P = .08).

Studies of life participation activities were reported in a high-quality systematic review.[70] The activities of interest were physical function (*eg*, activities of daily living, self-reported physical functioning with the SF-36), travel abilities or restrictions, ability to engage in recreational or social activities, freedom (*eg*, perceived independence, ability to perform usual tasks), and work outcomes (*eg*, employment or working capacity). The review included English language cohort and cross-sectional studies published between 1980 and April 2012 and using a variety of outcome measures. For the comparison of HD and PD, there were 39 studies. Of 41 measures of physical function (some studies reporting more than one measure), only 10 showed a significant difference between HD and PD with 3 favoring HD and 7 favoring PD. Of 2 measures of travel, there was one significant difference favoring HD. There were 18 measures of recreation, 4 with significant differences favoring PD. Of 8 measures of freedom, one favored HD and one favored PD. Similarly, of 13 measures of work, 2 favored HD and 2 favored PD. The authors reported that the results were consistent across study designs, locations (US vs non-US), quality rating (appropriate adjustment for confounders vs no or minimal adjustment), and year of publication (1980-1990, 1991-2000, 2001-2012).

Change in Dialysis Modality (Appendix C, Table 1)

Seven registry studies reported changes in dialysis modality. A USRDS study reported that 6% of HD patients switched to PD and 57% of PD patients switched to HD during the 2 year follow-up period.[26] A second USRDS reported similar findings; over a maximum follow-up of 5 years,

4% of HD patients switched modality at least once compared to 46% of PD patients.[31] A Canadian study reported technique survival for PD and HD was similar up to 10 months follow-up.[39] After 10 months and through 60 months of follow-up, technique survival was lower for the PD group. Another Canadian study found greater risk of technique failure with PD compared to HD (186/1000 person-years vs 165/1000 person-years; RR 1.15 [95% CI 1.01, 1.31]).[41] In 2 European studies, 25% (over 3 years)[44] and 11% (over 7 years)[46] of PD patients switched modalities compared to 4%[44] and 1%[46] of HD patients. One study reported median time at the modality switch was 12 months for PD and 4 months for HD.[46] A third European study reported that 0.6% of HD patients and 0.9% of PD patients changed dialysis modality during the follow-up period of up to 5 years.[48] The modality change occurred at a median of 11 months for the HD to PD patients and at a median of 13 months for the PD to HD patients. In the CHOICE cohort study, 25% of the patients who were initially on PD switched modality at least once over maximum follow-up of 7 years compared to 5% of those who were initially on HD.[51] From the NECOSAD cohort, 2 year technique survival was 96% for HD patients and 74% for PD patients.[53]

Transplantation (Appendix C, Table 1)

Transplantation was reported in 6 registry studies. One USRDS study reported that transplant rates during the first 2 years of dialysis were 6% for HD and 18% for PD.[26] Another USRDS study reported the hazard ratio for renal transplant over up to 6 years follow-up (PD vs HD) was 1.48 (95% CI 1.29, 1.70).[27] A study from Canada also reported higher transplantation over a maximum of 5 years follow-up in PD compared to HD (RR 1.16, 95% CI 1.06, 1.28).[41] Two European studies found comparable percentages of transplants between PD and HD; 17.9% (PD) and 17.7% (HD) in a multinational study with maximum follow-up of 3 years[44] and 2.3% (PD) and 3.5% (HD) in a study from France with maximum follow-up of 7 years.[46] The mean time to transplant after start of RRT was 25 months for the PD patients and 22 months for the HD patients.[46] Another European study, with maximum follow-up of 5 years, reported lower transplantation in the PD group (0.4%, median time 9.5 months) than in the HD group (2.1%, median time 11 months).[48] In the NECOSAD cohort, 15% of the original HD cohort and 21% of the original PD cohort underwent renal transplant during a follow-up period of up to 4 years.[53]

Table 3. US Studies Included in Systematic Review (Boateng 2011)

Author, Year Modalities	Inclusion Criteria	Patient Characteristics	Quality of Life	Other Outcomes
Kutner 2000[60] PD, HD **Risk of Bias: High** **Selection bias:** inadequate **Blinding:** inadequate **ITT:** unclear **Attrition bias:** inadequate **Selective outcome reporting:** no	Age ≥20, started on HD or PD July 1996-August 1997, not cognitively impaired, able to communicate in English or Spanish	N=226 (154 HD, 72 PD) Age (yr): 56* Gender (% male): 53 Race (%): white 46, black 48 *PD patients were younger and less likely black	-Baseline SF-36 (mean of 67.3 days on dialysis): no significant differences between HD and PD patients for any of the 8 dimensions -KDQOL: being on PD was associated with higher "staff encouragement" (the extent to which the dialysis staff encourages the patient to be independent and supports the patient in coping with kidney disease) and "satisfaction with care" received for dialysis	PD patient (vs HD) associated with ability to complete a greater number of chair rise cycles (sit-to-stand-to-sit)
Diaz-Buxo 2000[61] PD, HD **Risk of Bias: High** **Selection bias:** inadequate **Blinding:** unclear **ITT:** unclear **Attrition bias:** unclear **Selective outcome reporting:** no	Fresenius Medical Care North America patient, completed SF-36 in 1996	N=18,015 (16,755 HD, 1,260 PD) Age (yr): 59* Gender (% male): 52 Race (%): white 54 *PD patients younger and more likely white	-SF-36 PCS: no difference between HD (33.3±10.4) and PD (33.7±10.6); no difference when adjusted for case mix or for case mix plus laboratory variables -Physical function dimensions: HD scores lower than PD for physical function (unadjusted) and bodily pain (unadjusted and adjusted); HD scores higher for general health (unadjusted) -SF-36 MCS: no difference between HD (47.5±11.7) and PD (47.9±11.6); better scores for PD after adjustment for case mix (P = .015) and case mix plus laboratory variables (P = .014) -Mental function dimensions: HD scores higher than PD scores for vitality (unadjusted and adjusted); HD scores lower than PD scores for role-emotional and mental health (unadjusted and adjusted) and social functioning (adjusted)	NR
Wu 2004[62] (CHOICE) PD, HD **Risk of Bias: High** **Selection bias:** inadequate **Blinding:** N/A **ITT:** yes **Attrition bias:** inadequate **Selective outcome reporting:** no	Age ≥18, able to speak English or Spanish, excluded HHD patients; oversampled PD patients	N=928 incident patients (698 HD, 230 PD) who completed baseline CHEQ (89% of total study sample) Age (yr): 58* Gender (% male): 53 Race (%): white (68), black (28), other (5)* *PD patients younger and more likely white	-585 completed CHEQ at 1 year -Adjusted mean change over 1 year: a. HD patients showed greater improvement in 8 domains of SF-36 compared to PD; only "physical functioning" and "general health" domains were significantly different from PD at 1 year b. HD patients showed significantly greater improvement in sleep domain of CHEQ; PD patients showed significantly greater improvement in finance domain -Adjusted ORs for improvement in health status (PD vs HD): SF-36 Physical Composite 0.79 (0.52, 1.20) SF-36 Mental Composite 0.95 (0.62, 1.45) CHEQ Global QOL 0.90 (0.56, 1.45)	NR

CHEQ = CHOICE Health Experience Questionnaire; KDQOL = Kidney Disease Quality of Life instrument; MCS = mental health component summary; N/A = not applicable; PCS = physical component summary

Adverse Events (Appendix C, Table 4)

A report from the NECOSAD cohort identified adverse events.[71] Incidence rate ratios (HD vs PD) for the study period (maximum follow-up of 10 years) were 1.65 (95% CI 1.34, 2.03) for total infections, 4.10 (95% CI 3.06, 5.58) for dialysis technique-related infections, and 0.56 (95% CI 0.40, 0.79) for non-dialysis technique-related infections. A longitudinal study (mean follow-up 1.3 years) from Canada with 369 patients reported fewer access-related invasive interventions in the PD group than the HD group (1.0 vs 1.4 per patient-year; Rate Ratio 0.72 [95% CI 0.53, 0.96]).[72] A US study with 181 patients found no difference between HD and PD in median total infections per time at risk or infection rate per year at risk.[56] There was a higher bacteremia/fungemia infection rate in the HD group and a higher peritonitis rate in the PD group (both $P < .001$). A longitudinal study (follow-up of up to 19 months) from the Netherlands reported pancreatitis in one HD patient (0.4%) and 7 PD patients (5.4%) ($P < .001$).[73] A study from Belgium with a 10 year follow-up period reported reasons for switching dialysis modalities.[74] Among 35 patients who switched from HD to PD, cardiovascular problems were reported by 40%, access problems by 25%, and blood pressure problems by 12%. Among 32 patients who switched from PD to HD, peritonitis or exit-site infections were reported by 50%, adequacy and/or ultrafiltration problems by 25%, and extraperitoneal leakage of dialysis fluid by 11%. A cross-sectional study from the UK reported gastrointestinal symptoms.[75] Both HD and PD patients experienced a higher rate of symptoms compared to hospital outpatient controls and community controls with abdominal pain in 72% of HD patients and 65% of PD patients, laxative use in 43% of HD patients and 79% of PD patients, and irritable bowel syndrome in 21% of HD patients and 33% of PD patients.

Peritoneal Dialysis Compared to In-Home Hemodialysis

Two studies provided a comparison of PD and HHD.[9,14] One study was from the US[9] and the other from England and Wales.[14] Enrollment years and follow-up durations were similar ranging from 1995 to 2005 and 9 years, 3 months to 10 years, respectively. Sample sizes differed with the US study including 38,894 incident patients (1,641 out-of-center HD [mostly home])[9] and the UK study including 1,125 incident patients (225 HHD).[14] In the US study, HHD patients were more likely non-white compared to PD patients[9] while in the UK study, HHD patients were more likely white.[14] Both studies used Cox proportional hazards models with an intent-to-treat approach.

The US study found no significant difference in mortality risk between the 2 modalities (HR 1.04 [95% CI 0.98, 1.11]) (Table 4 and Appendix C. Table 1).[9] The UK study reported a significant survival benefit associated with HHD (HR 0.61 [95% CI 0.40, 0.93]).[14] The benefit was observed after adjustment for patients from the HHD group being more likely wait-listed for kidney transplant.

Neither of the studies reported interactions with age, gender, race, BMI, diabetes, cardiovascular disease, or duration of ESRD therapy, although the US study did note that the results did not differ among patients more likely to reside at home (based on age, ability to ambulate and transfer independently, and diabetes and/or cardiovascular disease) or more likely to reside in a long-term care facility.[9]

Table 4. Mortality – Home Hemodialysis (HHD) versus Peritoneal Dialysis (PD) – Registry Data

Country/ Region: Number of Reports	Study Years	Patients: Number of Reports or Sample Size	Overall Mortality: Number of Reports			Number of Studies Reporting Effects by:						
			No difference	Favor PD	Favor HHD	Age	Gender	Race	BMI	DM	CVD	ESRD Duration
REGISTRY STUDIES												
USA: 1	1995-2004	Incident: 1	1									
UK: 1	1997-2005	Incident: 1			1							

Other Outcomes

Cardiovascular Events, Hospitalization, Quality of Life, Cognition, Depression, Transplantation

Neither of the studies reported these outcomes for HHD compared to PD.

Change in Dialysis Modality (Appendix C, Table 1)

As noted above in the section describing studies comparing HHD to in-center HD, the study from the UK reported that median technique survival for HHD was 18 month (IQR 9 to 33 months).[14] Most patients underwent a kidney transplant or switched to in-center HD.

KEY QUESTION 2A. Do results differ depending on whether peritoneal dialysis was the initial therapy or the therapy used following failed in-center dialysis?

A prospective cohort study from Spain enrolled 489 incident PD patients.[76] Average follow-up was 13.4 months. Ninety-five (19%) had started dialysis on HD. The mortality rate was higher in patients that changed from HD to PD compared to those who initiated RRT with PD (11.5% vs 4.6%, P = .009). In a longitudinal study from Poland, 264 PD patients (67 of whom transferred to PD after a median of 18 months [range 3-268] on HD) were followed for a median of 21 months.[77] No significant difference was observed in survival for the transferred patients versus the initial PD patients (RR 1.68 [95% CI 0.87, 3.22]). The result was similar for the combination of patient and technique survival (RR 1.45 [95% CI 0.89, 2.37]). A registry study from the US with 40,869 patients and follow-up of one to 4 years reported that survival was higher for patients who initially received PD compared to those who transferred from HD.[78] At one year, the percentage of patients surviving was 86.7% in the initial PD group compared to 83.9 in the transfer to PD group. At 4 years, the values were 56.7% and 53.1%, respectively. The hazard ratio for patient survival for patients new to dialysis versus transfer from HD was 0.73 (P < .0001). It was noted that duration of ESRD was likely longer for the patients transferring from HD. Technique survival was longer for the initial PD patients. The hazard ratio for technique survival (new to dialysis versus transfer from HD) was 0.79 (P < .0001). Patients new to dialysis were more likely to undergo transplantation (HR 1.31, P < .0001). Details of these studies are presented in Appendix C, Tables 4-6.

Risk of Bias for Key Question 2

As noted for Key Question 1, we did not assess the risk of bias of individual registry studies. Registry studies are typically considered high risk of bias due to issues with selection bias and inability to assess and include all potential confounders in analyses. There was one high risk of bias RCT that addressed KQ2. Of 8 clinical cohort reports, 4 were rated as high risk of bias and 4 as moderate risk of bias. There were 7 longitudinal studies – 2 high risk of bias and 5 moderate risk of bias. All of the cross-sectional studies (k=6) were rated high risk of bias. Additional information is presented in Appendix C, Table 2.

KEY QUESTION 3. What are the a) health care system, b) provider, and c) patient factors associated with selection of and technique survival for home-based dialysis (including peritoneal dialysis)?

Summary of Findings

- Twenty-two articles (21 studies, 8 from the US) provided information on factors associated with selection of PD and 5 articles (none from the US) addressed factors associated with selection of HHD.

- For PD selection, the following factors were reported:

    - *Health Care System Factors:* One US cross-sectional study reported that provision of home-based dialysis (including PD) was more likely in larger dialysis facilities (defined as 62 patients or more) with more years of facility Medicare certification and facilities with a higher population of employed 18 to 54 year old patients. Home-based dialysis was less likely at facilities in more rural areas, facilities offering evening care, and facilities with higher treatment capacity (based on number of patients, number of HD stations, and availability of a late shift).

    - *Provider Factors:* Several studies found that provision of patient education about dialysis modalities and a determination of medical (including comorbid conditions and decreased strength, manual dexterity, vision, or hearing) and psychosocial suitability (including fear of self-cannulation, anxiety, decreased cognition, psychiatric conditions, or history of non-compliance) for PD were associated with greater selection of PD. No studies reported on provider factors such as provider age, training, knowledge about PD, etcetera.

    - *Patient Factors:* Autonomy, ability to travel, and compatibility with employment were identified as positive features of PD. Conversely, lack of understanding, living alone, lack of space in the home, inability to perform PD in the place of residence, fear of social isolation, fear of inability to perform PD, and preference for medical supervision were patient barriers to selection of PD.

- For HHD, the following factors were reported:

    - *Health Care System Factors:* As noted above, dialysis facility size, geographic location, and years of certification were all factors in provision of any home-based dialysis.

    - *Provider Factors:* From a provider perspective, patients with medical contraindications, psychosocial contraindications), unsuitable living conditions (including HHD not permitted, overcrowding, dampness/mold growth), lack of support in the home, and unplanned start or shorter pre-dialysis care by a nephrologist were less likely to be suitable for HHD. Providers with greater numbers of HHD patients reported having a dedicated education team.

- *Patient Factors:* Patient-reported barriers to and advantages of HHD were similar to those noted above for PD.

- Fifteen studies (8 from the US) reported factors associated with PD technique failure (the inverse of technique survival – a switch from PD to in-center HD):
  - *Health Care System Factors:* Patients from larger clinics had lower technique failure.
  - *Provider Factors:* No studies reported on provider factors associated with PD technique survival.
  - *Patient Factors:* African-American or indigenous race, increased BMI or obesity, elevated systolic blood pressure, use of HD before switching to PD, and peritoneal dialysis catheter problems were associated with higher rates of technique failure but each factor was reported in 4 or fewer of the 14 included studies. Mixed results were found for presence of diabetes, age, gender, distance from clinic/nephrologist, and need for assisted PD.

- Five studies (none from the US) reported factors associated with HHD technique failure:
  - *Health Care System Factors:* No studies reported on health care system factors associated with HHD technique survival.
  - *Provider Factors:* No studies reported on provider factors associated with HHD technique survival.
  - *Patient Factors:* Interference with home life, lack of carer support, caregiver anxiety, inability to perform cannulation, medical issues (including diabetes and access problems), and increased age were associated with increased technique failure in 4 studies; one identified no significant predictors of technique failure. Another study reported no difference in a composite outcome of time to all-cause hospitalization, technique failure, or death in patients categorized as dependent on or independent of assistance with nocturnal HHD.

Health Care System Factors (Appendix C, Table 5)

One study reported on facility factors associated with the provision of home-based treatment (either HHD or PD).[79] The cross-sectional study, done in the US, surveyed 4,653 dialysis facilities. Overall, 7.1% of patients (range across facilities 0% to 100%) were on home-based dialysis. Higher provision of home-based dialysis was associated with larger dialysis facilities (≥ 62 patients vs < 62 patients), more years of facility Medicare certification, a higher percentage of employed patients, and a higher percentage of patients between ages 18 and 54 years. Lower provision of home-based dialysis was associated with more rural location, location in a geographically larger zip code area, location in a zip code of high population density, facility offering a shift starting at 5 pm or later, facility that is part of a chain, facility with higher treatment capacity (determined by number of patients, number of stations, and presence or absence of a late shift), and higher percentage of black patients. “For-profit” status was not significantly associated with home-based dialysis. Lack of resources to support home-based

dialysis in smaller, more rural areas and unmeasured confounding factors may account for these findings.

Another study provided information on training time.[80] All 87 patients in the study received training on HHD; those randomized to nocturnal HHD underwent additional training. Eight patients were excluded from the analysis of training time. The mean number of training sessions was 28 (range 11 to 59) but no significant difference was noted in training time required for conventional HHD versus nocturnal HHD. Less training time was needed for patients with experience in self-care or both self-care and cannulation while a higher comorbidity score and higher age were related to increased training time required. Training time needed was not related to tests of cognition, education level, or SF-36 Physical Function.

Provider Factors/Provider Perspective (Appendix C, Table 5)

Peritoneal Dialysis

Selection

An Australian study asked nephrologists and chronic kidney disease (CKD) coordinators about information provided to CKD patients prior to selecting a dialysis modality.[81] Among 588 patients who progressed to dialysis, 17.5% did not receive information about treatment options. Patients known to the nephrologists for more than 3 months and patients treated at smaller renal units (< 100 patients) were more likely to receive information. Reasons for not providing information about PD included medical/surgical contraindications, unsuitable living conditions, low literacy, psycho-social contraindications, refusal by patient or family, option not available via service provider, and acute presentation.

A multidisciplinary team (nephrologist, pre-dialysis nurse, PD nurse and/or acute care nurse, social worker) determined contraindications, barriers to self-care, and availability of support in the home for 497 Canadian ESRD patients who had already undergone a minimum of one dialysis treatment.[82] Medical (obesity, abdominal scarring, ascites, diverticulitis, abdominal hernia) and social (residence or work did not permit PD) contraindications to PD were identified for 110/497 (22%). Barriers to self-care were identified for 245/387 (63%). Patient with barriers were older, more likely female, of lower weight and BMI, more likely to have a cardiovascular condition or cancer, and more likely to have started dialysis as an inpatient and at a higher eGFR. Barriers were categorized as physical (decreased strength, manual dexterity, vision, or hearing, immobility, poor health, or poor hygiene) or cognitive (language, history of non-compliance, psychiatric condition, dementia/poor memory). Among patients with barriers to self-care, those with family support were more likely to be eligible for PD (OR 3.1 [95% CI 1.6, 6.1]) and more likely to utilize PD (39% vs 23%, P = .009).

An earlier study from the same research group also used a multidisciplinary team to identify medical, psychological, and social conditions that could be barriers to PD.[83] A control group was included and consisted of patients who lived in regions without home care support. Of the 134 incident patients enrolled, 108 (81%) had at least one medical (decreased strength, manual dexterity, vision, or hearing, or immobility), psychological (anxiety, decreased cognition, psychiatric condition, history of non-compliance) or social (living alone and requiring assistance, residence or nursing home doesn't permit/support PD) barrier to PD. Each condition acting as a barrier reduced the odds of being eligible for PD. There was no difference in the likelihood of

choosing PD or the utilization of PD based on the availability of home care. Female patients and those receiving pre-dialysis care (at least 4 months of nephrology care) were more likely to choose and utilize PD. Patients living in a region with home care assistance, choosing PD, and consenting to follow-up had a mean rate of 4.6 home care visits per week. There were no differences in hospitalizations, modality switches, or deaths among patients receiving assisted PD compared to other dialysis modalities.

Nephrologists of 1,347 patients in the NECOSAD cohort were asked to provide information on patient contraindications for either PD or HD.[84] Among 225 patients with medical contraindications to PD, previous major abdominal surgery was the most common (38%) followed by cystic kidneys (7%), poor lung function (6%), chronic inflammatory bowel disease (4%), poor cardiac condition (4%), obesity (2%) and "other" (30%). Of 46 patients with medical contraindications to HD, poor cardiac condition was identified for 52%, acute start to dialysis for 7%, and "other" for 41%. There were 150 patients with social contraindications to PD. Most common was incapable of performing PD exchanges themselves (77%) with "other" for 23%. There were 4 patients with social contraindications to HD, all classified as "other."

Another study provided nephrologists with patient scenarios and asked whether they would recommend HD or PD.[85] Responses from 271 nephrologists (53% response rate) were analyzed. The mean age of the nephrologists was 46 years, 85% were male, and 72% were white. Thirty-five percent responded that they were equally trained in HD and PD while 61% were trained mostly in HD. Based on the scenarios, the nephrologists were significantly more likely to recommend PD for males, patients 51 to 65 years (compared to 30 to 50 years), patients who were compliant with treatment, patients with residual renal function above 250 ml/d of urine, and patients with an ejection fraction above 25%. They were less likely to recommended PD for patients with weight of 200 pounds or greater, patients with diabetes, and patients living alone. Race or HIV status did not independently influence the modality recommendations. Several conditions were not incorporated into the scenarios and were addressed separately. The percentage of nephrologists recommending HD over PD for different conditions was as follows: inflammatory bowel disease (96%), substance abuse (94%), malnutrition (93%), pregnancy (83%), hepatitis (40%), and myocardial infarction (33%). Ninety-eight percent of nephrologists rated patient involvement as extremely or very important followed by the nephrologist (91%), nurses and social workers (70%), family (65%), and other clinicians (12%).

A study from Canada identified reasons why patients were directed to a particular modality (PD or HD).[86] Of 150 patients, HD was recommended for 31 for social reasons (65%), unusable abdomen (29%), awaiting liver transplant (3%), or age (3%). PD was recommended for 14 patients due to cardiovascular disease (71%), difficult vascular access (21%), or residence too far from center (7%). PD was also recommended for 31 patients because they were diabetic. Fifty-five percent chose PD and 45% chose HD, primarily for social reasons. There were 74 patients with no specific condition and who were allowed free choice. Fifty percent chose HD and 50% chose PD. There was no gender preference for HD or PD.

Home Hemodialysis

Selection

A recent study reported results from survey of health practitioners who visited the Nephrology Dialysis Transplantation-Educational Web site.[87] The majority (61%) of responses were from Europe with 8% from North America. Among those who reported having HHD patients, the median number was 6 (range 1-150). Practitioners from dialysis units with more than 6 HHD patients were more likely to have a dedicated education team, more likely to place patients' choice of modality above all other factors, more likely to offer choice of HHD at all stages of CKD, and more likely to believe the evidence supporting extended dialysis schedules. Practitioners from facilities that had HHD patients were more likely to see no financial disadvantage, were more likely to believe the evidence for extended HHD, and had higher expectation of the proportion of patients who could do HHD.

The principal investigator and study coordinator from each of the 8 sites of the FHN Nocturnal Trial (nocturnal HHD compared to conventional HD) were asked to complete a survey focused on barriers to HHD.[80] The most common perceived barriers to patients electing to choose HHD (reported by > 66% of respondents) were lack of motivation, patients comfortable in-center, fear of self-cannulation, fear of needles falling out or catheter disconnecting, fear of inability to sleep during nocturnal dialysis, high level of comorbid disease, lack of family/partner support, fear of machine, and fear of inability to learn procedures. Home renovation costs were subsidized by outside sources so were not perceived as a barrier. The most common perceived incentives (reported by > 66% of respondents) were flexible scheduling, flexible prescription, less travel to dialysis unit, more liberal diet (with nocturnal HHD), partner encouragement, influence of other HHD patients, more privacy, putative improvement in well-being, and dissatisfaction with current therapy.

A survey of nurses from one health network in Canada included both home dialysis nurses (HHD, PD, and pre-dialysis clinic) and HD nurses.[88] The home dialysis nurses thought HHD was strongly preferred for working patients or students. The in-center HD nurses thought HD was strongly preferred for patients with poor socioeconomic status, multiple chronic illnesses, and no caregiver or social support. Home dialysis nurses thought that HHD benefited patient quality of life and survival and was lower in cost for patients and the healthcare system. HD nurses thought that HD was preferred for lower risk of catastrophic events. Physicians were rated as having the most influence on patients' choice of modality by 87% of the home dialysis nurses and 57% of the HD nurses.

The Australian study of information about treatment options (cited above in the PD section) also provided information about HHD.[81] Reasons for not providing information about HHD included medical/surgical contraindications, unsuitable living conditions, low literacy, no social/community support at home, psycho-social contraindications, and patient/family refusal. HHD patients were more likely known to the nephrologist for 3 months or longer and more likely to have a caregiver with them at information sessions.

Patient Factors (Table 5 and Appendix C, Table 5)

Peritoneal Dialysis

Selection

An RCT (n=70) from Canada compared outcomes following an educational intervention (written manuals, videos, small group session) or standard care.[89,90] The goal of the intervention was to increase patient selection of self-care dialysis defined as PD, HHD, and self-care HD. At baseline, there was no significant difference between the groups in the percentage of patients intending to start self-care dialysis. At completion of the study, the difference was significant (82% of the intervention group, 50% of the control group; P = .015).[89] Among those who were uncertain at baseline or who planned to start with HD, 64% of the intervention group and 17% of the control group (P = .01) planned to start self-care dialysis at the end of the intervention period. Participation in the intervention group was associated with increased odds of choosing self-care (OR 10.2 [95% CI 2.0, 50.3], P = .004).[89] Of the 12 patients who started dialysis during a mean follow-up of 339 days, 2 patients died and 2 of 3 intervention group (4 of 7 control group) patients started with self-care dialysis.[89] Additional analyses identified patient-reported perceived advantages of self-care dialysis.[90] The advantages were categorized as "freedom," "lifestyle," and "control." Freedom and lifestyle were significantly associated with intended choice of self-care dialysis (OR 9.1 [95% CI 2.0, 41.3], P = .004 for freedom; OR 7.0 [95% CI 1.6, 29.7], P = .008 for lifestyle). The perception of no advantage of self-care dialysis was associated with reduced odds of selecting that modality (OR 0.06 [95% CI 0.01, 0.24], P < .001). In the intervention group (but not the control group) there was an increase in the percentage identifying freedom and control as advantages and a decrease in the percentage reporting no advantage.[90] An earlier report of a cross-sectional survey of patients attending a progressive renal insufficiency clinic (active promotion of self-care dialysis) categorized barriers to self-care as knowledge, attitudes, and skills.[91] For knowledge, lack of explanation of self-care and lack of understanding were the most frequently identified barriers. In the attitudes category, fear of social isolation, concerns about being unsupervised, lack of self-efficacy in performing self-care, and fear of substandard care were identified. Needle phobia, lack of space at home, and visual impairment were cited.

A study from Austria compared patients who voluntarily chose to attend a 2-day pre-dialysis education program to a standard care group.[92] Of 70 patients from the education group who progressed to dialysis during the study period, 32 (46%) chose HD and 38 (54%) chose PD. Of 157 standard care patients who progressed to dialysis, 113 (72%) chose HD and 44 (28%) chose PD. The odds ratio for choosing PD following participation in the education program was 3.35 (95% CI 1.82, 6.14).

One US study compared a treatment options program (TOPs) to standard information in a non-randomized trial.[93] One analysis included 30,217 incident patients, 20.057 of whom attended TOPs. A second analysis included 2,800 matched pairs (TOPs or standard education matched on age, gender, race, diabetes, and geographic area). Of the 20,057 TOPs attendees, 27% chose in-center HD, 24% chose home-based HD, 13% chose transplant, 0.2% chose no therapy, and 35% did not make a choice. Follow-up data were available for 5,565. Twenty-five percent started a home-based dialysis therapy (predominantly PD). Among patients who did not attend TOPS, 3% started a home-based dialysis therapy. It was noted that TOPs attendees were younger, more

likely white, and had fewer comorbid conditions. Of the 2,800 matched pairs, 24% of TOPs attendees and 4% of non-attendees chose PD (OR 7.73 [95% CI 3.26, 18.32]).

Participants in the CHOICE study were asked to complete a survey about satisfaction with dialysis care.[94] The analysis focused on patients from centers that offered both HD and PD. PD patients were more likely to rate as "excellent" the amount of information they received on choosing HD or PD (relative probability 2.65 [95% CI 2.21, 3.02]) and the amount of dialysis information (relative probability 2.07 [95% CI 1.78, 2.32]).

A recent retrospective cohort study from Canada identified reasons for not choosing PD after expressing an intention to initiate PD.[95] PD was actually initiated by 59% of those who expressed an intention to initiate PD. Patient reasons included preference for hospital-based treatment (37%) and lack of space in home (1.6%). Medical reasons included an acute start to dialysis (37%), abdominal surgeries (8%), hernia (3%), and obesity (2%).

A prospective cohort study from France reported outcomes from patients who expressed a preference for PD or HD.[96] HHD was not an option in the region of France where the study took place. Of 177 patients who received information on dialysis modalities prior to starting dialysis, 82 (46%) preferred PD. Forty-five of these patients went to RRT with 21 (47%) receiving PD. Of 49 patients preferring HD, 33 went to RRT with 32 (97%) receiving HD. Of 34 patients who were undecided, 11 went to RRT with 9 (82%) receiving HD. Twelve patients were reluctant to undergo dialysis. Three went to RRT with all receiving HD.

A separate group of 51 patients in this study had been on HD for less than one month at the time of the information sessions having received no formal information prior to starting on HD.[96] Fourteen of these patients (27%) preferred PD and, of 12 patients alive at 3 months, 4 (33%) had switched to PD. Twenty-six preferred to stay with HD and 25 were alive at 3 months. Eleven were undecided but all stayed with HD and were alive at 3 months. Reasons for preferring PD included ability to receive treatment at home, autonomy, comfort to travel, and employment compatibility. Reasons for preferring HD included treatment in a medical facility, autonomy, socioeconomic criteria, socializing/security, and reluctance to have an intra-abdominal catheter. Mismatches between preference and treatment were noted only for 29 patients who expressed a preference for PD. The mismatches were due to medical causes (predominantly abdominal contraindications) in 48% and other causes (including medical center transfer, adverse opinion of family or employer, and change of opinion) in 52%.

A survey of patients in the UK who had already made a modality choice following an education program reported differences between HD (n=82) and PD (n=24) patients.[97] The PD patients were younger than the HD patients, had lower comorbidity scores, and were more likely married and employed or in school, and less likely living alone. Patients who chose PD identified the following factors as significantly more important than did the patients who chose HD: receiving written information on the modality, the modality fitting with lifestyle, and family/home/work circumstances. Patients who chose HD scored past medical history significantly more important than did the patients choosing PD.

A study from Italy looked at time of referral relative to start of dialysis (≤ 3 month or > 3 months) and, for patients referred more than 3 months before dialysis, the effects of a unstructured pre-dialysis clinic versus a formal multidisciplinary pre-dialysis care program.[98]

Patients at the study centers were encouraged to consider PD if they had no major clinical or psychological contraindications or personal unwillingness. Participation in modality selection was less common for patients referred 3 months or less before dialysis (63% vs 78%, P = .015) as was choice of PD (30% vs 48%, P = .006). There was no difference in participation in selection or choice of PD between patients receiving standard pre-dialysis care or multidisciplinary care. More patients receiving multidisciplinary pre-dialysis care had a planned dialysis start compared to those receiving standard care (91% vs 39%, P < .001) and choice of PD was higher in those with a planned start (56% vs 24%, P < .001).

A before and after study from the US evaluated the effect of a comprehensive infrastructure change in dialysis care.[99] All patients were invited to visit both HD and PD unit, received information booklets and films, and were encouraged to discuss dialysis with current patients. The intervention included nephrologist placement of PD catheters, identification and training of family members or nursing home staff, increased social support, early ESRD education, and provision of in-center intermittent PD for selected patients. Individual elements of the program were evaluated. There were significant increases in the number of PD patients following training of nursing home staff, training of family members and providing support, early ESRD education, improving home conditions, and nephrologist catheter placement. The percent of patients choosing PD increased from 19% to 76% (P = .001) and the percent of dialysis patients at the facility who were on PD increased from 16% to 40%.

In the study from Spain (reported above), patients who received PD by their choice had lower mortality than those forced to accept PD for medical reasons (3.5% vs 20.4%, P < .001).[76] The peritonitis rate was also lower (0.46 vs 0.82 per year at risk, P < .05).

Findings from an interview with 188 HD and PD patients who began dialysis at least 3 months prior found no significant difference in "depressed mood" (Beck Depression Index score > 9) but higher quality of life (General Health Perceptions score ≥ 70) in HD patients compared to PD patients.[100] There were no differences across modalities in patients reporting negative effects of their current dialysis modality for aspects of daily life (ability to perform daily tasks, ability to control your life, relationships, getting needed sleep, anxiety, or interest in sex). There was a difference in feelings about how you look with a higher percentage of CCPD patients reporting a negative effect compared to either CAPD patients or HD patients. Using a time trade-off format, approximately 38% of HD patients would switch to CAPD if it increased survival time by 20%; approximately 66% would switch for a 100% increase. Similar values were reported for CAPD and CCPD patients in regard to switching to HD.

Choice of PD or HD was reported for patients from the NECOSAD cohort.[84] Of 1,346, 864 (64%) made their own choice (52% HD, 48% PD). The choice of HD was significantly more likely for age groups 55 to 65 years, 65 to 70 years, and 70 years and older compared to 18 to 40 years. There was no significant difference for patients 40 to 55 compared to 18 to 40 years. Females and patients living alone were significantly more likely to choose HD while patients with greater serum albumin and who received pre-dialysis care were more likely to choose PD. Technique survival at 12 months for patients who chose their dialysis modality was 93% for HD patients and 74% for PD patients. At 24 months, the corresponding values were 91% and 62%.

Two studies from the US looked at factors associated with choice of PD as initial dialysis modality.[101,102] In a study of 2,344 incident HD and 670 incident PD patients, black or "other"

race (vs white), lower socioeconomic status, and older age (65 to 74 years vs 45 to 54 years) were associated with decreased likelihood of selecting PD. Gender, renal diagnosis, and timing of referral were not significant predictors.[101] In an earlier study of over 10,000 patients, African American race (vs white), age 20 or older (versus under 20 years), moderately or severely impaired functional status (vs normal), 12 or fewer years of education, and not being a home owner were associated with decreased choice of PD.[102] Employment or student status and living with family members were associated with increased use of PD although in a multivariable analysis, the association was not statistically significant. Gender was also not a significant predictor of choice.

Technique Survival

Fourteen studies presented data on factors associated with technique survival for PD.[78,103-115] One additional study reported change in technique survival over time comparing data from patients initiating PD between 1995 and 2000 with data from patients initiating PD from 2006 and 2009.[116] Additional study information is presented in Appendix C, Table 6.

Eight studies were from the US,[78,103,106,108-110,113,115] 2 from the Netherlands,[107,114] 2 from Canada,[111,116] and one each from Australia/New Zealand,[112] France,[104] and Ireland.[105] Sample sizes ranged from 118[114] to 41,197.[113] There were 7 registry studies,[78,103,104,111-113,116] 4 reports from prospective clinical cohort studies,[107,109,110,114] and 4 retrospective studies, each from a single center.[105,106,108,115] Follow-up times ranged from 1 to 9 years. Across the studies, the patient populations were similar with the exception of one study that enrolled only patients 75 years of age or older. In the remaining studies, mean ages ranged from 50 to 68 years and 49% to 65% were male.

Technique failure was defined in most studies as a switch from PD to HD. Four studies identified switches of 30 days or more[103,109,110,112] while others included switches of 60[104,113] or 90 days or more.[111,116] Five studies did not specify a duration of HD.[78,105,106,114,115] One study defined failure as a permanent switch to HD or death on PD.[107] Another study assessed catheter failure (removal of a dysfunctional PD catheter).[108]

Factors associated with technique failure are summarized on Table 5; more detailed information can be found in Appendix C, Table 6. Increased BMI or categorization as obese was associated with higher rates of technique failure in 3 of 4 studies evaluating that factor.[109,112,113] Increased systolic blood pressure (2 studies reporting)[103,114] and catheter problems (2 of 3 studies reporting)[108,112] were also associated with higher rates of technique failure. African-American race was associated with increased technique failure in 3 of 5 studies that reported results by race[103,109,115]; a sixth study observed increased technique failure in the indigenous population of Australia/New Zealand.[112] Findings were mixed for presence of diabetes, age, gender, PD type, and geographical distance to the clinic/nephrologist. A small US study found no difference in technique failure based on distance[109] while a large Canadian study found lower technique failure with increased geographical distance from the nephrologist.[111] The authors noted a slightly higher mortality risk among remote-living PD patients. One study reported higher technique failure in patients with cardiovascular disease and in patients with lower eGFR.[107] Patients from larger dialysis centers had lower rates of technique failure in 2 US studies.[78,110] Need for assisted PD was associated with decreased technique failure in a large study from France[104] but not in a smaller study from Ireland.[105]

The temporal study found a lower adjusted risk of technique failure among patients initiating PD between 2001 and 2005 compared to the 1995 to 2000 group (HR 0.89 [95% CI 0.82, 0.98]).[116] There was no significant difference between the 2006 to 2009 group and the 1995 to 2000 group (HR 0.95 [95% CI 0.85, 1.06]). Among patients older than 65 years, there was a lower risk of technique failure for both of the more contemporary groups compared to the 1995 to 2000 group.

Home Hemodialysis

Selection

Not all patient homes are suitable for HHD. An observational study from the UK reported on findings after visits to the homes of 249 patients who were medically suitable for HHD.[117] One-third of the homes did not meet the Decent Home Standards. Hazards to health/well-being included overcrowding (57%), dampness/mold growth (33%), inadequate facilities for sanitation and drainage (17%), risk of structural collapse (10%), inadequate domestic hygiene, pests, and refuse (8%), inadequate facilities for storing and preparing food (8%), and inadequate supply of uncontaminated water (3%). Due to spatial, health, and safety concerns, 30% of the homes were not suitable for either HD or PD.

A Canadian study of 236 patients initiating HHD or PD looked at differences between HHD and PD patients.[118] HHD patients tended to be male (70% vs 50%, P = .05), were younger (46 vs 62 years, P < .001), were less likely to have diabetes (24% vs 45%, P = .003), and had a longer delay between first renal replacement therapy and the start of HHD (4.8 years vs 0.34 years, P = .002).

Another Canadian study compared HHD patients (n=15) to PD (n=79) and in-center HD (n=59) patients.[119] HHD patients were younger, had a lower BMI, and were more likely working than either PD or in-center HD patients (all P < .05). HHD patients were more likely English-speaking than HD patients. There were no differences in eGFR or comorbidity index values at the start of dialysis. Patients reported not choosing HHD because of disinterest (25%), lack of social support (25%), inadequate space (5%), communication issues (5%), and inability to perform own dialysis (3%).

A third study from Canada surveyed 66 nocturnal HHD patients and 199 HD patients with no contraindications or other factors limiting ability for HHD.[120] The surveys were completed by 85% of the HHD patients and 77% of the HD patients. The nocturnal HHD patients were significantly younger, less likely to have diabetes, and had a higher physical quality of life (SF-12). There was no difference in gender, the mental component of the SF-12, perceived ability for self-care, perceived social support, or anxiety. HHD patients were more likely to be comfortable with self-cannulation, believe they will receive as good care as with HD, believe they can properly perform nocturnal HHD, and be less fearful of a catastrophic event.

Table 5. Overview of Factors Evaluated for Technique Failure (Switch from PD to In-center HD)

Study (N) Country	African American/ Race	↑ BMI or Obesity	Diabetes	↑Systolic BP	CVD	↓GFR	↑ Age	Gender	Catheter problems	CAPD (vs APD)	Other
Shen 2013[103] (1587) USA	↑			↑				↓ female			↑Disabled ↑On Medicare ↔Others
Lobbedez 2012[104] (9882) France			↔				↓	↑			↓Assisted PD (vs self-care) ↑HD before PD
Smyth 2012[105] (148) Ireland							↔		↔		↔Etiology of ESRD ↔Catheter method ↔Comorbidities ↔Assisted PD
Taveras 2012[106] (235) USA	↔						↑	↔			
Kolesnyk 2010[107] (709) Netherlands			↑		↑	↑	↑			↔	
Singh 2010[108] (315) USA	↔	↔	↔				↔	↔	↑		
Jaar 2009[109] (262) USA	↑	↑	↔				↔				↔Geographical distance to clinic ↔Others
Plantinga 2009[110] (236) USA											↓Clinic with > 50 PD patients
Tonelli 2007[111] (26,775) Canada											↓Geographical distance to nephrologist
Mujais 2006[78](40,869) USA			↑				↑			↑	
McDonald 2003[112] (9440) ANZ	↑ Indigenous	↑					↔		↑		
Snyder 2003[113] (41,197) USA		↑									
Jager 1999[114] (118) Netherlands				↑							↓Urine volume ≥1000 mL/24hr ↓Peritoneal ultrafiltration
Korbet 1999[115] (233) USA	↑										

ANZ = Australia/New Zealand; APD = ambulatory automated peritoneal dialysis; BMI = body mass index; BP = blood pressure; CAPD = continuous ambulatory peritoneal dialysis; CVD = cardiovascular disease; eGFR = estimated glomerular filtration rate; ESRD = end stage renal disease; PD = peritoneal dialysis

↑ = Significantly associated with higher rates of technique failure; ↔ = Not associated with higher rates of technique failure; ↓ = Significantly associated with lower rates of technique failure

Technique Survival (Appendix C, Table 6)

A prospective cohort study from the UK identified 142 HHD survivors and 24 who switched from HHD.[121] In a multivariate analysis, only comorbid diabetes was a significant predictor of technique failure (HR 3.96 [955CI 1.66, 9.49]). Patient-reported reasons for switching modalities (provided by 11 of 18 patients who were alive at the end of the study period) included family dynamics (20%), lack of carer support (17%), lack of confidence with procedure (15%), interference with home life (15%), and medical issues including access (12%).

A retrospective study from Canada included data from 177 patients (145 successful, 32 failures) who initiated training for nocturnal HHD.[122] The study site had a "home-first" policy whereby only patients with absolute contraindications were not invited to trial for HHD. In a multivariable analysis, ESRD due to diabetes and renting current residence were significantly associated with failure. The most common reasons for failure associated with training for HHD included inappropriate housing, deteriorating medical status, inability to cope with burden of HHD, non-adherence, and test failure. The most common reasons for technique failure included deteriorating medical status, inability to cope with burden of HHD, change in residence, inadequate family support, caregiver anxiety, and inability to perform cannulation.

A second report from the same study site looked at differences in outcomes between patients characterized as dependent (partially or totally n=47) or independent (n=152) based on need for assistance with nocturnal HHD.[123] The adjusted hazard ratio for a composite outcome of time to all-cause hospitalization, technique failure, or death was not significant (HR 1.25 [95% CI 0.76, 2.04]). The need for back-up dialysis runs at an in-center or training facility did not differ between dependent and independent patients but dependent patients did require more home visits by nurses (RR 2.03 [95% CI 1.39, 2.97]).

An analysis of data from the CAN-SLEEP Collaborative Group cohort study also included only nocturnal HHD patients.[124] Most patients (74%) were able to perform HHD independently. Among 247 patients, there were 10 technique failures. The only significant predictor of failure was age with an HR of 1.09 (95% CI 1.03, 1.16) for each 1 year increase in age. Using a composite outcome of death or technique failure (36 events), age and diabetes were significant predictors.

A prospective cohort study from Canada included all patients who began training for HHD.[125] Patients had experienced a mean of 30 months of dialysis before entering the program. During follow-up of up to 3 years, 37 patients dropped out of the program including 13 who received transplants, 14 who died, 2 with inadequate social support, 2 with medical reasons, 2 with inadequate dialysis, 1 who moved, 1 who withdrew from dialysis, and 2 with unspecified reasons. No significant predictors of technique survival were identified.

Risk of Bias for Key Question 3

We did not assess the risk of bias of individual registry studies. Registry studies are typically considered high risk of bias due to issues with selection bias and inability to assess and include all potential confounders in analyses. Other studies pertaining to Key Question 3 were one high risk of bias RCT and 2 CCTS (both moderate risk of bias), 5 reports of clinical cohort studies (4 rated high risk of bias and one moderate risk of bias), 24 cohort studies (2 low, 8 moderate, and

14 high risk of bias), and 9 cross-sectional studies (one low, one moderate, and 7 high risk of bias).

KEY QUESTION 4. In the published literature, what are the costs of home hemodialysis or peritoneal dialysis compared to in-center hemodialysis?

Summary of Findings

Fifteen studies (2 from the US) reported cost outcomes. Cost analyses have typically reported lower costs for HHD and PD compared to in-center HD. However, what costs are considered in the analyses and factors that can influence costs (*eg*, failure rates, patient age, and comorbidity) vary across studies.

Costs of Home Hemodialysis versus In-Center HD (Appendix C, Table 7)

Cost-utility analysis of data from the randomized Alberta nocturnal HHD study found frequent nocturnal HHD led to incremental cost savings of $6700 Canadian dollars (US$5872 in 2014) and an additional 0.38 QALYs compared to conventional HD but the savings and quality of life improvements varied by technique failure rate, training time, and dialysis modalities from which patients are drawn.[126] The study was also limited by the small sample size and short study duration. Results from a modeling study, based on data from Australia, Canada, and the United Kingdom, found costs of conventional HHD and frequent HHD were similar to costs of in-center HD in the first year but over time conventional HHD and frequent HHD could be less costly than in-center HD depending on the frequency of dialysis.[127] The model predicted that conventional HHD would save payers between $7612 (US$6668 in 2014) and $12,403 (US$10,865) over the first year of conventional in-center HD. An Australian study, based on new ESRD patients in the ANZDATA Registry from 2005 to 2010, estimated that switching patients from hospital HD to HHD would produce a net saving of $47 million Australian dollars by 2010 (US$40 million in 2014), suggesting changes in clinical practice would not only reduce costs but also improve patient quality of life.[128] However, the analysis did not incorporate indirect costs such as lost earnings and productivity and direct out-of-pocket costs to patients and their care givers. These results were supported by an earlier cost-effectiveness modeling study based on data from a systematic review.[129] A Finnish study reported no significant differences in the total costs between HHD and satellite HD and costs for both modalities were clearly less than those reported for hospital HD in other studies.[130] The results were limited by the younger age and shorter dialysis duration compared to general dialysis patients, limiting the application of the results to older and frailer patient populations. A Canadian study that analyzed patients' conventional HD costs during the 12 months before study entry found reduced costs and improved quality of life after switching to quotidian HHD, but the study was very small and under-powered to detect statistically significant differences in costs.[131] Older analyses have reported that reductions in costs associated with HHD compared to conventional HD are linked to a lesser need for nursing and other personnel and the exclusion of overhead costs of dialysis center or unit management.[132,133]

Costs of Peritoneal Hemodialysis (PD) versus In-Center HD (Appendix C, Table 7)

A recent Canadian study, based on data from the Alberta renal programs, found PD patients and patients who transitioned from HD to PD had significantly lower total health care costs at one and 3 years. Patients who had PD technique failure had costs similar to, not in excess of, HD patients at 3 years, supporting an economic rationale for a PD-first policy in all eligible patients.[134] A study from Spain reported costs related to dialysis access at 1 year from the time of

first dialysis.[135] There were significantly more access-related interventions in the HD groups (tunneled cuffed catheter or arteriovenous fistula) than the PD group. Access-related costs were significantly higher for the tunneled cuffed catheter HD group (€4208, US$4467 in 2015) compared to the arteriovenous fistula HD group (€1555, US$1651) or PD group (€1171, US$1244). A retrospective cohort study based on a US health insurance database reported that PD patients had significantly lower total healthcare costs during the year following initiation of dialysis, largely a result of higher emergency department visits and hospitalizations in the HD group.[136] Median total per-patient healthcare costs over the 12-month follow-up period for the PD and HD patients were $129,997 and $173,507, respectively. Findings from a UK study also reported lower costs associated with PD compared to in-center HD.[137] Costs associated with PD were mainly the costs of solutions and management of anemia while costs associated with HD were mainly due to disposables, nursing, and the overheads associated with running the dialysis unit. Other analyses also estimated that PD was the more economically advantageous dialysis modality[138-140] and a longer time on PD better sustained this economic advantage even after a switch to conventional HD.[139] Several of these PD cost analysis studies were limited by basing the analyses from the health-care provider perspective or including direct costs only and not incorporating indirect costs such as lost earnings and productivity.[134,138,139]

SUMMARY AND DISCUSSION

Key Findings and Strength of Evidence

- We found few randomized or controlled clinical trials or prospective clinical cohort studies comparing home-based and in-center kidney dialysis. Available clinical trials were small in size and had short follow-up durations.

- Most of the data on mortality is from registry studies. Results from these studies should be interpreted with caution due to likely residual confounding and selection bias.

- Home hemodialysis (HHD) versus in-center HD:

    - We found low strength of evidence (findings from registry studies) that HHD is associated with improved overall survival compared to in-center HD (Table 6). There were few studies of variations of HHD (including longer duration or more frequent sessions).

    - There is evidence from generally low-quality studies to suggest no difference in cardiovascular mortality, no difference or improved quality of life with HHD, no difference in access survival, no difference in transplantation rate, and no difference in all-cause hospitalization rate. In 2 studies reporting, a higher percentage of HHD patients switched dialysis modalities over follow-up periods of up to 4 years.

- Peritoneal dialysis (PD) versus in-center HD:

    - We found low strength of evidence (findings from registry studies) that there is no difference in overall mortality between PD to in-center HD (Table 6). However, most studies reporting outcomes over time noted an early survival advantage for PD patients with no difference after 2 to 3 years of treatment.

    - There were inconsistent findings for quality of life outcomes with studies reporting no differences or higher scores on some elements of quality of life in PD or in-center HD patients. With limited reporting, results were mixed for cardiovascular outcomes, adverse events, transplantation, and hospitalization. Over follow-up periods of 2 to 7 years, higher percentages of PD patients switched dialysis modalities.

- Only 2 studies compared HHD and PD with mixed results for mortality. Other outcomes were not reported.

- Factors associated with increased selection of home-based dialysis:

    - Facility factors: larger facility, more years of Medicare certification, providing care for more employed patients or patients in the 18 to 54 year age range, earlier initiation of pre-dialysis care, increased patient/family education;

    - Patient factors: well-informed about choices, patient preference (more autonomy, more flexible schedule, and less travel to dialysis), family/caregiver support;

- Provider factors: team approach (physician, nurse, social worker) to determining patient eligibility (medical and psychosocial).

· Factors associated with decreased selection of home-based dialysis:

- Facility factors: location in more rural area, location in high density zip code area, availability of an evening shift, higher percentage of black patients;

- Patient factors: lack of knowledge, living alone, lack of space in the home, inability to perform PD in the place of residence, fear of social isolation, fear of inability to perform PD, and preference for medical supervision.

· Factors associated with technique failure:

- Facility factors: lower technique failure if receiving care from larger dialysis facilities;

- Patient factors: higher technique failure if lack of caregiver support, caregiver anxiety, medical issues (including diabetes or psychosocial problems), treatment interferes with home life, African-American race (vs white), HD before PD;

- Provider factors: none identified.

· Costs are lower with HHD and PD compared to in-center HD but costs considered in the analyses and factors that can influence costs (failure rates, patient comorbidity) varied across studies.

Table 6. Strength of Evidence for Mortality Outcome

Outcome (studies reporting)	Results	Risk of Bias	Consistency	Directness	Precision	Strength of Evidence
Overall Mortality HHD vs HD (6 registry studies)	4 of 6 studies reported decreased overall mortality with HHD	high	consistent	direct	precise	low
Overall Mortality PD vs HD (19 registry studies)	4 studies reported decreased mortality with PD 6 studies reported increased mortality with PD 9 studies reported no difference in mortality	high	inconsistent	direct	imprecise	low

HHD = home hemodialysis; HD = in-center hemodialysis; PD = peritoneal dialysis

This evidence report summarizes literature on the comparative effectiveness and harms of home-based versus in-center dialysis. Home-based dialysis is a potentially effective option of considerable interest to Veterans and could permit VA to expand internal dialysis capacity. However, it is not well known if this is feasible within the Veteran population, due to in part to a greater prevalence of patients of older age and a greater number of comorbidities in the VA system. None of the included studies were conducted at VA medical centers.

Data on clinical outcomes come predominately from large registry studies, not randomized controlled trials. While authors attempted to control for confounding, significant residual confounding from both measured and unmeasured variables likely exists. Patients who undergo home dialysis are generally different than those who undergo in-center dialysis. In the United States patients undergoing home dialysis are generally younger and healthier than those treated with in-center hemodialysis. Also, patients without insurance and those without pre-dialysis care who present emergently requiring dialysis are much more likely to be initiated on in-center hemodialysis. These differences in patient characteristics can be inferred by the greater rate of transplantation among patients undergoing peritoneal dialysis compared to those undergoing in-center hemodialysis, which may then result in artificially increased death rates in PD groups in later periods of follow-up. Given these stark differences between patient populations it is difficult to compare outcomes across these populations, irrespective of the type of statistical technique employed.

DISCUSSION

Our findings are in agreement with earlier reviews and guidelines. A guideline from Caring for Australians with Renal Impairment (CARI) concluded that no clinical care recommendations could be made that would be based on Level I or Level II evidence.[141] The authors offered clinical care suggestions based on Level III or Level IV evidence including that PD may provide equivalent or better survival in the first few years, the HD may offer better long-term survival, and that timely transfer from PD to HD may improve survival. Based on opinion, it was suggested that survival be considered in the context of life quality as perceived by the patient when selecting a dialysis modality.

Other reviews have identified health care system, provider, and patient factors that are important in selection of home-based dialysis. Golper et al summarized barriers to home dialysis as educational issues (patient education; physician education, training, and experience; and dialysis staff education and experiences), governmental issues (reimbursement, financial support for home caregivers, accreditation and certification, required home visits, and regulatory policies that limit access to innovative equipment and solutions), and business practices and philosophies of dialysis providers (availability and delivery of equipment and supplies, business conflicts with patient care, laboratory and pharmacy services availability, space for training and clinic visits, and staffing).[142]

A second review focused on establishing a successful HHD program.[143] Patient education (including training on and practice with the equipment), physician training, nurse training (to prepare them to train patients), and staff support for patients and caregivers are essential. The creation of centralized training facilities (combining resources from multiple practices) and the use of continuous quality improvement cycles to monitor and modify treatment protocols were also suggested. The authors provided information on best demonstrated practices related to choice of dialysis equipment, dialysis schedule, vascular access, and remote monitoring; design of the patient training program; home assessment; post-training expectations; and patient or family burnout.

In a 2006 publication, patient preference (in the absence of a strong indications for or against a particular modality), medical factors, social issues, and non-medical issues (including financial reimbursement, late referral to a nephrologist, and nephrologist attitudes, opinions, educational

deficits, and biases) were described as contributing factors in selection of a dialysis modality.[144] The authors proposed an integrated care approach with early referral, aggressive management of CKD, promotion of living donor transplantation as first-line treatment for ESRD, unbiased education about all dialysis modalities, encouragement for suitable patients to select a home-based modality as initial therapy, and recognition that treatment modalities may be complementary rather than competing in providing optimal outcomes.

A 2013 meta-analysis focused on the modality decision-making process.[145] The analysis included 16 qualitative studies of adults (total n=410) with CKD. All but one of the studies was conducted in North America, Europe, or Australia/New Zealand. Across the studies, 3 themes emerged. First, patients perceived they had little true choice about commencing dialysis or dialysis modality – dialysis was necessary for survival. Often the choice was made in a short time frame by family or physician due to unforeseen medical situations. Second, minimizing intrusiveness was important. Patients believed that dialysis should allow for a good quality of life in addition to prolonging life. Third, knowledge (for both the patient and family members) and social support were important. The authors concluded that there is a need for CKD patients and their caregivers to participate in planned and timely discussions about dialysis modalities, including home-based care. Healthcare professionals should prepare patients and families for decision-making and provide information about different dialysis modalities and potential effects on quality of life, values, autonomy, and sense of self.

Overall treatment satisfaction with PD was the focus of another 2013 systematic review.[146] Included were 39 qualitative studies of the experiences, beliefs, and attitudes about PD from adults on long-term PD. Sample sizes in the individual studies ranged from 2 to 45 with 4 studies not reporting sample size. All but 4 studies were from North America, Europe, or Australia/New Zealand. Seven major themes were identified and these were subsequently organized into a thematic schema. “Resilience and confidence” (determination, overcoming anxieties associated with diagnosis of ESRD) and positive “support structure” (strong family relationship, peer support, professional dedication) contributed to a positive adjustment to PD. A positive adjustment resulted in perceptions of “control” (bodily awareness, independence and self-efficacy, information seeking) and “freedom” (treatment integration, social functioning, ability to travel). “Overwhelming responsibility” (disruptive intrusion, family burden, onerous treatment regimen) and negative “support structure” (social abandonment, desire for holistic care) contributed to a negative adjustment to PD which resulted in perceptions of a “sick identity” (damage to self-esteem, invisible suffering) and “disablement” (physical incapacitation, social loss and devaluation). It was concluded that while PD can have advantages for patients, strategies to strengthen social support and promote confidence are necessary for achieving positive adjustment and treatment satisfaction.

There is limited data on caregiver burden associated with dialysis and whether HHD is more stressful for caregivers. In a study from Italy, where HHD is rare, patients and caregivers were interviewed.[147] The 22 adult patients were currently receiving in-center HD; some were potentially eligible for HHD. The 20 caregivers, identified by the patients, were adults who provided care or support on a regular basis. The participants were selected to represent both genders and a range of ages, durations of dialysis, years of caregiving, and relationships to patients. Positive and negative themes were identified. On the positive side, flexibility and freedom, comfort in familiar surroundings, and altruistic motivation (setting an example for others) emerged. Negative themes included disrupted sense of normality, family burden, housing

constraints, concern over healthcare by “amateurs,” and isolation from peer support. Specifically, both patients and caregivers thought that HHD would be an “overwhelming responsibility” for a caregiver. Caregiving would require “significant personal sacrifices” that would impact work and social lives. Caregivers were concerned about seeing the patient “suffer” while undergoing dialysis, their ability to assist the patient with treatment and technical problems or complications that might arise, and their ability to manage “medical responsibilities.” Caregivers also reported that they perceived patients were content with their in-center care and that they benefited from peer support. The authors identified education, providing support for caregivers and family members, minimizing the intrusiveness of HHD, maintaining patient access to medical and technical support, minimizing social isolation, and promoting self-efficacy as ways to increase acceptability and selection of HHD. Suri et al reported results from the Frequent Hemodialysis Network Trials.[148] Patients in the Daily Trial completed dialysis in-center either 3 or 6 times per week while those in the Nocturnal Trial completed dialysis at home with either conventional dialysis 3 times per week or nocturnal dialysis 6 times per week. The analysis included patients who reported having an unpaid caregiver. Scores on a perceived burden scale at 4 and 12 months were lower than baseline (indicating less perceived caregiver burden) for the Daily Trial participants regardless of dialysis schedule and for the conventional home dialysis patients. Scores increased from baseline (indicating greater perceived caregiver burden) at 4 and 12 months for the nocturnal home dialysis patients. The authors suggested that the findings may play a role in the choice of frequent home nocturnal dialysis.

LIMITATIONS

Two studies found no difference in transplantation rates between HHD and HD. This finding may be a result of the length of time before a donor kidney becomes available. Studies with short follow-up could demonstrate no difference.

If there is an advantage of HHD over HD, it may be related to the different frequencies of dialysis or treatment times per session that are possible with HHD.[22]

Quality of life outcomes should be interpreted with caution. Often the studies are comparing groups of patients with different amounts of time on dialysis (*eg*, quality of life assessed at 3 months in one group versus 15 months in the other group). Familiarity with and adjustment to dialysis and/or disease progression might be more important factors in reported quality of life than the dialysis modality. In addition, baseline characteristics (*eg*, age, comorbidities) of the patients in the treatment groups differ and might account for differences in reported quality of life. Finally, assessment of quality of life during an in-center HD session versus at home or during a routine office visit (no dialysis) may yield different quality of life scores. The use of generic versus disease specific assessment tools should also be considered.

Applicability of Findings to the VA Population

Twenty of the 32 registry studies were completed in the United States or Canada. Across all registry studies, mean ages ranged from 47 to 75 years and between 50% and 67% of included patients were male. There were few exclusion criteria, suggesting that the patients were representative of the ESRD population. However, the cohort years for all but 7 of the registry studies were prior to 2008.

We found no compelling evidence that HHD and PD differ from in-center HD in survival, quality of life, hospitalizations, or costs. Differences, where they exist, could be due to unmeasured differences in patient populations and strong selection biases (by patients, caregivers, or providers). However, HHD and PD are commonly used as the dialysis method of choice in other countries. We also found some evidence that caregiver support was an important factor in identifying candidates likely suitable for HHD or PD.

RESEARCH GAPS/FUTURE RESEARCH

Despite the large number of studies included in this report considerable gaps exist. The comparative effectiveness of HHD or PD to in-center HD (including outcomes of mortality, hospitalizations, quality of life, patient satisfaction, and adverse events) and whether treatment choice and technique success vary by modality, patient, provider, or facility factors remains relatively unknown. This is predominately because considerable differences likely exist among individuals selected (or selecting) different treatment modalities. While difficult to undertake, a large randomized trial comparing different modalities would be useful. Other research needs would be to evaluate methods to understand barriers to and improve implementation of HHD or PD and provide individuals with sufficient skill building and caregiver support in attempts to maximize benefits. Of note HHD and PD are widely used as treatment options of choice in other developed countries.

CONCLUSIONS

Low-strength evidence suggests that home-based dialysis may provide similar health outcomes and at similar or lower costs for many patients compared to in-center hemodialysis. Therefore, home-based dialysis may be an acceptable and sometimes preferred alternative to in-center hemodialysis. Information is limited on factors important in addressing selection of and barriers to home-based dialysis and remains an area of important research and health policy.

REFERENCES

1. Piccoli GB, Ferraresi M, Consiglio V, et al. Why home hemodialysis? A systematic "marketing" analysis. *J Nephrol.* Mar-Apr 2012;25(2):159-169.
2. Mowatt G, Vale L, MacLeod A. Systematic review of the effectiveness of home versus hospital or satellite unit hemodialysis for people with end-stage renal failure. *Int J Technol Assess Health Care.* 2004;20(3):258-268.
3. US Renal Data System. *2014 Annual Data Report: An Overview of the Epidemiology of Kidney Disease in the United States.* Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases;2014.
4. Higgins H, Green S. Cochrane Handbook for Systeamtic Reviews of Interventions Version 5.1.0. *The Cochrane Collaboration* 2011; http://handbook.cochrane.org. Accessed August 31, 2014.
5. Viswanathan M, Ansari MT, Berkman ND, et al. Assessing the Risk of Bias of Individual Studies in Systematic Reviews of Health Care Interventions. *Methods Guide for Effectiveness and Comparative Effectiveness Reviews*. Rockville (MD)2008.
6. Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. *BMC medical research methodology.* 2007;7:10.
7. Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions--agency for healthcare research and quality and the effective health-care program. *Journal of clinical epidemiology.* May 2010;63(5):513-523.
8. Weinhandl ED, Liu J, Gilbertson DT, Arneson TJ, Collins AJ. Survival in daily home hemodialysis and matched thrice-weekly in-center hemodialysis patients. *J Am Soc Nephrol.* May 2012;23(5):895-904.
9. MacRae JM, Rose CL, Jaber BL, Gill JS. Utilization and outcome of 'out-of-center hemodialysis' in the United States: a contemporary analysis. *Nephron.* 2010;116(1):c53-59.
10. Woods JD, Port FK, Stannard D, Blagg CR, Held PJ. Comparison of mortality with home hemodialysis and center hemodialysis: a national study. *Kidney Int.* May 1996;49(5):1464-1470.
11. Marshall MR, Walker RC, Polkinghorne KR, Lynn KL. Survival on home dialysis in New Zealand. *PloS one.* 2014;9(5):e96847.
12. Marshall MR, Hawley CM, Kerr PG, et al. Home hemodialysis and mortality risk in Australian and New Zealand populations. *Am J Kidney Dis.* Nov 2011;58(5):782-793.
13. Nesrallah GE, Lindsay RM, Cuerden MS, et al. Intensive hemodialysis associates with improved survival compared with conventional hemodialysis. *J Am Soc Nephrol.* Apr 2012;23(4):696-705.

14. Nitsch D, Steenkamp R, Tomson CRV, Roderick P, Ansell D, MacGregor MS. Outcomes in patients on home haemodialysis in England and Wales, 1997-2005: a comparative cohort analysis. *Nephrol Dial Transplant.* May 2011;26(5):1670-1677.

15. Culleton BF, Walsh M, Klarenbach SW, et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. *Jama.* Sep 19 2007;298(11):1291-1299.

16. McGregor DO, Buttimore AL, Lynn KL, Nicholls MG, Jardine DL. A Comparative Study of Blood Pressure Control with Short In-Center versus Long Home Hemodialysis. *Blood purification.* 2001;19(3):293-300.

17. Xue H, Li NC, Lacson E, Jr., Brunelli SM, Lockridge RS. Catheter-related bacteremia and mortality in frequent nocturnal home hemodialysis. *Hemodialysis international. International Symposium on Home Hemodialysis.* Apr 2015;19(2):242-248.

18. Kjellstrand CM, Buoncristiani U, Ting G, et al. Short daily haemodialysis: survival in 415 patients treated for 1006 patient-years. *Nephrol Dial Transplant.* Oct 2008;23(10):3283-3289.

19. Lindsay RM, Leitch R, Heidenheim AP, Kortas C, London Daily/Nocturnal Hemodialysis S. The London Daily/Nocturnal Hemodialysis Study--study design, morbidity, and mortality results. *Am J Kidney Dis.* Jul 2003;42(1 Suppl):5-12.

20. Weinhandl ED, Nieman KM, Gilbertson DT, Collins AJ. Hospitalization in daily home hemodialysis and matched thrice-weekly in-center hemodialysis patients. *Am J Kidney Dis.* Jan 2015;65(1):98-108.

21. Heidenheim AP, Muirhead N, Moist L, Lindsay RM. Patient quality of life on quotidian hemodialysis. *Am J Kidney Dis.* Jul 2003;42(1 Suppl):36-41.

22. Griva K, Davenport A, Harrison M, Newman S. An evaluation of illness, treatment perceptions, and depression in hospital- vs. home-based dialysis modalities. *Journal of psychosomatic research.* Oct 2010;69(4):363-370.

23. Wight JP, Edwards L, Brazier J, Walters S, Payne JN, Brown CB. The SF36 as an outcome measure of services for end stage renal failure. *Quality in health care : QHC.* Dec 1998;7(4):209-221.

24. Molzahn AE, Northcott HC, Dossetor JB. Quality of life of individuals with end stage renal disease: perceptions of patients, nurses, and physicians. *ANNA journal / American Nephrology Nurses' Association.* Jun 1997;24(3):325-333; discussion 334-325.

25. Quintaliani G, Buoncristiani U, Fagugli R, et al. Survival of vascular access during daily and three times a week hemodialysis. *Clinical nephrology.* May 2000;53(5):372-377.

26. Lukowsky LR, Mehrotra R, Kheifets L, Arah OA, Nissenson AR, Kalantar-Zadeh K. Comparing mortality of peritoneal and hemodialysis patients in the first 2 years of dialysis therapy: a marginal structural model analysis. *Clin J Am Soc Nephrol.* Apr 2013;8(4):619-628.

27. Lievense H, Kalantar-Zadeh K, Lukowsky LR, et al. Relationship of body size and initial dialysis modality on subsequent transplantation, mortality and weight gain of ESRD patients. *Nephrol Dial Transplant.* Sep 2012;27(9):3631-3638.

28. Mehrotra R, Chiu Y-W, Kalantar-Zadeh K, Bargman J, Vonesh E. Similar outcomes with hemodialysis and peritoneal dialysis in patients with end-stage renal disease. *Arch Intern Med.* Jan 24 2011;171(2):110-118.

29. Weinhandl ED, Foley RN, Gilbertson DT, Arneson TJ, Snyder JJ, Collins AJ. Propensity-matched mortality comparison of incident hemodialysis and peritoneal dialysis patients. *J Am Soc Nephrol.* Mar 2010;21(3):499-506.

30. Collins AJ, Weinhandl E, Snyder JJ, Chen SC, Gilbertson D. Comparison and survival of hemodialysis and peritoneal dialysis in the elderly. *Seminars in dialysis.* Mar-Apr 2002;15(2):98-102.

31. Abbott KC, Glanton CW, Trespalacios FC, et al. Body mass index, dialysis modality, and survival: analysis of the United States Renal Data System Dialysis Morbidity and Mortality Wave II Study. *Kidney Int.* Feb 2004;65(2):597-605.

32. Vonesh EF, Snyder JJ, Foley RN, Collins AJ. The differential impact of risk factors on mortality in hemodialysis and peritoneal dialysis. *Kidney Int.* Dec 2004;66(6):2389-2401.

33. Stack AG, Molony DA, Rahman NS, Dosekun A, Murthy B. Impact of dialysis modality on survival of new ESRD patients with congestive heart failure in the United States. *Kidney Int.* Sep 2003;64(3):1071-1079.

34. Xue JL, Everson SE, Constantini EG, et al. Peritoneal and hemodialysis: II. Mortality risk associated with initial patient characteristics. *Kidney Int.* Feb 2002;61(2):741-746.

35. Collins AJ, Hao W, Xia H, et al. Mortality risks of peritoneal dialysis and hemodialysis. *Am J Kidney Dis.* Dec 1999;34(6):1065-1074.

36. Bloembergen WE, Port FK, Mauger EA, Wolfe RA. A comparison of mortality between patients treated with hemodialysis and peritoneal dialysis. *J Am Soc Nephrol.* Aug 1995;6(2):177-183.

37. Lowrie EG, Huang WH, Lew NL. Death risk predictors among peritoneal dialysis and hemodialysis patients: a preliminary comparison. *Am J Kidney Dis.* Jul 1995;26(1):220-228.

38. McDonald SP, Marshall MR, Johnson DW, Polkinghorne KR. Relationship between dialysis modality and mortality. *J Am Soc Nephrol.* Jan 2009;20(1):155-163.

39. Yeates K, Zhu N, Vonesh E, Trpeski L, Blake P, Fenton S. Hemodialysis and peritoneal dialysis are associated with similar outcomes for end-stage renal disease treatment in Canada. *Nephrol Dial Transplant.* Sep 2012;27(9):3568-3575.

40. Schaubel DE, Morrison HI, Fenton SS. Comparing mortality rates on CAPD/CCPD and hemodialysis. The Canadian experience: fact or fiction? *Perit Dial Int.* Sep-Oct 1998;18(5):478-484.

41. Fenton SS, Schaubel DE, Desmeules M, et al. Hemodialysis versus peritoneal dialysis: a comparison of adjusted mortality rates. *Am J Kidney Dis.* Sep 1997;30(3):334-342.

42. Quinn RR, Hux JE, Oliver MJ, Austin PC, Tonelli M, Laupacis A. Selection bias explains apparent differential mortality between dialysis modalities. *J Am Soc Nephrol.* Aug 2011;22(8):1534-1542.

43. Liem YS, Wong JB, Hunink MGM, de Charro FT, Winkelmayer WC. Comparison of hemodialysis and peritoneal dialysis survival in The Netherlands. *Kidney Int.* Jan 2007;71(2):153-158.

44. van de Luijtgaarden MWM, Noordzij M, Stel VS, et al. Effects of comorbid and demographic factors on dialysis modality choice and related patient survival in Europe. *Nephrol Dial Transplant.* Sep 2011;26(9):2940-2947.

45. Haapio M, Helve J, Kyllonen L, Gronhagen-Riska C, Finne P. Modality of chronic renal replacement therapy and survival--a complete cohort from Finland, 2000-2009. *Nephrol Dial Transplant.* Dec 2013;28(12):3072-3081.

46. Sens F, Schott-Pethelaz A-M, Labeeuw M, Colin C, Villar E, Registry R. Survival advantage of hemodialysis relative to peritoneal dialysis in patients with end-stage renal disease and congestive heart failure. *Kidney Int.* Nov 2011;80(9):970-977.

47. Locatelli F, Marcelli D, Conte F, et al. Survival and development of cardiovascular disease by modality of treatment in patients with end-stage renal disease. *J Am Soc Nephrol.* Nov 2001;12(11):2411-2417.

48. Mircescu G, Stefan G, Garneata L, Mititiuc I, Siriopol D, Covic A. Outcomes of dialytic modalities in a large incident registry cohort from Eastern Europe: the Romanian Renal Registry. *Int Urol Nephrol.* Feb 2014;46(2):443-451.

49. Traynor JP, Thomson PC, Simpson K, et al. Comparison of patient survival in non-diabetic transplant-listed patients initially treated with haemodialysis or peritoneal dialysis. *Nephrol Dial Transplant.* Jan 2011;26(1):245-252.

50. Korevaar JC, Feith GW, Dekker FW, et al. Effect of starting with hemodialysis compared with peritoneal dialysis in patients new on dialysis treatment: a randomized controlled trial. *Kidney Int.* Dec 2003;64(6):2222-2228.

51. Jaar BG, Coresh J, Plantinga LC, et al. Comparing the risk for death with peritoneal dialysis and hemodialysis in a national cohort of patients with chronic kidney disease.[Summary for patients in Ann Intern Med. 2005 Aug 2;143(3):I17; PMID: 16061913]. *Ann Intern Med.* Aug 2 2005;143(3):174-183.

52. Noordzij M, Korevaar JC, Bos WJ, et al. Mineral metabolism and cardiovascular morbidity and mortality risk: peritoneal dialysis patients compared with haemodialysis patients. *Nephrol Dial Transplant.* Sep 2006;21(9):2513-2520.

53. Termorshuizen F, Korevaar JC, Dekker FW, et al. Hemodialysis and peritoneal dialysis: comparison of adjusted mortality rates according to the duration of dialysis: analysis of The Netherlands Cooperative Study on the Adequacy of Dialysis 2. *J Am Soc Nephrol.* Nov 2003;14(11):2851-2860.

54. Stack AG, Murthy BVR, Molony DA. Survival differences between peritoneal dialysis and hemodialysis among "large" ESRD patients in the United States. *Kidney Int.* Jun 2004;65(6):2398-2408.

55. Ganesh SK, Hulbert-Shearon T, Port FK, Eagle K, Stack AG. Mortality differences by dialysis modality among incident ESRD patients with and without coronary artery disease. *J Am Soc Nephrol.* Feb 2003;14(2):415-424.

56. Aslam N, Bernardini J, Fried L, Burr R, Piraino B. Comparison of infectious complications between incident hemodialysis and peritoneal dialysis patients. *Clin J Am Soc Nephrol.* Nov 2006;1(6):1226-1233.

57. Mittal SK, Ahern L, Flaster E, Mittal VS, Maesaka JK, Fishbane S. Self-assessed quality of life in peritoneal dialysis patients. *Am J Nephrol.* May-Jun 2001;21(3):215-220.

58. Harris SA, Lamping DL, Brown EA, Constantinovici N, North Thames Dialysis Study G. Clinical outcomes and quality of life in elderly patients on peritoneal dialysis versus hemodialysis. *Perit Dial Int.* Jul-Aug 2002;22(4):463-470.

59. Boateng EA, East L. The impact of dialysis modality on quality of life: a systematic review. *Journal of renal care.* Dec 2011;37(4):190-200.

60. Kutner NG, Zhang R, McClellan WM. Patient-reported quality of life early in dialysis treatment: effects associated with usual exercise activity. *Nephrology nursing journal : journal of the American Nephrology Nurses' Association.* Aug 2000;27(4):357-367; discussion 368, 424.

61. Diaz-Buxo JA, Lowrie EG, Lew NL, Zhang H, Lazarus JM. Quality-of-life evaluation using Short Form 36: comparison in hemodialysis and peritoneal dialysis patients. *Am J Kidney Dis.* Feb 2000;35(2):293-300.

62. Wu AW, Fink NE, Marsh-Manzi JVR, et al. Changes in quality of life during hemodialysis and peritoneal dialysis treatment: generic and disease specific measures. *J Am Soc Nephrol.* Mar 2004;15(3):743-753.

63. Plantinga LC, Fink NE, Harrington-Levey R, et al. Association of social support with outcomes in incident dialysis patients. *Clin J Am Soc Nephrol.* Aug 2010;5(8):1480-1488.

64. Jansen DL, Heijmans MJWM, Rijken M, et al. Illness perceptions and treatment perceptions of patients with chronic kidney disease: different phases, different perceptions? *Br J Health Psychol.* May 2013;18(2):244-262.

65. Thong MS, Kaptein AA, Krediet RT, Boeschoten EW, Dekker FW. Social support predicts survival in dialysis patients. *Nephrol Dial Transplant.* Mar 2007;22(3):845-850.

66. Merkus MP, Jager KJ, Dekker FW, De Haan RJ, Boeschoten EW, Krediet RT. Quality of life over time in dialysis: the Netherlands Cooperative Study on the Adequacy of Dialysis. NECOSAD Study Group. *Kidney Int.* Aug 1999;56(2):720-728.

67. Lee AJ, Morgan CL, Conway P, Currie CJ. Characterisation and comparison of health-related quality of life for patients with renal failure. *Current medical research and opinion.* Nov 2005;21(11):1777-1783.

68. Kalirao P, Pederson S, Foley RN, et al. Cognitive impairment in peritoneal dialysis patients. *Am J Kidney Dis.* Apr 2011;57(4):612-620.

69. Wyld M, Morton RL, Hayen A, Howard K, Webster AC. A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments. *PLoS medicine.* 2012;9(9):e1001307.

70. Purnell TS, Auguste P, Crews DC, et al. Comparison of life participation activities among adults treated by hemodialysis, peritoneal dialysis, and kidney transplantation: a systematic review. *Am J Kidney Dis.* Nov 2013;62(5):953-973.

71. van Diepen AT, Hoekstra T, Rotmans JI, et al. The association between dialysis modality and the risk for dialysis technique and non-dialysis technique-related infections. *Nephrol Dial Transplant.* Dec 2014;29(12):2244-2250.

72. Oliver MJ, Verrelli M, Zacharias JM, et al. Choosing peritoneal dialysis reduces the risk of invasive access interventions. *Nephrol Dial Transplant.* Feb 2012;27(2):810-816.

73. Bruno MJ, van Westerloo DJ, van Dorp WT, et al. Acute pancreatitis in peritoneal dialysis and haemodialysis: risk, clinical course, outcome, and possible aetiology. *Gut.* Mar 2000;46(3):385-389.

74. Van Biesen W, Vanholder RC, Veys N, Dhondt A, Lameire NH. An evaluation of an integrative care approach for end-stage renal disease patients. *J Am Soc Nephrol.* Jan 2000;11(1):116-125.

75. Cano AE, Neil AK, Kang J-Y, et al. Gastrointestinal symptoms in patients with end-stage renal disease undergoing treatment by hemodialysis or peritoneal dialysis. *Am J Gastroenterol.* Sep 2007;102(9):1990-1997.

76. Portoles J, Del Peso G, Fernandez-Reyes MJ, Bajo MA, Lopez-Sanchez P, Gcdp. Previous comorbidity and lack of patient free choice of technique predict early mortality in peritoneal dialysis. *Perit Dial Int.* Mar-Apr 2009;29(2):150-157.

77. Liberek T, Renke M, Skonieczny B, et al. Therapy outcome in peritoneal dialysis patients transferred from haemodialysis. *Nephrol Dial Transplant.* Sep 2009;24(9):2889-2894.

78. Mujais S, Story K. Peritoneal dialysis in the US: evaluation of outcomes in contemporary cohorts. *Kidney Int Suppl.* Nov 2006(103):S21-26.

79. Walker DR, Inglese GW, Sloand JA, Just PM. Dialysis facility and patient characteristics associated with utilization of home dialysis. *Clin J Am Soc Nephrol.* Sep 2010;5(9):1649-1654.

80. Pipkin M, Eggers PW, Larive B, et al. Recruitment and training for home hemodialysis: experience and lessons from the Nocturnal Dialysis Trial. *Clin J Am Soc Nephrol.* Sep 2010;5(9):1614-1620.

81. Morton RL, Howard K, Webster AC, Snelling P. Patient INformation about Options for Treatment (PINOT): a prospective national study of information given to incident CKD Stage 5 patients. *Nephrol Dial Transplant.* Apr 2011;26(4):1266-1274.

82. Oliver MJ, Garg AX, Blake PG, et al. Impact of contraindications, barriers to self-care and support on incident peritoneal dialysis utilization. *Nephrol Dial Transplant.* Aug 2010;25(8):2737-2744.

83. Oliver MJ, Quinn RR, Richardson EP, Kiss AJ, Lamping DL, Manns BJ. Home care assistance and the utilization of peritoneal dialysis. *Kidney Int.* Apr 2007;71(7):673-678.

84. Jager KJ, Korevaar JC, Dekker FW, Krediet RT, Boeschoten EW, Netherlands Cooperative Study on the Adequacy of Dialysis Study G. The effect of contraindications and patient preference on dialysis modality selection in ESRD patients in The Netherlands. *Am J Kidney Dis.* May 2004;43(5):891-899.

85. Thamer M, Hwang W, Fink NE, et al. US nephrologists' recommendation of dialysis modality: results of a national survey. *Am J Kidney Dis.* Dec 2000;36(6):1155-1165.

86. Prichard SS. Treatment modality selection in 150 consecutive patients starting ESRD therapy. *Perit Dial Int.* Jan-Feb 1996;16(1):69-72.

87. Jayanti A, Morris J, Stenvinkel P, Mitra S. Home hemodialysis: beliefs, attitudes, and practice patterns. *Hemodialysis international. International Symposium on Home Hemodialysis.* Oct 2014;18(4):767-776.

88. Tennankore KK, Hingwala J, Watson D, Bargman JM, Chan CT. Attitudes and perceptions of nephrology nurses towards dialysis modality selection: a survey study. *BMC Nephrol.* 2013;14:192.

89. Manns BJ, Taub K, Vanderstraeten C, et al. The impact of education on chronic kidney disease patients' plans to initiate dialysis with self-care dialysis: a randomized trial. *Kidney Int.* Oct 2005;68(4):1777-1783.

90. McLaughlin K, Jones H, VanderStraeten C, et al. Why do patients choose self-care dialysis? *Nephrol Dial Transplant.* Dec 2008;23(12):3972-3976.

91. McLaughlin K, Manns B, Mortis G, Hons R, Taub K. Why patients with ESRD do not select self-care dialysis as a treatment option. *Am J Kidney Dis.* Feb 2003;41(2):380-385.

92. Ribitsch W, Haditsch B, Otto R, et al. Effects of a pre-dialysis patient education program on the relative frequencies of dialysis modalities. *Perit Dial Int.* Jul-Aug 2013;33(4):367-371.

93. Lacson E, Jr., Wang W, DeVries C, et al. Effects of a nationwide predialysis educational program on modality choice, vascular access, and patient outcomes. *Am J Kidney Dis.* Aug 2011;58(2):235-242.

94. Rubin HR, Fink NE, Plantinga LC, Sadler JH, Kliger AS, Powe NR. Patient ratings of dialysis care with peritoneal dialysis vs hemodialysis. *Jama.* Feb 11 2004;291(6):697-703.

95. Keating PT, Walsh M, Ribic CM, Brimble KS. The impact of patient preference on dialysis modality and hemodialysis vascular access. *BMC Nephrol.* 2014;15:38.

96. Maaroufi A, Fafin C, Mougel S, et al. Patients' preferences regarding choice of end-stage renal disease treatment options. *Am J Nephrol.* 2013;37(4):359-369.

97. Chanouzas D, Ng KP, Fallouh B, Baharani J. What influences patient choice of treatment modality at the pre-dialysis stage? *Nephrol Dial Transplant.* Apr 2012;27(4):1542-1547.

98. Ravani P, Marinangeli G, Stacchiotti L, Malberti F. Structured pre-dialysis programs: more than just timely referral? *Jn, J.* Nov-Dec 2003;16(6):862-869.

99. Gadallah MF, Ramdeen G, Torres-Rivera C, et al. Changing the trend: a prospective study on factors contributing to the growth rate of peritoneal dialysis programs. *Adv Perit Dial.* 2001;17:122-126.

100. Bass EB, Wills S, Fink NE, et al. How strong are patients' preferences in choices between dialysis modalities and doses? *Am J Kidney Dis.* Oct 2004;44(4):695-705.

101. Winkelmayer WC, Glynn RJ, Levin R, Owen W, Jr., Avorn J. Late referral and modality choice in end-stage renal disease. *Kidney Int.* Oct 2001;60(4):1547-1554.

102. Barker-Cummings C, McClellan W, Soucie JM, Krisher J. Ethnic differences in the use of peritoneal dialysis as initial treatment for end-stage renal disease. *Jama.* Dec 20 1995;274(23):1858-1862.

103. Shen JI, Mitani AA, Saxena AB, Goldstein BA, Winkelmayer WC. Determinants of peritoneal dialysis technique failure in incident US patients. *Perit Dial Int.* Mar-Apr 2013;33(2):155-166.

104. Lobbedez T, Verger C, Ryckelynck JP, Fabre E, Evans D. Is assisted peritoneal dialysis associated with technique survival when competing events are considered? *Clin J Am Soc Nephrol.* Apr 2012;7(4):612-618.

105. Smyth A, McCann E, Redahan L, Lambert B, Mellotte GJ, Wall CA. Peritoneal dialysis in an ageing population: a 10-year experience. *Int Urol Nephrol.* Feb 2012;44(1):283-293.

106. Taveras AE, Bekui AM, Gorban-Brennan N, Raducu R, Finkelstein FO. Peritoneal dialysis in patients 75 years of age and older--a 22-year experience. *Adv Perit Dial.* 2012;28:84-88.

107. Kolesnyk I, Dekker FW, Boeschoten EW, Krediet RT. Time-dependent reasons for peritoneal dialysis technique failure and mortality. *Perit Dial Int.* Mar-Apr 2010;30(2):170-177.

108. Singh N, Davidson I, Minhajuddin A, Gieser S, Nurenberg M, Saxena R. Risk factors associated with peritoneal dialysis catheter survival: a 9-year single-center study in 315 patients. *J.* Oct-Dec 2010;11(4):316-322.

109. Jaar BG, Plantinga LC, Crews DC, et al. Timing, causes, predictors and prognosis of switching from peritoneal dialysis to hemodialysis: a prospective study. *BMC Nephrol.* 2009;10:3.

110. Plantinga LC, Fink NE, Finkelstein FO, Powe NR, Jaar BG. Association of peritoneal dialysis clinic size with clinical outcomes. *Perit Dial Int.* May-Jun 2009;29(3):285-291.

111. Tonelli M, Hemmelgarn B, Culleton B, et al. Mortality of Canadians treated by peritoneal dialysis in remote locations. *Kidney Int.* Oct 2007;72(8):1023-1028.

112. McDonald SP, Collins JF, Johnson DW. Obesity is associated with worse peritoneal dialysis outcomes in the Australia and New Zealand patient populations. *J Am Soc Nephrol.* Nov 2003;14(11):2894-2901.

113. Snyder JJ, Foley RN, Gilbertson DT, Vonesh EF, Collins AJ. Body size and outcomes on peritoneal dialysis in the United States. *Kidney Int.* Nov 2003;64(5):1838-1844.

114. Jager KJ, Merkus MP, Dekker FW, et al. Mortality and technique failure in patients starting chronic peritoneal dialysis: results of The Netherlands Cooperative Study on the Adequacy of Dialysis. NECOSAD Study Group. *Kidney Int.* Apr 1999;55(4):1476-1485.

115. Korbet SM, Shih D, Cline KN, Vonesh EF. Racial differences in survival in an urban peritoneal dialysis program. *Am J Kidney Dis.* Oct 1999;34(4):713-720.

116. Perl J, Wald R, Bargman JM, et al. Changes in patient and technique survival over time among incident peritoneal dialysis patients in Canada. *Clin J Am Soc Nephrol.* Jul 2012;7(7):1145-1154.

117. Forbes SH, McCafferty K, Lawson T, Stoby-Fields M, Raftery M, Yaqoob MM. Is lack of suitable housing a barrier to home-based dialysis therapy for patients with end-stage renal disease? A cohort study. *BMJ open.* 2013;3(2).

118. Rioux J-P, Bargman JM, Chan CT. Systematic differences among patients initiated on home haemodialysis and peritoneal dialysis: the fallacy of potential competition. *Nephrol Dial Transplant.* Jul 2010;25(7):2364-2367.

119. Zhang A-H, Bargman JM, Lok CE, et al. Dialysis modality choices among chronic kidney disease patients: identifying the gaps to support patients on home-based therapies. *Int Urol Nephrol.* Sep 2010;42(3):759-764.

120. Cafazzo JA, Leonard K, Easty AC, Rossos PG, Chan CT. Patient-perceived barriers to the adoption of nocturnal home hemodialysis. *Clin J Am Soc Nephrol.* Apr 2009;4(4):784-789.

121. Jayanti A, Nikam M, Ebah L, Dutton G, Morris J, Mitra S. Technique survival in home haemodialysis: a composite success rate and its risk predictors in a prospective longitudinal cohort from a tertiary renal network programme. *Nephrol Dial Transplant.* Oct 2013;28(10):2612-2620.

122. Schachter ME, Tennankore KK, Chan CT. Determinants of training and technique failure in home hemodialysis. *Hemodialysis international. International Symposium on Home Hemodialysis.* Jul 2013;17(3):421-426.

123. Tennankore KK, Kim SJ, Chan CT. The feasibility of caregiver-assisted home nocturnal hemodialysis. *Nephron.* 2012;122(1-2):17-23.

124. Pauly RP, Maximova K, Coppens J, et al. Patient and technique survival among a Canadian multicenter nocturnal home hemodialysis cohort. *Clin J Am Soc Nephrol.* Oct 2010;5(10):1815-1820.

125. Komenda P, Copland M, Er L, Djurdjev O, Levin A. Outcomes of a provincial home haemodialysis programme--a two-year experience: establishing benchmarks for programme evaluation. *Nephrol Dial Transplant.* Aug 2008;23(8):2647-2652.

126. Klarenbach S, Tonelli M, Pauly R, et al. Economic evaluation of frequent home nocturnal hemodialysis based on a randomized controlled trial. *J Am Soc Nephrol.* Mar 2014;25(3):587-594.

127. Komenda P, Gavaghan MB, Garfield SS, Poret AW, Sood MM. An economic assessment model for in-center, conventional home, and more frequent home hemodialysis. *Kidney Int.* Feb 2012;81(3):307-313.

128. Howard K, Salkeld G, White S, et al. The cost-effectiveness of increasing kidney transplantation and home-based dialysis. *Nephrology.* Feb 2009;14(1):123-132.

129. Gonzalez-Perez JG, Vale L, Stearns SC, Wordsworth S. Hemodialysis for end-stage renal disease: a cost-effectiveness analysis of treatment-options. *Int J Technol Assess Health Care.* 2005;21(1):32-39.

130. Malmstrom RK, Roine RP, Heikkila A, et al. Cost analysis and health-related quality of life of home and self-care satellite haemodialysis. *Nephrol Dial Transplant.* Jun 2008;23(6):1990-1996.

131. Kroeker A, Clark WF, Heidenheim AP, et al. An operating cost comparison between conventional and home quotidian hemodialysis. *Am J Kidney Dis.* Jul 2003;42(1 Suppl):49-55.

132. Lee H, Manns B, Taub K, et al. Cost analysis of ongoing care of patients with end-stage renal disease: the impact of dialysis modality and dialysis access. *Am J Kidney Dis.* Sep 2002;40(3):611-622.

133. Goeree R, Manalich J, Grootendorst P, Beecroft ML, Churchill DN. Cost analysis of dialysis treatments for end-stage renal disease (ESRD). *Clin Invest Med.* Dec 1995;18(6):455-464.

134. Chui BK, Manns B, Pannu N, et al. Health care costs of peritoneal dialysis technique failure and dialysis modality switching. *Am J Kidney Dis.* Jan 2013;61(1):104-111.

135. Coentrao LA, Araujo CS, Ribeiro CA, Dias CC, Pestana MJ. Cost analysis of hemodialysis and peritoneal dialysis access in incident dialysis patients. *Perit Dial Int.* Nov-Dec 2013;33(6):662-670.

136. Berger A, Edelsberg J, Inglese GW, Bhattacharyya SK, Oster G. Cost comparison of peritoneal dialysis versus hemodialysis in end-stage renal disease. *The American journal of managed care.* Aug 2009;15(8):509-518.

137. Baboolal K, McEwan P, Sondhi S, Spiewanowski P, Wechowski J, Wilson K. The cost of renal dialysis in a UK setting--a multicentre study. *Nephrol Dial Transplant.* Jun 2008;23(6):1982-1989.

138. Kontodimopoulos N, Niakas D. An estimate of lifelong costs and QALYs in renal replacement therapy based on patients' life expectancy. *Health Policy.* Apr 2008;86(1):85-96.

139. Shih Y-CT, Guo A, Just PM, Mujais S. Impact of initial dialysis modality and modality switches on Medicare expenditures of end-stage renal disease patients. *Kidney Int.* Jul 2005;68(1):319-329.

140. Sennfalt K, Magnusson M, Carlsson P. Comparison of hemodialysis and peritoneal dialysis--a cost-utility analysis. *Perit Dial Int.* Jan-Feb 2002;22(1):39-47.

141. Stanley M, Cari. The CARI guidelines. Peritoneal dialysis versus haemodialysis (adult). *Nephrology.* Apr 2010;15 Suppl 1:S24-31.

142. Golper TA, Saxena AB, Piraino B, et al. Systematic barriers to the effective delivery of home dialysis in the United States: a report from the Public Policy/Advocacy Committee of the North American Chapter of the International Society for Peritoneal Dialysis. *Am J Kidney Dis.* Dec 2011;58(6):879-885.

143. Young BA, Chan C, Blagg C, et al. How to overcome barriers and establish a successful home HD program. *Clin J Am Soc Nephrol.* Dec 2012;7(12):2023-2032.

144. Nesrallah G, Mendelssohn DC. Modality options for renal replacement therapy: the integrated care concept revisited. *Hemodialysis international. International Symposium on Home Hemodialysis.* Apr 2006;10(2):143-151.

145. Harwood L, Clark AM. Understanding pre-dialysis modality decision-making: A meta-synthesis of qualitative studies. *Int J Nurs Stud.* Jan 2013;50(1):109-120.

146. Tong A, Lesmana B, Johnson DW, Wong G, Campbell D, Craig JC. The perspectives of adults living with peritoneal dialysis: thematic synthesis of qualitative studies. *Am J Kidney Dis.* Jun 2013;61(6):873-888.

147. Tong A, Palmer S, Manns B, et al. The beliefs and expectations of patients and caregivers about home haemodialysis: an interview study. *BMJ open.* 2013;3(1).

148. Suri RS, Larive B, Hall Y, et al. Effects of frequent hemodialysis on perceived caregiver burden in the Frequent Hemodialysis Network trials. *Clin J Am Soc Nephrol.* May 2014;9(5):936-942.

APPENDIX A. SEARCH STRATEGY

Database: Ovid MEDLINE(R)

1 hemodialysis, home/ or Peritoneal dialysis/
2 ((hemodial$ or haemodial$ or peritoneal dial$ or HHD or NHHD) adj5 (home$ or in-home or out-center$ or out-centre$ or self-admin$ or self-manag$ or self-care or self-treatment$)).mp
3 renal dialysis.mp. or Renal Dialysis/ or exp Kidneys, Artificial/ or haemodialysis.mp. or hemodialysis.mp.
4 (home$ or in-home or out-center$ or out-centre$ or self-admin$ or self-manag$ or self-care or self-treatment$).mp.
5 3 and 4
6 1 or 2 or 5
7 exp Renal Insufficiency, Chronic/ or exp Kidney Failure, Chronic/ or (end-stage kidney or end-stage renal or endstage kidney or endstage renal).mp. or (ESKD or ESKF or ESRD or ESRF).mp.
8 6 and 7
9 limit 8 to (english language and yr="1995 -Current")
10 limit 9 to "all child (0 to 18 years)"
11 limit 10 to "all adult (19 plus years)"
12 10 not 11
13 9 not 12
14 Randomized controlled trials as topic/
15 Randomized controlled trial/
16 Random allocation/
17 Double blind method/
18 Single blind method/
19 Clinical trial, phase iii.pt.
20 Clinical trial, phase iv.pt.
21 Controlled clinical trial.pt.
22 Randomized controlled trial.pt.
23 ((singl$ or doubl$ or treb$ or trip$) adj (blind$3 or mask$3)).mp.
24 Random$ allocat$.mp.
25 (allocat$ adj2 random$).mp.
26 or/14-25
27 Meta analysis/
28 Meta analys$.mp.
29 (systematic adj (review or overview)).mp.
30 meta analysis.pt.
31 or/27-30
32 exp cohort studies/ or (cohort adj (study or studies)).tw. or Cohort analy$.tw. or (Follow up adj (study or studies)).tw. or (observational adj (study or studies)).tw. or Longitudinal.tw. or comparative study/ or follow-up studies/ or prospective studies/ or cohort.mp. or compared.mp. or multivariate.mp. or Case-Control Studies/ or (case control or case-control).mp.
33 13 and 26 [RCTs/CCTs]
34 13 and 31 [SRs/MAs]
35 13 and 32 [cohort/case-control]
36 35 not (33 or 34) [cohort/case-control not already in lists for RCTs/CCTs/SRs/MAs]

APPENDIX B. PEER REVIEW COMMENTS/AUTHOR RESPONSES

REVIEWER COMMENT	RESPONSE
1. Are the objectives, scope, and methods for this review clearly described?	
Yes	
Yes	
Yes	
2. Is there any indication of bias in our synthesis of the evidence?	
No	
No	
Yes: Because home hemodialysis is not used frequently in the US, many studies have less than 100 subjects; the arbitrary cut off to discount articles with fewer than 100 subjects may lead to bias against home hemodialysis.	Our decision to exclude studies with fewer than 100 subjects was reviewed and approved by our stakeholders and TEP members. We included RCTs regardless of the number of subjects. Small observational studies are not likely to be informative and controlling for confounding variables is difficult.
3. Are there any published or unpublished studies that we may have overlooked?	
Yes: There are other studies that have evaluated risk factors for technique failure (or technique survival) in PD that are not included; some of these looked at technique failure as a secondary outcome where the primary outcome was mortality and may have been missed if a more detailed review of the articles on risk factors for survival in PD (that did not compare modalities) were not evaluated. The factors assessed in this report appear to be mainly demographics and comorbidity and do not involve dialysis related factors such as infection, transport characteristics, ultrafiltration failure. There are reports using the CANUSA study, those by Davies et al that look at these factors.	We have added additional studies identified in our literature search that reported risk factors for survival in PD only. Regarding the factors assessed in the report, our protocol, approved by stakeholders and TEP members, specified that we would look at health system organizational factors, provider knowledge, and patient factors associated with technique selection and technique success (or failure). Therefore, dialysis factors were outside the scope of the review.
No	
Yes: Please see the review below. Articles on home hemodialysis comparison to transplant mortality were not included (Pauly, Nephrol Dial Transplant. 2009 Sep;24(9):2915-9.) as well as smaller articles on caregiver burden and new articles that have been published more recently.	Our Key Questions focused on comparisons of home-based dialysis with other dialysis locations so transplantation was outside the scope of the review. We have updated the literature search (to December 2014). Please see above response regarding small studies.
4. Please write any additional suggestions or comments below. If applicable, please indicate the page and line numbers from the draft report.	
1. It is commented in the review that a greater proportion of individuals on home therapy transfer to in-center HD. What is missing is information on the reason individuals transfer. This could provide more information on factors such as care giver burden.	1. We reviewed the studies reporting greater proportions with change from HHD to HD. None reported reasons for transfer.

2. While registry data shows that PD patients tend to be younger on average. It misses the fact that there is a smaller but significant population of PD patients who are older and who receive PD care with the help of a care giver. This may be more relevant to the VA population. One article that might be relevant with this regards is an analysis by Lobbedez et CJASN 2012 using the French Language Peritoneal Dialysis Registry, where a large proportion of patients received PD with help, most was with family help though they also have a nurse program. For the VA, what might be helpful is if home dialysis support was covered by aid and attendance (if PD or home HD were the option the patient wanted). 3. It seems odd in the analysis of factors associated with technique failure that dialysis related factors were not assessed- e.g. infection, access failure, ultrafiltration failure etc. 4. Small point- there appears to be an error on page 40, Lacson paper it was not home based HD, it was home based dialysis, which was predominantly PD.	2. We have added the Lobbedez reference and an additional reference (Smyth 2012) identified in our search that reported on assisted vs independent PD. 3. Please see above response regarding factors associated with technique failure. 4. We have clarified that the home-based dialysis in this study was predominantly PD.
This is a scholarly and highly informative systematic review of the comparative effectiveness of in-center versus home dialysis modalities, and the factors that portend the relative success or failure of their adoption. The concise analysis of the quality of the available literature and recommendations for future research are highly instructive. Particularly intriguing are the findings of the association of age, race, gender, and comorbidities with differential success of home RRT adoption, technique survival, and clinical and economic outcomes. The following questions are offered from the specific to the more speculative: 1. Please clarify what appears to be a contradictory statement on page 8: "Decreased use of HHD or PD was found in more rural facilities… or in high population density zip code areas,… " Is there a bimodal association of home RRT with domiciliary regional density? 2. Did any studies examine patient satisfaction as an outcome measure per se or is this another knowledge gap to consider in a research agenda for the VA? 3. Does the literature specifically report on patient- reported barriers to adoption of home RRT? (ie in contrast to Provider-perceived patient barriers to greater home RRT 4. For all forms of home RRT – is there any Interaction between likelihood of adoption or technique survival of home RRT based on the following patient characteristics: a. eGFR at RRT start? b. Geography of Patient Domicile(rural, ..) c. Type of patient domicile (SNF versus private home versus other) d. Existence/severity of mental health disorders at RRT initiation e. Existence of communicable comorbidities (HIV, HCV)	Thank you. 1. The study authors do not provide an explanation. However, the findings may not be contradictory. It is likely that facilities in more rural locations do not have resources to support PD while facilities in high population density locations likely have higher percentages of African American patients. The registry studies from the US (Lukowsky 2013, Lievense 2012, Mehrotra 2011, etc.) have shown that PD patients are more likely white. There may also be unmeasured confounding factors, such as socioeconomic status. 2. One US non-randomized study with 226 patients (Kutner 2000, Table 3) measured satisfaction with care (a scale from the KDQOL instrument). We also summarized results from a systematic review of 39 studies of experiences, beliefs, and attitudes about PD (Tong 2013). Nine studies were from the US. There does appear to be a knowledge gap around patient satisfaction, particularly for HHD, and we have added this to the "Research Gaps" section. 3. Three studies (from Europe, the UK, and Canada)

f. Type of home RRT technology employed (CAPD v APD ; Nxstage vs conventional HD equipment) g. For PD: Characteristics of PD transport capacity (eg high vs low transporter) h. For HHD: low SBP; type of vascular access, 5. What are the health system factors that associate with home RRT adoption and technique survival? a. Quantity of pre-dialysis specialty care? Quantity of Predialysis primary care? b. Use of caregiver/patient economic incentive or economic burden relief? c. Dedicated transition-to-ESRD team? (ie standardized process/criteria for initiation) d. Provision of comprehensive care in home (ie all care is home based not just RRT)? e. Use of telehealth as healthcare support system ? f. Use of Specialty care staff to provide RRT in home vs Primary care oversight of RRT? g. Dedicated Home dialysis training centers? h. Availability of in-center RRT respite centers? i. Modality of patient education re home RRT? [electronic (video, internet) vs written material,; group education vs 1:1 in-person training] j. Supply side drivers (ie available capacity for delivery of in-center RRT) k. Any unique features offered by non-US national healthcare systems that associate with home RRT? 6. Can table 1.p 20 , table 2 p27, table 5 p 44, and table 3 p84 be amended to include a column for studies reporting effects by health system characteristics and/or mental health disorders on technique failure and mortality associated w in-center HD vs home RRT modalities? 7. Can a table be created that summarizes the literature reporting on patient, provider, and health system factors that impact home RRT uptake (in contrast to technique survival)? 8. Based on the literature review, Can a preferred population for home RRT be defined? (Eg age < 65, married, absence of CVD, preferred vasc access (for home HD), 9. Based on findings, what resources need to be brought to bear to enable expanded RRT capacity for Veterans through greater uptake/survival of home RRT ? a. Education: Patient Education tools? Staff training tools? b. Economic incentives : To patients? To providers? c. Health system infrastructure: home RRT centers, enhanced home telecommunication d. Health system redesign: Staffed home RRT delivery? (would require training program for family caregivers ,or community nurses, or expanded dialysis specialty staff pool) 10. Based on literature review, how might VA better serve as a data repository to enhance understanding of relative merit of in-center vs home RRT (eg VA as large	included patient-reported barriers to PD (Keating 2014, Chanouzas 2012, Maaroufi 2013) and two studies from Canada included patient-reported barriers to HHD (Zhang 2010, Cafazzo 2009). 4. We have added bullet points in the executive summary and full report to highlight the patient, facility, and provider factors associated with home-based dialysis selection and technique survival that we identified in our literature search. 5. See #4 6. The requested information is not available. 7. See #4 8. The preferred population would be those who have the longest technique survival. However, due to likely selection bias in the reported studies, it is not possible to conclude who is best suited. 9. This is a complex question with little evidence to support decision making. The available evidence is from observational studies. It appears that increased uptake is associated with comprehensive pre-dialysis education, facilities with a larger volume of patients (suggesting perhaps one program per network), and caregiver support. There is no evidence that telehealth capability increases uptake but there may be parallels with caregiver support. 10. A VA dialysis cohort could address a number of deficiencies in the existing data. A survey of all patients starting dialysis could provide information about factors influencing modality selection. Patients could then be surveyed periodically to assess quality of life and caregiver burden, comparing home-based and in-center modalities. Other outcomes of interest could also be captured.

national RRT registry,-what missing data would be particularly useful to capture?)	
Title: VAESP-D-15-00001 General Comments: This is a systematic review of the literature comparing home dialysis modalities to in-center dialysis regarding benefits and harms. The authors evaluated randomized controlled trials, and observational studies with at least 100 subjects. The review is extensive, but the review suffers from several concerns listed below. Major Concerns: 1. The authors limited inclusion of studies that were greater than 100 subjects. The authors should consider studies with 50+ patients at least for home hemodialysis (HHD), since most HHD programs in the United States (US) have been small prior to 2006. 2. There are several newer references that have been published recently regarding nocturnal dialysis outcomes from the Frequent Hemodialysis network that compare nocturnal dialysis to in-center dialysis and more frequent dialysis at home. In particular, there is an article on caregiver burden and nocturnal HHD that the authors may want to include (Clin J Am Soc Nephrol. 2014 May;9(5):936-42). 3. The authors state that most evidence from registry is of high potential for bias and of low quality. There has never been a large randomized trial of home dialysis versus in-center dialysis. Given that there is potential for bias due to patient characteristics, observational studies that attempt to adjust for potential bias by adjustment or study design (case-control), may give useful information, although not as high quality as a randomized controlled trial. 4. The authors do not include information regarding mortality comparing home dialysis to transplantation, which is another outcome that should be considered, given the potential bias of patient selection for in-center vs. home hemodialysis or PD (Pauly et al, Nephrol Dial Transplant. 2009 Sep;24(9):2915-9.). 5. The authors state in the executive summary that “However, the applicability of these findings to the Veteran population may be limited. HHD and PD patients typically were younger and with fewer comorbidities than likely seen in Veterans”, which seems to be an overstatement given the paucity of the data. Other countries, such as Australia/New Zealand and Canada have elderly patients with comorbid conditions preferentially on home dialysis therapies. This seems that it may be a bias of the authors against home dialysis modalities! 6. Catheter related infections and home dialysis. New data has emerged regarding risks from observational studies (Hemodial Int. 2015 Feb 3. doi: 10.1111/hdi.12245. [Epub ahead of print). 7. The sections of the review should have bullet points at the end that summarize the findings. The executive review has no references at all. References could be enumerated and included.	1. See response above regarding sample size of included studies. 2. We did not include results from the FHN nocturnal trial because the 6 times/wk and 3 times/wk groups were both largely treated at home. The caregiver paper cited (Suri 2014) provides only an indirect comparison of home vs in-center HD caregiver burden but has been included in the Discussion section of the review. 3. We agree that a large randomized trial of HHD vs HD is not likely. We report the results from the observational/registry studies including the adjusted outcomes. 4. See response above regarding the comparison of HHD to transplantation. 5. We have modified the Applicability section. 6. We have added this study (Xue 2015). 7. We have attempted to improve the readability of the review. We typically do not include references in the Executive Summary. 8. We have added this reference (Marshall 2014) along with others identified in our updated literature search. 9. We reviewed our reporting of the RCTs to confirm that length of follow-up was presented. 10. As noted above, we have attempted to improve the readability of the review.

8. Recent findings evaluate mortality between HHD and PD patients that the authors should consider (PLoS One. 2014 May 7;9(5):e96847. doi: 10.1371/journal.pone.0096847. eCollection 2014.). 9. Many of the randomized trials were short term (6-12 months), thus is no long-term follow up of RCTs, which should be stated where appropriate. 10. The entire review is too long. The authors should try to shorten and place more information in tables for comparison.	

APPENDIX C. EVIDENCE TABLES

Table 1. REGISTRY STUDIES - Study Characteristics and Survival, Technique Failure, and Transplantation Outcomes for Key Questions 1 and 2

Author, Year Dialysis Modalities Study Purpose	Cohort Years Country	Sample Size Inclusion Criteria	Patient Characteristics	Data Adjusted For Modeling Technique Analysis	Length of Follow-up	Key Findings
United States Renal Data System (USRDS)/Centers for Medicare and Medicaid Services (CMS)						
Weinhandl 2015[20] HD, HHD (NxStage System One users) Assess hospitalization risk in patients treated with HHD vs HD	2006-2010 USA (NxStage and USRDS) Likely overlap with Weinhandl 2012	N=3480 incident HHD patients (new to NxSTAGE) N=17,400 matched prevalent HD patients HHD: 5 or 6 sessions/week, Medicare as primary payer HD: 3 sessions/week	Age (yrs): 54 Gender (% male): 66 Race (%) black (27), nonblack (73)	Age, race, gender, primary cause of ESRD, ESRD duration, dual Medicare/Medicaid enrollment, comorbid conditions, BMI, catheter insertion (past 3 months), hospitalization (past 3 months), transplant wait list, affiliation of dialysis provider, exposure to epoetin, iron, vit D (for matching) Poisson regression ITT	Max of 5 years	-Hospital admissions (HHD vs HD), RR All cause: 1.03 (0.99, 1.08) Cardiovascular: 0.83 (0.78, 0.88) Infection: 1.32 (1.24, 1.40) Vascular access dysfunction: 1.01 (0.90, 1.13)
Lukowsky 2013[26] PD, HD Examine survival differences over 1st 24 months accounting for modality changes, transplantation rates and laboratory measures	2001-2004 USA (USRDS and DaVita)	N=23,718 incident patients Included if no missing data on dialysis modalities and key predictors	Age (yrs): 63* Gender (% male): 54 Race (%): white (44), black (29), Hispanic (17), Asian (3)* *PD patients younger, more likely white or Asian, less likely black or Hispanic	Age, gender, race, diabetes, marital status, employment, comorbidities, laboratory variables Marginal structural model (MSM); Kaplan-Meier survival; Cox proportional hazards ITT (modality at day 90)	Max of 2 years	-Mortality (PD vs HD); Cox 12 months: 0.62 (0.51, 0.75) 24 months: 0.81 (0.72, 0.92) -Mortality (PD vs HD); MSM 12 months: 0.59 (0.44, 0.78) 24 months: 0.52 (0.34, 0.80) -Switched modality: HD to PD: 6%, PD to HD: 57% -Transplant rates (during 1st 2 years of dialysis): 6% HD, 18% PD

Author, Year Dialysis Modalities Study Purpose	Cohort Years Country	Sample Size Inclusion Criteria	Patient Characteristics	Data Adjusted For Modeling Technique Analysis	Length of Follow-up	Key Findings
Lievense 2012[27] PD, HD Interrelation-ship between body size and initial dialysis modality on transplantation, mortality, and weight gain	2001-2006 USA (USRDS and DaVita)	N=4,008 propensity-matched pairs (incident PD and HD patients) Age ≥18, no prior renal transplant, BMI 12-61; excluded if no data on age, dialysis modality at day 90, or variables needed for propensity matching	Age (yrs): 58 Gender (%male): 54 Race (%): Caucasian (55), black (21), Hispanic (14) HD patients more likely to be black	3 models: 1. minimally adjusted (modality and entry calendar quarter) 2. case-mix adjusted (#1 plus age, gender, race, ethnicity, comorbid conditions, smoking, insurance, marital status) 3. case-mix and laboratory (#2 and laboratory variables) ITT	Max of 6 years	-Mortality (PD vs HD) Model 3: HR 0.88 (0.81, 0.95) -Renal Transplant (PD vs HD) Model 3: HR 1.48 (1.29, 1.70); similar findings across strata of BMI
Weinhandl 2012[8] HD, HHD (NxStage System One users) Assess relative mortality of daily HHD and thrice-weekly HD using data from patients matched on 1st date of follow-up, demographics, and measures of disease severity	2005-2008 USA (USRDS and NxStage re gistry)	N=1873 incident HHD patients (new to NxSTAGE) N=9365 matched prevalent HD patients HHD: linked to USRDS, 5 or 6 prescribed sessions/week, Medicare primary payer status during 3 months before NxStage use or starting RRT during 6 months before NxStage use HD: 3 times/week	Age (yrs): 53 Gender (% male): 63 Race (%): black (28), other (72)	Age, gender, race, diabetes, hospital days, BMI, ESRD duration, other comorbidities (for matching) Matched 1 HHD patient with 5 HD patients Cox proportional hazards ITT (modality on index date of HHD patient; followed to earlier of death or end of study)	Max of 4 years	-Mortality (HHD vs HD); Cox (unadjusted), ITT Overall: 0.87 (0.78, 0.97) 1-6 months: 0.88 (0.78, 0.98) 25+ months: 0.92 (0.66, 1.28) -Cardiovascular mortality (HHD vs HD); Cox (unadjusted), ITT 0.92 (0.78, 1.09) -Change in dialytic modality HHD: 26% (97% to HD, 3% to PD) HD: 3% HR 10.4 (8.9, 12.3) -Transplant HHD: 10.2% HD: 10.8% HR 1.06 (0.89, 1.25)

Author, Year Dialysis Modalities Study Purpose	Cohort Years Country	Sample Size Inclusion Criteria	Patient Characteristics	Data Adjusted For Modeling Technique Analysis	Length of Follow-up	Key Findings
Weinhandl 2010[29] PD, HD Compare survival of HD and PD patients in a matched-pair cohort and subsets defined by age, CVD, and DM	2003 USA	N=12,674 incident patients (matched pairs, 6337 PD, 6337 HD) ≥ 18 years; began HD or PD immediately, no missing data for age, gender, race, or ethnicity	Age (yrs): 59* Gender (% male): 54* Race (%): white (70), African American (22), Asian (1)* *Matched pairs	Age, gender, race, ethnicity, primary ESRD cause, laboratory variables, GFR, comorbid conditions Propensity scores to match HD patients to PD patients Kaplan-Meier survival estimates Cox proportional hazards ITT (modality at initiation or at day 90)	Max of 4 years	-Mortality (PD vs HD), HR – All years ITT from day 0: 0.92 (0.86, 1.00) ITT from day 90: 1.05 (0.96, 1.16) -Mortality (PD vs HD), HR – Year 1 ITT from day 0: 0.70 (0.62, 0.78) ITT from day 90: 0.90 (0.76, 1.06) -Mortality (PD vs HD), HR – Year 2 ITT from day 0: 1.10 (0.95, 1.29) ITT from day 90: 1.19 (1.02, 1.38)
Mehrotra 2011[28] PD, HD Test hypothesis that initial dialysis modality has no effect on life expectancy of patients with ESRD using marginal structural models	1996-2004 USA	N=64,406 incident PD patients N=620,020 incident HD patients Modality on day 90 was HD, CAPD, or APD	Age (yrs): 18-44 (15%), 45-64 (37%), 65+ (49%)* Gender (% male): 53 Race (%): white (63), black (30), Asian (4)* *PD patients younger, more likely white	Age, gender, race, current employment status, facility characteristics, cause of ESRD, comorbid conditions, eGFR, BMI, laboratory variables Nonproportional hazards models using a piecewise exponential survival model MSM with inverse probability of treatment and censoring weighting ITT (modality on day 90)	Max of 5 years (median follow-ups of 25-30 months for different cohorts)	Mortality (PD vs HD), HR, MSM 2002-2004 cohort: 1.03 (0.99, 1.06)

Author, Year Dialysis Modalities Study Purpose	Cohort Years Country	Sample Size Inclusion Criteria	Patient Characteristics	Data Adjusted For Modeling Technique Analysis	Length of Follow-up	Key Findings
MacRae 2010[9] PD (delivered in residential setting), In-center HD (staff-assisted or self-care), HHD (out-of-center HD delivered in home or long-term care facility) Use and outcome of HHD	1995-2004 USA	N=458,329 incident patients Age ≥18 years, primary insurer was Medicare of Medicaid, stable on single dialysis modality for at least 60 days; excluded if kidney transplant was initial treatment modality or if modality could not be determined	Age (yrs): 18-44 (12%), 45-59 (20%), 60-74 (40%), 75+ (28%)* Gender (% male): 52 Race (%): white (64), black (30), Asian (3), Native American (1)* *HHD and PD patients younger than HD, HHD more likely non-white than HD, PD more likely white than HD	Age, gender, race, cause of ESRD, diabetes, history of CVD, self-reported functional status, dialysis era, median income, employment status Kaplan-Meier (univariate) Cox regression (multivariate) Propensity score matching (secondary sensitivity analysis) ITT	Max of 9 years 3 months, minimum of 2 months	-Mortality, multivariate HRs* HHD vs HD: 1.10 (1.04, 1.17) HHD vs PD: 1.04 (0.98, 1.11) -Propensity score matching HHD& HD: No association between modality and improved survival (HR not reported) HHD&PD: 1.11 (1.03, 1.19) (HHD vs PD) *Results did not differ among patients more likely to reside at home (<50 years, able to ambulate and transfer independently, no diabetes or CVD) or more likely to reside in long-term care facility (>60, unable to ambulate or transfer independently, diabetes and/or CVD)
Abbott 2004[31] PD, HD Determine whether association between obesity and survival differed for HD vs PD patients and whether obese patients had differing survival with one modality vs another	1996 USA (USRDS Dialysis Morbidity and Mortality Wave II [DMMS])	N=3337 (1662 PD, 1675 HD) incident patients (all eligible patients initiating PD and a 20% random sample of patients initiating HD) Survived more than 90 days on dialysis	Age (yrs): 59* Gender (% male): 53 Race (%): African-American (28)* *PD patients younger, less likely African-American	BMI, age, race, gender, diabetes as cause of renal failure, comorbid conditions, ability to walk independently, laboratory variables, malnutrition, renal transplantation, use of aspirin, ACE inhibitors, beta-blockers, calcium channel blockers, and HMG-CoA reductase inhibitors Cox proportional hazards ITT	Max of 5 years	-Mortality (unadjusted): PD: 989/1662 (60%) HD: 1100/1675 (66%); P = .0003 -PD a significant modifier of effect of obesity on survival: Adj HR 1.41 (1.06, 1.88) -Change in dialytic modality (at least once) PD: 46% HD: 4%

Author, Year Dialysis Modalities Study Purpose	Cohort Years Country	Sample Size Inclusion Criteria	Patient Characteristics	Data Adjusted For Modeling Technique Analysis	Length of Follow-up	Key Findings
Vonesh 2004[32] PD, HD Identify key patient characteristics for which risk of death differs by dialysis modality and adjust mortality comparisons between HD and PD by stratifying on those factors	1995-2000 USA	N=398,940 incident patients (2 cohorts, 1995-1998 N=185,704 and 1998-2000 N=213,236) Incident patients surviving 1st 90 days	Age (yrs): 18-44 (14%), 45-64 (35%), 65+ (51%)* Gender (% male): 54 Race (%): white (54), black (30), other (15%)* *PD patients younger, more likely white	Cohort period, age, gender, race, cause of ESRD, comorbid conditions, BMI, GFR, laboratory variables Interval Poisson regression (proportional and non-proportional hazards models) ITT (modality at initial treatment [≥60 days prior to and including day 90])	Max of 3 years	-Mortality (HD vs PD), RR, ITT No Comorbid Conditions, Non-Diabetes Cause Age 18-44: 1.24 (1.07, 1.44) Age 45-65: 1.13 (1.02, 1.25) Age ≥65: 1.13 (1.05, 1.21) One or More Comorbid Conditions, Diabetes as Cause Age 18-44: 1.10 (0.92, 1.32) Age 45-65: 0.82 (0.77, 0.87) Age ≥65: 0.80 (0.76, 0.85) -Over Follow-up Time: risk of death initially higher for HD then either reaches level of PD (for non-DM patients and younger DM patients) or becomes lower than PD (older DM patients)
Stack 2003[33] (see Table 3 - Stack 2004[54] for BMI data and Ganesh 2003[55] for CAD data) PD, HD Explore hypothesis that patients new to ESRD with history of CHF experience greater survival with PD compared to HD	1995-1997 USA	N=107,922 incident patients ≥ 18 years; excluded if renal transplant within 1st 90 days; modality at 90 days could not be determined, missing data (demographic, comorbidity, laboratory) of interest	Age (yrs): 62* Gender (% male): 53* Race (%): white (63), black (31), Asian (4)* *PD patients younger, more likely white or Asian, less likely black, more likely male	Age, gender, race, diabetes as cause of ESRD, comorbid conditions, BMI, laboratory variables, eGFR Cox regression ITT (modality at initiation) AT (censored from contributing additional time at risk when switched modalities)	Max of 2 years (median 12 months)	-Mortality (PD vs HD), RR, ITT 0-6 months: 0.92 (0.87, 0.98) 0-24 months: 1.11 (1.07, 1.16) -Mortality, RR, AT *With CHF, Diabetes* Stay on HD: 1.00 (reference) Stay on PD: 1.29; P < .001 Switch to HD: 1.50; P < .001 Switch to PD: 1.72; P < .001 *No CHF, No Diabetes* Stay on HD: 1.00 Stay on PD: 0.90; P < .01 Switch to HD: 1.46; P < .001 Switch to PD: 1.28; P < .001

Author, Year Dialysis Modalities Study Purpose	Cohort Years Country	Sample Size Inclusion Criteria	Patient Characteristics	Data Adjusted For Modeling Technique Analysis	Length of Follow-up	Key Findings
Collins 2002[30] PD, HD Survival in elderly patients accounting for comorbidity before dialysis	1995-1997 USA	N=70,208 incident patients ≥ 67 years, able to ascertain a stable dialysis modality (>60 days), able to classify gender, race, renal network of residence, primary cause of renal failure	Age (yrs): 75* Gender (% male): 51* Race (%): white 72,* black 24, other 4 *PD patients younger, more likely male, more likely white	Age, gender, race, geographic location, Charlson comorbidity index, baseline GFR, prior hospital days, incidence year, primary cause of renal failure Interval Poisson regression ITT (censored at switch to different modality)	Up to 4 years	-In an elderly population, PD appears to be associated with a higher risk of death than HD in both diabetics and non-diabetics
Xue 2002[34] PD, HD Determine association of clinical characteristics at initiation of PD and HD with 1-year mortality	1995-1997 USA	N=112,077 incident patients Alive on day 91 after enrollment	Age (yrs): NR Gender (% male): 53 Race (%): white (66), black (34)	Model 1: Age, gender, race, incidence year Model 2: Model 1 plus BMI, laboratory data Cox proportional hazards ITT (modality on day 91)	1 year	-Mortality (PD vs HD), HR *Diabetics* Model 1: 1.05 (0.99, 1.11) Model 2: 1.13 (1.07, 1.20) *Non-diabetics* Model 1: 0.77 (0.72, 0.81) Model 2: 0.88 (0.83, 0.94)

Author, Year Dialysis Modalities Study Purpose	Cohort Years Country	Sample Size Inclusion Criteria	Patient Characteristics	Data Adjusted For Modeling Technique Analysis	Length of Follow-up	Key Findings
Collins 1999[35] PD, HD Assess differential death rate patterns of PD and HD over time	1991-1994 USA	N=117,158 incident patients Medicare eligible, survived at least 90 days	Age (yrs): NR Gender (% male): NR Race (%): NR Females < 55 years of any race more likely on HD; white and black males 55+ more likely on HD	Age, gender, race, modality, and interactions Poisson regression Cox regression ITT (modality at day 90)	Max of 3 years, 6 months	-Mortality (PD vs HD), RR (values not reported) *Diabetes:* PD mortality risk lower at 3 months follow-up, significantly higher at 12 months follow-up and remains higher through 24 months (but not significant at every 3 month time interval) *No Diabetes:* PD mortality risk lower than HD through 9 months follow-up; no significant difference from 12 to 24 months -Cardiovascular mortality (PD vs HD); age 55 and older only *Diabetes:* males and females had reduced risk of cardiac death (RR 0.90 for both) relative to males age 55+ receiving in-center HD *No Diabetes:* males and females had reduced risk of cardiac death (RR 0.70 for both) relative to males age 55+ receiving in-center HD
Woods 1996[10] HD, HHD (in training on day 30 after onset of ESRD to exclude those likely receiving dialysis from a nurse visiting the home) Relative risk of survival with HHD adjusting for patient characteristics and comorbid conditions	1986-1987 USA	N=3172 incident patients (USRDS Special Study of Case Mix Severity Standard Analysis File) Age 18-90 years, Medicare-entitled for dialysis within ≤90 days of ESRD; excluded PD, Asian or unknown race, history of cardiac arrest, neoplasm with metastases, hepatic cirrhosis, or clinically undernourished	Age (yrs): 58* Gender (% male): 51 Race (%): white (59), black, Native American/Alaska Native (41) *HHD patients younger	Age, gender, diabetes, comorbid conditions Cox proportional hazards ITT (modality at day 30)	Max of 4.1 years	-Mortality (HHD vs HD), adj RR (age, gender, diabetes): 0.56 (0.34, 0.92); P = .02 -Additional adj for comorbid conditions: 0.58 (0.35, 0.95); P = .03

Author, Year Dialysis Modalities Study Purpose	Cohort Years Country	Sample Size Inclusion Criteria	Patient Characteristics	Data Adjusted For Modeling Technique Analysis	Length of Follow-up	Key Findings
Bloembergen 1995[36] PD (CAPD/ CCPD) HD Compare mortality adjusting for demographic characteristics	1987, 1988, 1989 (3 cohorts) USA (Note: some patients contributed to >1 cohort)	170,700 PY with prevalent patients CAPD/CCPD or in-center HD; started ESRD therapy >3 months before start of cohort year; no change in modality during 60 days before cohort year	Age (yrs): 60* Gender (% male): 50 Race (%): white (60), black (36),* other (4) *PD patients younger, less likely black	Age, gender, race, cause of ESRD, duration of ESRD therapy (<1 year or >1 year) Poisson regression ITT (switches in dialysis modality during 1 year follow-up were not considered)	12 months (each cohort)	-All cause death rate (PD compared to HD): RR 1.19 (P < .001) -RR accentuated if female, diabetic, or on therapy for ESRD for > 1 year
Patient Statistical Profile System (PSP) from National Medical Care, Inc (NMC)						
Lowrie 1995[37] PD (CAPD/ APD), HD Explore relationship between survival and processes of care among PD patients vs HD	Receiving dialysis on 1/1/1992 or starting dialysis during 1992 USA	N=17,926 prevalent and incident patients 3 times weekly HD, CAPD, or APD (single therapy), intermittent PD excluded; complete clinical and laboratory data	Age (yrs): 58* Gender (% male): 51 Race (%): white (50), black (40), Asian (2)* *PD patients younger and more likely to be white	Age, gender, diagnosis, race, laboratory factors Cox proportional hazards ITT (modality at entry into study)	Max of 1 year	Risk of death (PD vs HD) RR 1.32 (P = .005)

Author, Year Dialysis Modalities Study Purpose	Cohort Years Country	Sample Size Inclusion Criteria	Patient Characteristics	Data Adjusted For Modeling Technique Analysis	Length of Follow-up	Key Findings
Australia and New Zealand Dialysis and Transplant Registry (ANZDATA)						
Marshall 2014[11] PD, HD, HHD Compare survival between home dialysis and facility HD	1997-2011 New Zealand (Note: some patients were classified in multiple modality categories)	N=6,419 incident patients Age ≥ 18	Age (yrs): 59* Gender (% male): 59 Race (%): NZ European (46), NZ Maori (32), Asian (6), Pacific (17) *PD patients older, less likely male and more likely NZ European and less likely Pacific than facility HD patients HHD patients younger, more likely male, and more likely NZ European and less likely Pacific than facility HD patients	Age, gender, ethnicity, primary kidney disease, eGFR, late referral for nephrology pre-dialysis care (<3 months), DM, BMI, comorbid conditions, smoking, year of dialysis inception Cox proportional hazards AT (modality received)	Max of 15 years	-Mortality (PD vs HD) HR 0.98 (0.90, 1.06) Follow-up < 3 years: HR 0.80 (0.72, 0.88) Follow-up > 3 years: HR 1.33 (1.17, 1.50) -Mortality (HHD vs HD) HR 0.48 (0.41, 0.56) Follow-up < 3 years: HR 0.41 (0.32, 0.53) Follow-up > 3 years: HR 0.57 (0.46, 0.70)
Marshall 2011[12] PD, HD, HHD, Freq/ext HD, Freq/ext HHD Compare survival with medical comorbidity as source of selection bias and intermediary variable	1996-2007 Australia or New Zealand (Note: some patients were classified in multiple modality categories)	N=26,016 incident patients (856,007 patient months of follow-up) Age ≥ 18	Age (yrs): 60* Gender (% male): 59* Ethnicity (%): white/other (75),* Aboriginal/Torres islander (7), Asian (4), NZ Maori/Pacific (11) *Home HD patients more likely younger, male, white/other	Age, gender, ethnicity, primary kidney disease, eGFR at dialysis inception, late referral for nephrology pre-dialysis care (<3 months), DM, BMI, comorbid conditions, country/state at inception, year of treatment Marginal structural modeling AT	Max of 11 years and 9 months	-Mortality, HR HHD vs HD Overall: 0.51 (0.44, 0.59) 12 months: 0.37 (0.24, 0.56) 24 months: 0.49 (0.39, 0.62) -Mortality, HR PD vs HD Overall: 1.10 (1.06, 1.16) 12 months: 0.80 (0.73, 0.87) 24 months: 0.93 (0.88, 1.00) -Cardiovascular cause of death (%) HHD: 65% HD: 47% PD: 54% -Overall Mortality, HR vs conventional HD Freq/Ext HD: 1.16 [0.94, 1.44] Freq/Ext HHD: 0.53 [0.41, 0.68]

Author, Year Dialysis Modalities Study Purpose	Cohort Years Country	Sample Size Inclusion Criteria	Patient Characteristics	Data Adjusted For Modeling Technique Analysis	Length of Follow-up	Key Findings
McDonald 2009[38] PD (CAPD, APD), HD (including hospital, satellite, and home-based) Relationship between dialysis modality and mortality	1991-2005 Australia or New Zealand	N=25,287 incident patients All patients commencing dialysis and surviving ≥90 days	Age (yrs): 60 (median)* Gender (% male): 58* Race (%): Aboriginal and Torres Strait Islander (ATSI) 7, Maori/Pacific Islander (MPI) 10%* *PD patients older, less likely male, less likely ATSI, more likely MPI	BMI, age, gender, race, comorbidities, late referral, country of initial treatment, vintage Cox regression Propensity score matched cohort Shared frailty Cox model for unmeasured variation between centers ITT (treatment modality at 90 days)	3 months to 14 years and 3 months	-Mortality, multivariate Cox, HR, PD vs HD 1st year: 0.80 (0.81, 0.96) ≥1 year: 1.32 (1.26, 1.38) -Mortality, propensity Score, HR, PD vs HD 1st year: 0.99 (0.89, 1.10) ≥1 year: 1.35 (1.27, 1.42) -HR (relative to Start on HD, Stay on HD) 1st year, Start on PD, Stay on PD: 0.87 (0.78, 0.97) 1st year, Start on PD, Switch to HD: 1.36 (1.04, 1.78) 1st year, Start on HD, Switch to PD: 1.09 (0.97, 1.23) ≥1 year, Start on PD, Stay on PD: 1.28 (1.22, 1.31) ≥1 year, Start on PD, Switch to HD: 1.13 (0.95, 1.34) ≥1 year, Start on HD, Switch to PD: 1.34 (1.26, 1.43)
Canadian Organ Replacement Register (CORR)						
Yeates 2012[39] PD, HD Compare survival outcomes hypothesizing worsening of PD survival during the study period	1991-2004 Canada	N=46,839 incident patients Age 18 or older, no pre-emptive renal transplant or extra-renal transplant	Age (yrs): 18-34 years: 7% 35-64 years: 43%* 65+ years: 50%* Gender (% male): 58* Race (%): Caucasian: 75, Aboriginal: 5, Asian: 5, Black: 3, Other 12 *PD higher % in 35-64 year range; HD higher % in 65+ range	Case-mix differences, region, age, gender, race, cause of primary renal disease, diabetes, co-morbidity (Charlson) Proportional hazards and non-proportional hazards models; piecewise exponential survival AT (reclassified every time modality was switched) ITT (modality at 90 days)	Max of 17 years	-Mortality, adj HR (PD vs HD), ITT Overall (1991-2004): 1.08 (1.04, 1.11) 2001-2004 cohort: 0.99 (0.92, 1.06)* -Early survival advantage for PD patients (through 2 years); in 2000-2004 cohort - no difference between HD and PD after 2 years -Technique survival to 60 months: PD group separates from HD group (lower technique survival for PD group) at 10 months *Adj HR significant for 1991-1995 and 1996-2000 cohorts

Author, Year Dialysis Modalities Study Purpose	Cohort Years Country	Sample Size Inclusion Criteria	Patient Characteristics	Data Adjusted For Modeling Technique Analysis	Length of Follow-up	Key Findings
Schaubel 1998[40] PD (CAPD/ CCPD), HD Compare adjusted mortality rates	1990-1995 Canada	N=14,483 incident patients Initiated treatment 1/1990-12/1995 with data available on pre-dialysis comorbid conditions	Age (yrs): NR Gender (% male): NR Race (%): NR	Age, follow-up time, primary renal diagnosis, pre-dialysis comorbid conditions ITT (modality at 90 days) analyzed with Cox regression	0 to 6 years	-Mortality rate ratio (PD vs HD): 0.93 (0.87, 0.99) -Reduction in mortality associated with PD diminished with longer follow-up; reduction was non-significant at ≥24 months follow-up
Fenton 1997[41] PD (CAPD/ CCPD), HD Compare mortality controlling for age, primary renal diagnosis, center size, and comorbid conditions	1990-1994 Canada	N=10,633 incident patients Initiated treatment 1/1990-12/1994 with data available on pre-dialysis comorbid conditions	Age (yrs): 0-14 years: 2% 15-44 years: 23% 45-64 years: 36% 65+ years: 39%* Gender (% male): NR Race (%): NR] *HD patients older than PD patients	Age, primary renal diagnosis, RRT center size, pre-dialysis comorbid conditions AT (modality switches incorporated) analyzed with Poisson regression ITT (modality at 90 days) analyzed with Cox regression	0 to 5 years	-5 year survival: PD 35%, HD 36% -Initially better survival on PD but difference between modalities diminishes and after 3 years slightly favors HD -Mortality rate ratio (PD vs HD): 0.95 (0.88, 1.03) -Transplantation RR (PD vs HD): 1.16 (1.06, 1.28) -Technique failure rates PD: 186/1000 PY HD: 165/1000 PY RR 1.15 (1.01, 1.31)

Author, Year Dialysis Modalities Study Purpose	Cohort Years Country	Sample Size Inclusion Criteria	Patient Characteristics	Data Adjusted For Modeling Technique Analysis	Length of Follow-up	Key Findings
Institute for Clinical Evaluative Sciences (ICES, Canada)						
Quinn 2011[42] PD, HD RR for mortality (PD vs HD) for patients with ≥ 4 months pre-dialysis care and starting elective outpatient dialysis; objectives - isolate association between modality and mortality; how different analytical approaches influence results	1998-2006 Canada	N=6573 incident patients Age ≥ 18, ≥ 1 Ontario Health Insurance Plan (OHIP) claim for any form of dialysis, ≥ 2 years OHIP coverage before dialysis	Age (yrs): 63 Gender (% male): NR Race (%): NR	Demographics, comor-bidities, hospitalization, days in hospital past year Cox proportional hazards; adjusted using corrected group-prognosis method; 3 cohorts: Primary: CKD, ≥4 months pre-dialysis care, started dialysis electively Secondary :1) All patients starting outpatient dialysis; 2) All patients alive (PD or HD) at 90d ITT (modality at baseline)	Max of 7 years and 9 months	-Primary Cohort, adj HR (PD vs HD): 0.96 (0.88, 1.06) No change in relative hazard of death at 12 or 24 months -Secondary Cohorts: RR of death on PD compared to HD increased over time
Dutch End-Stage Renal Disease Registry (RENINE)						
Liem 2007[43] PD, HD Compare mortality of HD and PD patients	1987-2002 Netherlands	N=16,643 incident patients Age 18 or older; at least 30 days of RRT; survived first 90 days of RRT; no pre-emptive transplant; no more than 1 episode of recovery of renal function; treated at center with at least 20 dialysis patients and at least 5 PD patients	Age (yrs): 59* Gender (% male): 59* Race (%): NR *PD patients younger and more likely male	Age, gender, year of start of dialysis, dialysis center, cause of ESRD Multivariable Cox proportional hazards model ITT (modality on day 91 was definite modality)	Mean: 2.4 years	-Mortality, Adj HR (PD vs HD): 0.99 (0.94, 1.05) -Mortality risk (PD vs HD) increased with age, with presence of DM, and with greater time (>15 months)

Author, Year Dialysis Modalities Study Purpose	Cohort Years Country	Sample Size Inclusion Criteria	Patient Characteristics	Data Adjusted For Modeling Technique Analysis	Length of Follow-up	Key Findings
European Renal Association-European Dialysis and Transplant Association (ERA-EDTA)						
van de Luijtgaarden 2011[44] PD, HD Assess modality choice within subgroups (age, DM, IHD, PVD, CD, and malignancy) and association between choice and survival in subgroups	1998-2006 Austria, Belgium (French speaking), Spain (Catalonia), Greece, Norway, Sweden, UK	N=15,828 incident patients Age ≥20 years; data available on diabetes (DM), ischemic heart disease (IHD), peripheral vascular disease (PVD), cerebrovascular disease (CD), malignancies	Age (yrs): 63* Gender (% male): 62 Race (%): NR *PD patients younger than HD patients	Age, gender, country, DM, IHD< PVD, CD, malignancy Kaplan-Meier and Cox proportional hazards ITT (modality at 91 days)	Max of 3 years (mean 1.6 years)	-Adj HR (PD relative to HD): 0.82 (0.75, 0.90) -Transplantation PD: 17.9% HD: 17.7% -Switched modalities PD: 25% HD: 4%
Finnish Registry for Kidney Diseases						
Haapio 2013[45] PD, HD Association of modality with survival	2000-2009 Finland	N=4463 incident patients (1217 PD, 3246 HD [including 105 HHD]) Age ≥ 20	Age (yrs): 62* Gender (% male): 64 Race (%): NR *PD patients younger (also higher % of PD patients on transplant wait list)	Age, gender, ESRD diagnosis, comorbidities, laboratory variables, kidney transplant wait list status at 3 months from RRT start Cox proportional hazards ITT (modality on day 91)	Max of 10 years; median 2.8 years	-Mortality (PD vs HD), RR 1.07 (0.94, 1.22)

Author, Year Dialysis Modalities Study Purpose	Cohort Years Country	Sample Size Inclusion Criteria	Patient Characteristics	Data Adjusted For Modeling Technique Analysis	Length of Follow-up	Key Findings
French Renal Epidemiology and Information Network (REIN)						
Sens 2011[46] PD, HD Compare mortality risks by dialysis modality in patients who started dialysis with associated CHF	2002-2008 France	N=4401 incident patients Age ≥ 18, history of CHF at first RRT Excluded if unplanned 1st dialysis session or preemptive transplant	Age (yrs): 73* Gender (% male): 67* Race (%): NR *PD patients older and less likely male	Age, gender, use of central venous catheter at dialysis initiation, comorbidities at first RRT Cox proportional hazards Propensity score ITT (modality at day 90)	0 days to max of 7 years	-Mortality, adj HR (PD vs HD): 1.48 (1.33, 1.65) -Propensity score adjustment: 1.55 (1.37, 1.77) -Cardiovascular mortality HD: 35% PD: 40%, P = .04 -Renal transplant, P = .06 PD: 2.3% (mean time of 25 months after RRT) HD: 3.5% (mean time of 22 months) -Switched modalities PD: 10.5% (median time 12 months) HD: 0.6% (median time 4 months)
International Quotidian Dialysis Registry (IQDR) and Dialysis Outcomes and Practice Patterns Study (DOPPS)						
Nesrallah 2012[13] HHD (intensive, ≥ 5.5 hours/ session, 3-7 sessions/week) HD (conventional, < 5.5 hours/ session; 3 sessions/week) Whether intensive hemodialysis associated with better survival than conventional hemodialysis	2000-2010 Multi-national (Canada, France, USA)	N=1726 (338 incident and prevalent patients [HHD], 1388 matched HD) HHD patients from IQDR (none using NxStage device); HD patients from DOPPS	Age (yrs): 52* Gender (% male): 65* Race (%): white (73), black (11), other (16) *HHD patients were younger, more likely male	Age, gender, race, diabetes Matched intensive and conventional HD patients (up to 10 per intensive patient) by country, duration of ESRD, and propensity score Kaplan-Meier product-limit method; Cox regression ITT (modality at index date)	Median of 1.8 years; max of 4 years	-Mortality, adj HR (HHD vs HD): 0.53 (0.33, 0.86) -Renal transplant HHD: 9.5/100 PY (7.6, 12.1) HD: 8.8/100 PY (6.7, 11.6) -Switched modalities HHD: 48 switched to HD HD: 0 switched to HHD

Author, Year Dialysis Modalities Study Purpose	Cohort Years Country	Sample Size Inclusion Criteria	Patient Characteristics	Data Adjusted For Modeling Technique Analysis	Length of Follow-up	Key Findings
Lombardy Dialysis and Transplant Registry						
Locatelli 2001[47] PD, HD Compare influence of HD and PD on overall mortality and risk of developing *de novo* CVD	1994-1997 Italy	N=4064 incident patients (N=3120 for analysis of new CVD) Inclusion: NR	Age (yrs): 62 Gender (% male): 60 Race (%): NR	Age, gender Univariate survival (Kaplan-Meier) and Cox proportional hazards regression ITT (modality at 1 month)	Max of 4 years	-Death rate: PD 13.9/100 PY, HD 12.0/100 PY (not considering changes in modality) -Death due to cardiac causes (not considering changes in modality) PD: 11.4% HD: 21.1% -Mortality (adj) at 4 years (PD vs HD): 0.91 (0.79, 1.06) -Cardiovascular disease risk (*de novo*), PD vs HD: 1.06 (0.79, 1.43) -Ischemic heart disease *(de novo),* PD vs HD: 1.00 (0.61, 1.64) -Congestive heart failure *(de novo)*, PD vs HD: 1.07 (0.66, 1.72) -Switch from PD to HD: 17% -Switch from HD to PD: 3% -New CVD (adj RR); (PD vs HD): 1.06 (0.79, 1.43)
Romanian Renal Registry						
Mircescu 2014[48] PD, HD Compare survival of HD and PD patients	2008-2011 Romania	N=9252 incident patients (8252 HD [including HHD], 1000 PD) Age ≥ 18	Age (yrs): 61 Gender (% male): 57* Race (%): NR *HD group had higher percentage of males	Age, gender, primary renal disease Kaplan-Meier and Cox proportional hazards ITT (modality at 90 days)	Max of 5 years	-Mortality (PD vs HD), HR 1.01 (0.89, 1.51) -Cardiovascular mortality PD: 47% HD: 49% (P = .70) -Switch from HD: 0.6% (median of 11 months) -Switch from PD: 0.9% (median of 13 months) -Renal transplant PD: 0.4% HD: 2.1%

Author, Year Dialysis Modalities Study Purpose	Cohort Years Country	Sample Size Inclusion Criteria	Patient Characteristics	Data Adjusted For Modeling Technique Analysis	Length of Follow-up	Key Findings
Scottish Renal Registry						
Traynor 2011[49] PD, HD Assess survival in patients active on renal transplant list (avoiding confounding by comorbidity and primary renal disease)	1982-2006 Scotland	N=3197 incident patients Adults, active on the renal transplant list at some point after start of dialysis, did not have primary renal disease of diabetic nephropathy	Age (yrs): 47 (median) Gender (% male): 60* Race (%): NR *HD group had higher percentage of males	Age, gender, primary renal disease Kaplan-Meier and Cox regression ITT (modality at start)	0 days to 25 years	-Kaplan-Meier: no difference in survival between HD and PD (log rank P = .996) -Cox regression (adj HR) – predictors of mortality HD: 0.97 (0.80, 1.18) Male: 0.94 (0.78, 1.13) Age at start of RRT: 1.05 (1.04, 1.06)
United Kingdom Renal Registry (UKRR)						
Nitsch 2011[14] PD, HHD (median delay after start of RRT = 12 months), hospital HD, satellite HD (dialysis unit with no inpatient renal facilities on-site) Compare HHD patients with age- and sex-matched PD, hospital HD, and satellite HD patients	1997-2005 England, Wales	N=2475 incident patients* (N=225 HHD, N=900 Hospital HD, N=900 PD, N=450 Satellite HD) ≥ 18 years *median delay before starting HHD = 12 months	Age (yrs): 48 Gender (% male): 71 Race (%): white (79), Asian (11), black (7)* *HHD patients more likely to be white	Age, gender, primary renal disease, year of start of dialysis Cox proportional hazards Frequency matching for age and gender: 4 hospital HD, 4 PD, and 2 satellite HD patients for each HHD patient ITT (modality at day 90)	1 to 10 years	-Survival HHD vs PD: HR 0.61 (0.40, 0.93) Satellite vs PD: HR 0.94 (0.65, 1.37) Satellite vs HHD: 1.06 (0.55, 2.04) -Technique Survival - HHD 18 months (median), IQR 9-33 Switch from HHD to HD: 30* Switch from HHD to PD: 1* Transplant: 70* *Of 130 patients with known reasons for stopping HHD

ACE = angiotensin-converting enzyme; AT = as treated (analysis); BMI = body mass index; CAD = coronary artery disease; CAPD = continuous ambulatory peritoneal dialysis; CCPD = continuous cycling peritoneal dialysis; CHF = congestive heart failure; CVD = cardiovascular disease; DM = diabetes mellitus; eGFR = estimated glomerular filtration rate; ESRD = end stage renal disease; Freq/Ext = more frequent and/or longer duration than conventional, may include nocturnal and short daily regimens; GFR = glomerular filtration rate; HD = hemodialysis (in-center); HHD = home hemodialysis; HR = hazard ratio; ITT = intention-to-treat (analysis); NR = not reported; PD = peritoneal dialysis; PY = person years; RR = relative risk; RRT = renal replacement therapy

Table 2. TRIALS Study Characteristics and Survival, Technique Failure, and Transplantation Outcomes for Key Questions 1 and 2

Author, Year Dialysis Modalities	Study Years Country	Sample Size Inclusion Criteria	Patient Characteristics	Analysis	Length of Follow-up	Key Findings Risk of Bias
Randomized Controlled Clinical Trials (RCTs)						
Culleton 2007[15] Alberta Kidney Disease Network HD (3 times/ week, 52% in-center, 28% home, 20% self-care) HHD (5-6 times/ week, minimum of 6 hours)	2004-2006 Canada	N=51 Age ≥ 18, currently receiving in-center, self-care, or home dialysis 3 times/week and willing to train for and commence nocturnal HHD; excluded if lacking physical or mental capacity to train for nocturnal HHD	Age (yr): 54 Gender (% male): 63 Race (%): white (86)	Analysis of covariance and t-tests or Wilcoxon rank sum test ITT with last-value-carried-forward for mssing values	6 months	-Mortality HD: 0/25 (0%) HHD: 1/26 (3.8%); P = 0.33 **Risk of Bias: Moderate** **Allocation generation/concealment:** adequate **Blinding:** partially **Incomplete outcomes:** no **Selective outcome reporting:** partially
Korevaar 2003[50] PD HD *Trial stopped early because of disappointing inclusion rates (required n=100)	1997-2000 Netherlands	N=38 New ESRD patients; age ≥18; dialysis as first RRT; no medical, social, or logistic objections to PD	Age (yr): 58* Gender (% male): 58 Race (%): NR HD patients older	Primary outcome: Quality-adjusted life year (QALY) score in first 2 years of dialysis Secondary outcome: Survival with Kaplan-Meier method and Cox proportional hazards (adjustment for age, comorbidity, primary kidney disease) ITT and AT (survival times censored 60 days after modality switch)	Max of 5 years	-Mortality (HD vs PD), ITT HR 3.8 (1.1, 12.6), P = .03 Adj HR 3.6 (0.08, 15.4), P = .09 **Risk of Bias: High** **Allocation generation/concealment:** adequate **Blinding:** nephrologist and patient not blinded **Incomplete outcomes:** QALY analysis included 28/38 patients; survival analysis included all patient randomized **Selective outcome reporting:** no

Author, Year Dialysis Modalities	Study Years Country	Sample Size Inclusion Criteria	Patient Characteristics	Analysis	Length of Follow-up	Key Findings Risk of Bias
McGregor 2001[16] HD (3.5-4.5 hours, 3 times/week) HHD (6-8 hours, 3 times/week)	NR New Zealand	N=9, cross-over RCT HHD of >6 hours, 3 times/week for >6 months; no antihypertensive medications, mean pre-dialysis BP over previous month <160/90 mmHg; excluded diabetes, overt cardiac disease, prior nephrectomy, any recent illness	Age (yr): 48 Gender (% male): 44 Race (%): Caucasian (89), Polynesian (11)	Analysis of variance with repeated measures Student's t-test or Wilcoxon tests for differences between means	8 weeks per arm	-Mortality: no deaths in either group **Risk of Bias: High** **Allocation generation/concealment:** unclear **Blinding:** partially (echocardiographer blinded; other outcomes unclear) **Incomplete outcomes:** no **Selective outcome reporting**: no
Controlled Clinical Trials (CCTs)						
Xue 2015[17] HD (3 times/ week) HHD (nocturnal, 5-6 times/week)	1997-2010 (HHD) 2007-2010 (HD) USA	N=63 HHD N=121 HD (matched to HHD patients based on age, gender, race, dialysis vintage, and DM) Inclusion: NR 20 months (censored at change to fistula/graft, transfer to PD, or kidney transplant)	Age (yr): 54 Gender (% male): 58 Race (%): white (57), black (43)	NR	NR	-Death HHD: 0 HD: 3/121 (3%) (P = .96) -Transfer to PD HHD: 0 HD: 8/121 (6.6%) (P = .96) **Risk of Bias: High** **Allocation generation/concealment:** N/A **Blinding:** no **Incomplete outcomes:** no **Selective outcome reporting:** no

Author, Year Dialysis Modalities	Study Years Country	Sample Size Inclusion Criteria	Patient Characteristics	Analysis	Length of Follow-up	Key Findings Risk of Bias
Kjellstrand 2008[18] HD HHD	1982-2005 USA, Italy, France, UK	N=415 (150 HD, 265 HHD) Patients started daily dialysis to 1) improve quality of life and survival or 2) serious medical complications during dialysis (typically unsuitable for HHD) ESRD for mean of 5.0±5.7 years (range 0-31) before starting daily dialysis; 9% started on daily dialysis	Age (yr): 52 (range 13-89)* Gender (% male): 71 Race (%): NR Daily dialysis for mean of 2.4±2.6 years (range 0-23); mean treatment time 136±35 minutes, mean frequency 5.8±0.5 times/week *HD patients were older (56 vs 49 years, P < .0001)	Kaplan-Meier and Cox-Mantel log rank for survival Backward stepwise Cox proportional hazards for factors influencing survival	1006 patient years	-Three factors independently associated with mortality 1. In-center dialysis: HR 2.42 (1.54, 2.79), P = .0001 2. Secondary renal disease: HR 2.72 (1.76, 4.20), P < .0001 3. Age > 52 (mean age): HR 2.39 (1.49, 3.83), P = .0003 -Correcting for age and diagnosis RR = 0.44 (death in daily at home group vs daily in-center group) **Risk of Bias: Moderate** **Allocation generation/concealment:** N/A **Blinding:** N/A **Incomplete outcomes:** no **Selective outcome reporting:** no
Lindsay 2003[19] Heidenheim 2003[21] London Daily/ Nocturnal Hemodialysis Study HD (3 /wk, 3.5-4.5 hrs) HHD1 (nocturnal 5-6 /wk, 6-8 hrs) HHD2 (daily 5-6 /week, 1.5-2.5 hrs)	1998-2001 Canada	N=46 (22 HD controls, 13 HHD1, 11 HHD2) Age >18, on conventional HD for at least 3 months, expected to survive 1 year Matched controls on age, gender, comorbidity, and original dialysis modality	Age (yr): 47 Gender (% male): 67 Race (%): NR	One-way and repeated measures analysis of variance Student's paired t-test	18 months	-Mortality HD: 3/22 (14) HHD1: 3/13 (23%), P = .47 vs HD HHD2: 0/11 (0%), P = .20 vs HD -All-cause hospitalization, admissions per patient-year HD: 0.93 HHD1: 0.95, P = .96 vs HD HHD2: 0.49, P = .23 vs HD **Risk of Bias: High** **Allocation generation/concealment:** N/A **Blinding:** no **Incomplete outcomes:** yes – patients were replaced during course of trial **Selective outcome reporting:** no

Author, Year Dialysis Modalities	Study Years Country	Sample Size Inclusion Criteria	Patient Characteristics	Analysis	Length of Follow-up	Key Findings Risk of Bias
Clinical Cohort Studies						
Jaar 2005[51] CHOICE PD, HD	1995-1998 USA	N=1041 incident patients (767 HD, 274 PD) Age >17, able to speak English or Spanish	Age (yr): 58* Gender (% male): 54 Race (%): white (67)* *PD patients younger, more likely white	Cox proportional hazards Adjusted model: demographics, clinical factors, laboratory variables Propensity score matching (baseline characteristics) ITT (modality at 4 weeks after enrollment [an average of 10 weeks after starting dialysis])	Max of 7 years	-Switched dialysis modality at least once: PD 25%, HD 5% -Relative hazard of death (PD vs HD), ITT Multivariate Model: 1.61 (1.13, 2.30) Propensity Score Model: 1.74 (1.23, 2.46) *-First year of follow-up* (PD vs HD), ITT Multivariate Model: 1.39 (0.64, 3.06) Propensity Score Model: 1.47 (0.69, 3.15) *-Second year of follow-up* Multivariate Model: 2.34 (1.19, 4.59) Propensity Score Model: 2.05 (1.07, 3.92) -Non-significant interactions for: Age (P > .2); Diabetes (P > .2) **Risk of Bias: Moderate** **Selection bias:** adequate **Blinding:** partially **ITT:** yes **Attrition bias:** unclear **Selective outcome reporting:** no
Noordzij 2006[52] NECOSAD PD, HD	1997-2004 Netherlands	N=1629 incident patients (1043 HD, 586 PD) Age ≥18, dialysis was 1st RRT	Age (yr): 59* Gender (% male): 61* Race (%): NR *PD patients significantly younger and more likely male	Adjusted for age, comorbidity score, primary kidney disease, SGA, laboratory variables Cox proportional hazards with frailty term to correct for dependency between repetitive hospitalizations within the same patient ITT (modality at 3 months after initiation)	Max of 7.8 years, min of 5 months (medians: 29 months PD, 28 months HD)	-Switched dialysis modality: PD 30%, HD 5% -Hospitalized at least once: PD 46%, HD 58% -Survival (2 year): PD 86%, HD 74% -Deaths during study period: PD 146/586 (25%), HD 444/1043 (43%) **Risk of Bias: Moderate** **Selection bias:** unclear **Blinding:** unclear **ITT:** adequate **Attrition bias:** adequate **Selective outcome reporting:** no

Author, Year Dialysis Modalities	Study Years Country	Sample Size Inclusion Criteria	Patient Characteristics	Analysis	Length of Follow-up	Key Findings Risk of Bias
Thong 2007[65] NECOSAD-2 PD, HD	1998-2002 Netherlands	N=528 incident patients who returned SSL (87%) Age >18 years, no previous history of RRT, survived 1st 3 months of dialysis	Age (yr): 59 Gender (% male): 59 Race (%): Caucasian 94	Social Support List (SSL) at 3 months from start of PD or HD; "Interaction" and "Discrepancy" scales; both include a) social companionship, b) daily emotional support, and c) emotional support with problems Cox proportional hazards adjusted for demographics, comorbidity, serum albumin, functional ability, depressive symptoms, and treatment modality	Max of 6 years, mean of 2.5 years	*Adj RR (per unit increase) for social support on all-cause mortality* Interaction scale: 0.998 (0.982, 1.014) Discrepancy scale (perceiving that not enough social support is received): 1.022 (1.003, 1.042) HD vs PD: effect of social support on mortality was similar; confidence intervals were wider due to smaller number per group; only daily emotional support component of "Discrepancy" was significant for HD patients after adjustment **Risk of Bias: High** **Selection bias:** adequate **Blinding:** unclear **ITT:** unclear **Attrition bias:** unclear **Selective outcome reporting:** no

Author, Year Dialysis Modalities	Study Years Country	Sample Size Inclusion Criteria	Patient Characteristics	Analysis	Length of Follow-up	Key Findings Risk of Bias
Termorshuizen 2003[53] NECOSAD-2 PD, HD	Not reported Netherlands	N=1222 incident patients (742 HD, 480 PD) Age >18, survived first 3 months of dialysis	Age (yr): <45: 19% 45-60: 30% 60-70: 25% 70+: 26%* Gender (% male): 61* Race (%) NR *HD patients older and more likely female	Cox proportional hazards (multivariate model adjusted for age, gender, primary kidney disease, comorbidity index, SGA score, residual renal function, other laboratory variables ITT (modality at 3 months) AT (follow-up ended at day 60 after 1st transfer to other modality)	Max of 48 months	-Technique survival (2 year): HD 96%, PD 74% -Transplantation: HD (15% of original HD cohort), 21% of original PD cohort) -Mortality (multivariate RR, HD vs PD, ITT censoring) 3-12 months: 1.32 (0.80, 2.18) 12-24 months: 1.06 (0.66, 1.72) 24-36 months: 0.55 (0.34, 0.87) 36-48 months: 0.42 (0.24, 0.73) Age <60, no diabetes, 3-24 months: 0.77 (0.34, 1.73) Age <60, diabetes, 3-24 months: 6.35 (1.42, 28.36) Age 60+, no diabetes, 3-24 months: 1.03 (0.62, 1.72) Age 60+, diabetes, 3-24 months: 1.28 (0.65, 2.52) **Risk of Bias: Moderate** **Selection bias:** unclear **Blinding:** unclear **ITT:** adequate **Attrition bias:** adequate **Selective outcome reporting:** no

AT = as treated (analysis); BMI = body mass index; BP = blood pressure; CAD = coronary artery disease; CAPD = continuous ambulatory peritoneal dialysis; CCPD = continuous cycling peritoneal dialysis; CHF = congestive heart failure; COPD = chronic obstructive pulmonary disease; CVD = cardiovascular disease; DM = diabetes mellitus; eGFR = estimated glomerular filtration rate; ESRD = end stage renal disease; Freq/Ext = more frequent and/or longer duration than conventional; GFR = glomerular filtration rate; HD = hemodialysis (in-center); HHD = home hemodialysis; HR = hazard ratio; ITT = intention-to-treat (analysis); KDQOL = Kidney Disease Quality of Life questionnaire; MOS = Medical Outcomes Study; NR = not reported; PD = peritoneal dialysis; PY = person years; QOL = quality of life; RR = relative risk; RRT = renal replacement therapy; SGA = Subjective Global Assessment

[a] 31 patients dropped out of the study, 30 were missing data on the 4 outcome criteria

Table 3. REGISTRY STUDIES – Interactions

Author, Year Modalities Cohort Years Sample Size	Age	Gender	Race	BMI	Diabetes Mellitus (DM)	Cardiovascular Disease	Duration of ESRD Therapy
United States Renal Data System (USRDS)							
Lukowsky 2013[26] PD, HD 2001-2004 N=23,718 incident patients	Mortality (PD vs HD); MSM; P for interaction = .26 *Age ≤ 65 years* 12 months: 0.67 (0.50, 0.92) 24 months: 0.58 (0.43, 0.79) *Age > 65 years* 12 months: 0.68 (0.51, 0.92) 24 months: 0.27 (0.12, 0.61)	NR	NR	NR	Mortality (PD vs HD); MSM; P for interaction = .07 *Diabetes* 12 months: 0.81 (0.63, 1.05) 24 months: 0.34 (0.18, 0.63) *No Diabetes* 12 months: 0.51 (0.36, 0.74) 24 months: 0.64 (0.47, 0.87)	NR	NR
Weinhandl 2010[29] PD, HD 2003 N=12674 incident patients (matched pairs)	Association of dialysis modality modified by age (HR ≥ 1 favoring HD for patients ≥ 65 years); P for interaction < .01	NR	NR	NR	Association of dialysis modality modified by presence of diabetes (HR > 1 favoring HD for patients with DM); P for interaction < .01	Association of dialysis modality modified by presence of cardiovascular disease (HR > 1 favoring HD for patients with CVD); P for interaction < .01	NR
MacRae 2010[9]PD, NRHD, HHD 1995-2004 N=458,329 incident patients	NR	NR	NR	NR	NR	NR	NR

Author, Year Modalities Cohort Years Sample Size	Age	Gender	Race	BMI	Diabetes Mellitus (DM)	Cardiovascular Disease	Duration of ESRD Therapy
Abbott 2004[31] PD, HD 1996 N=3337 incident patients	NR	NR	NR	BMI≥30 associated with improved survival for HD patients: Adj HR 0.89 [0.81, 0.99] Not PD patients: Adj HR 0.99 [0.86, 1.15] P = .001 for interaction	NR	NR	NR
Vonesh 2004[32] PD, HD 1995-2000 N=398,940 incident patients	Mortality, RR (age 18-44 as reference) *Age 45-64 years*:* HD 1.57 PD 1.97 *Age ≥ 65 years*:* HD 2.80 PD 3.82 *P < .0001 for interaction	Mortality, RR (female as reference) HD 0.97 PD 0.97 P = .41 for interaction	Mortality, RR (white as reference, P value for interaction) *Black:* HD 0.74 PD 0.77 P = NS *Asian:* HD 0.61 PD 0.53 P < .01 *Other/NA:* HD 0.73 PD 0.77 P = .048	Mortality, RR (BMI 18.5-25 as reference, P value for interaction) *BMI < 18.5:* HD 1.32 PD 1.32 P = NS *BMI 25.1-30:* HD 0.82 PD 0.87 P < .01 *BMI >30:* HD 0.75 PD 0.92 P < .0001	Mortality, RR (non-diabetes as cause of ESRD as reference) *Diabetes as cause:* HD 1.13 PD 1.45 P < .0001 for interaction	Mortality, RR *CHF* HD 1.23 PD 1.37 P < .0001 for interaction *CAD* HD 1.07 PD 1.23 P < .0001 for interaction	NR

Author, Year Modalities Cohort Years Sample Size	Age	Gender	Race	BMI	Diabetes Mellitus (DM)	Cardiovascular Disease	Duration of ESRD Therapy
Stack 2004[54] (see Stack 2003[33]) PD, HD 1995-1997 N=134,728 incident patients	NR	NR	Significant race-modality interaction (P = NR) Whites, BMI >30: RR 1.28 (1.08, 1.51) Non-whites: RR 1.01 (0.74, 1.37)	-Significant interactions (P < .001) between 1) modality, BMI, and survival 2) modality, diabetes, and survival -Mortality (PD vs HD), RR, ITT, 0-24 months *Diabetes* BMI-1: 0.99 (0.83, 1.17) BMI-2: 1.12 (0.98, 1.29) BMI-3: 1.26 (1.13, 1.43) BMI-4: 1.15 (1.02, 1.30) BMI-5: 1.44 (1.27, 1.63) *No Diabetes* BMI-1: 1.07 (0.96, 1.19) BMI-2: 1.01 (0.90, 1.13) BMI-3: 0.96 (0.85, 1.08) BMI-4: 1.04 (0.91, 1.18) BMI-5: 1.22 (1.05, 1.41)		NR	NR
Ganesh 2003[55] (see Stack 2003[33]) PD, HD 1995-1997 N=107,922 incident patients	NR	NR	NR	NR	-Significant interactions (P < .001) between 1) modality, CAD, and survival 2) modality, diabetes, and survival -Mortality (PD vs HD), ITT, RR, 0-24 months (P for interaction) *Diabetes* CAD: 1.23 (1.12, 1.34) No CAD: 1.17 (1.08, 1.26); P = .09 *No Diabetes* CAD: 1.20 (1.10, 1.32) No CAD: 0.99 (0.93, 1.05); P < .0001		NR

Author, Year Modalities Cohort Years Sample Size	Age	Gender	Race	BMI	Diabetes Mellitus (DM)	Cardiovascular Disease	Duration of ESRD Therapy
Stack 2003[33] (see Stack 2004[54] for BMI data and Ganesh 2003[55] for CAD data) PD, HD 1995-1997 N=107,922 incident patients	NR	NR	NR	NR	-Significant interactions (P < .001) between 1) modality, CHF, and survival 2) modality, diabetes, and survival -Mortality (PD vs HD), RR, 0-24 months *With CHF* Diabetes: 1.30 (1.20, 1.41) No Diabetes: 1.24 (1.14, 1.35) *No CHF* Diabetes: 1.11 (1.02, 1.21) No Diabetes: 0.97 (0.91, 1.04)		NR
Bloembergen 1995[36] PD, HD 1987, 1988, 1989 (3 cohorts) 170,700 PY with prevalent patients	-RR varied significantly by age (P < .001) -Death rate significantly higher for PD than HD for age >55 years (P = .01) but not <55 years	Accentuated RR (PD compared to HD) if female but both significant Females: RR 1.30 (P < .001) Males: RR 1.11 (P < .001)	-No statistically significant effect of race	NR	Accentuated RR (PD compared to HD) if DM was cause of ESRD but both significant Diabetes: RR 1.38 (P < .001) No Diabetes: RR 1.11 (P < .001)	NR	NR

Author, Year Modalities Cohort Years Sample Size	Age	Gender	Race	BMI	Diabetes Mellitus (DM)	Cardiovascular Disease	Duration of ESRD Therapy
Australia and New Zealand Dialysis and Transplant Registry (ANZDATA)							
Marshall 2014[11] PD, HD, HHD 1997-2011	Effect of modality on mortality risk is not modified within subcategories of age		-For PD: 1) NZ Europeans and those without type 2 DM have lower risk (vs HD) in early period (<3 years) and no difference in late period 2) NZ Maori, Pacific, and those with type 2 DM have no difference in mortality risk (vs HD) in the early period but increased risk in the late period -For HHD: Pacific have no difference in mortality risk (vs HD)	Effect of modality on mortality risk is not modified within subcategories of BMI	See Race	Minor modification of effect of modality on mortality risk by medical comorbidity but results not materially different from overall population	Minor modification of effect of modality on mortality risk by year of dialysis inception but results not materially different from overall population

Author, Year Modalities Cohort Years Sample Size	Age	Gender	Race	BMI	Diabetes Mellitus (DM)	Cardiovascular Disease	Duration of ESRD Therapy
Marshall 2011[12] PD, HD, HHD, Freq/ext HD, Freq/ext HHD 1996-2007 N=26,016 incident patients (856,007 patient months of follow-up)	Significant interaction by age at dialysis inception, P = .03 Decrease in relative mortality risk associated with HHD was less for older age group (> 74 years)	NR	Significant interaction by ethnicity, P < .001 Decrease in relative mortality risk associated with HHD was less for non-whites and non-Asians (*ie,* aboriginal/Torres islanders and NZ Maori/Pacific people)	NR	Significant interaction by baseline DM, P < .001 -Mortality, HHD vs HD *Diabetes* 0.65 (0.52, 0.80) *No Diabetes* 0.44 (0.37, 0.54) -Mortality, PD vs *HD* *Diabetes* 1.23 (1.16, 1.31) *No Diabetes* 1.01 (0.94, 1.07)	NR	NR
McDonald 2009[38] PD, HD (including HHD) 1991-2005 N=25,287 incident patients	-Significant interaction (P < .001) between age and risk of PD vs HD mortality in 90- to 356- day period -No significant interaction (P = .7) in > 365 day period -Clinically and statistically significant interaction among PD risk, age, and comorbidity	NR	No *clinically significant* interactions	-No significant interaction (P = .2) with modality for 90- to 365-day mortality -Significant interaction (P = .002) for ≥365 day mortality but effect size was *clinically similar* across all BMI categories	No significant interaction between presence of DM at RRT start and adj HR for PD relative to HD at < 365 days (P = .6)or ≥ 365 days (P = .4)	NR	-Significant interaction between vintage and HR (PD relative to HD) from 90-365 days (P = .03) and for ≥ 365 days (P = .01) but *little clinical significance*

Author, Year Modalities Cohort Years Sample Size	Age	Gender	Race	BMI	Diabetes Mellitus (DM)	Cardiovascular Disease	Duration of ESRD Therapy
Institute for Clinical Evaluative Sciences (ICES, Canada)							
Quinn 2011[42] PD, HD 1998-2006 N=6573 incident patients	NR	NR	NR	NR	No significant interaction between diabetes and treatment modality in primary cohort (P = NR)	NR	NR
Dutch End-Stage Renal Disease Registry (RENINE)							
Liem 2007[43] PD, HD 1987-2002 N=16,643 incident patients	Age by modality HR (PD vs HD): 1.01 (P for interaction < .001)	NR	NR	NR	Diabetes by modality HR (PD vs HD): 1.22 (P for interaction = 0.002)	NR	NR
European Renal Association-European Dialysis and Transplant Association (ERA-EDTA)							
van de Luijtgaarden 2011[44] PD, HD 1998-2006 N=15,828 incident patients	NR	Interaction between dialysis modality and gender for patients with IHD, DM, and PVD (P = NR) Survival advantages of PD observed for males but not females	NR	NR	NR	See Gender column	NR

Author, Year Modalities Cohort Years Sample Size	Age	Gender	Race	BMI	Diabetes Mellitus (DM)	Cardiovascular Disease	Duration of ESRD Therapy
Finnish Registry for Kidney Diseases							
Haapio 2013[45] PD, HD 2000-2009 N=4463 incident patients	No significant interaction between age and modality (P = .06)	No significant interaction between gender and modality (P = .53)	NR	NR	No significant interaction between ESRD diagnosis (including DM) and modality (P = .07)	NR	NR
International Quotidian Dialysis Registry (IQDR) and Dialysis Outcomes and Practice Patterns Study (DOPPS)							
Nesrallah 2012[13] HHD (intensive) HD 2000-2010 N=338 (HHD, incident and prevalent) N=1388 (HD)	Non-significant interaction (P = .36) with age <52 years [HR 0.36] vs ≥ 52 years [HR 0.60]	NR	NR	NR	NR	NR	Non-significant interactions: 1 to 3.5 years [HR 0.95] vs < 1 year [HR 0.65]: P = .65 ≥ 3.5 years [HR 0.32] vs < 1 year [HR 0.65]: P = .39 Median duration of ESRD = 3.5 years
French Renal Epidemiology and Information Network (REIN)							
Sens 2011[46] PD, HD 2002-2008 N=4401 incident CHF patients	No significant interaction between modality and other variables including age and DM (P > .05)	NR	NR	NR	NR	No significant interaction between modality and NYHA stage (P = .86)	NR

AT = as treated (analysis); BMI = body mass index; BMI-1 = 8.8-20.9; BMI=2 = 20.9-23.5; BMI-3 = 23.5-26.1; BMI-4 = 26.1-30.0; BMI-5 = >30; CAPD = continuous ambulatory peritoneal dialysis; CCPD = continuous cycling peritoneal dialysis; CD = cerebrovascular disease; CHF = congestive heart failure; CVD = cardiovascular disease; DM = diabetes mellitus; eGFR = estimated glomerular filtration rate; ESRD = end stage renal disease; Freq/Ext = more frequent and/or longer duration than conventional; GFR = glomerular filtration rate; HD = hemodialysis (in-center); HHD = home hemodialysis; HR = hazard ratio; IHD = ischemic heart disease; IQR = interquartile range; ITT = intention-to-treat (analysis); NR = not reported; NYHA = New York Heart Association; PD = peritoneal dialysis; PVD = peripheral vascular disease; PY = person-years; RR = relative risk; RRT = renal replacement therapy

Table 4. TRIALS and OBSERVATIONAL STUDIES - Study Characteristics and Hospitalization, Quality of Life, and Adverse Event Outcomes for Key Questions 1 and 2

Author, Year Dialysis Modalities	Study Years Country	Sample Size Inclusion Criteria Length of Follow-up	Patient Characteristics Study Risk of Bias	Hospitalization	Quality of Life, Cognition, Depression	Adverse Events
Randomized Controlled Clinical Trials (RCTs)						
Culleton 2007[15] Alberta Kidney Disease Network HD (3 times/ week) HHD (5-6 times/ week, minimum of 6 hours)	2004-2006 Canada	N=51 Age ≥ 18, currently receiving in-center, self-care, or home dialysis 3 times/week and willing to train for and commence nocturnal HHD; excluded if lacking physical or mental capacity to train for nocturnal HHD 6 months	Age (yr): 54 Gender (% male): 63 Race (%): white (86) **Risk of Bias: Moderate** **Allocation generation/concealment:** adequate **Blinding:** partially **Incomplete outcomes:** no **Selective outcome reporting:** partially	All-cause hospitalization (per patient over 6 months) HD: 0.84 HHD: 0.62	Quality of life 1. Change in EuroQoL-5D over 6 months, HHD vs HD: Between group difference 0.05 (-0.07, 0.17), P = 0.43 2. Change in KDQOL over 6 months, HHD-HD a. Effects of Kidney Disease: 8.6 (2.0, 15.2), P = .01 b. Burden of Kidney Disease: 9.4 (1.3, 17.5), P = .02	-Infection requiring a procedure, # patients with ≥1 event HD: 4/25 (16%) HHD: 4/26 (15%), P = 1.0 -Vascular access surgical intervention, # patients with ≥1 event HD: 5/25 (20%) HHD: 3/26 (12%); P = .47
Korevaar 2003[50] PD HD *Trial stopped early because of disappointing inclusion rates (required n=100)	1997-2000 Netherlands	N=38 New ESRD patients; age ≥18; dialysis as first RRT; no medical, social, or logistic objections to PD Max of 5 years	Age (yr): 58* Gender (% male): 58 Race (%): NR HD patients older **Risk of Bias: High** **Allocation generation/concealment:** adequate **Blinding:** nephrologist and patient not blinded **Incomplete outcomes:** QALY analysis included 28/38 patients; survival analysis included all patient randomized **Selective outcome reporting:** no	NR	QALY score, Mean (SD), ITT PD: 54.0 (18.9) HD: 59.1 (11.7) Adj difference 3.1 (-9.9, 16.1), P = .63	NR

Author, Year Dialysis Modalities	Study Years Country	Sample Size Inclusion Criteria Length of Follow-up	Patient Characteristics Study Risk of Bias	Hospitalization	Quality of Life, Cognition, Depression	Adverse Events
McGregor 2001[16] HD (3.5-4.5 hours, 3 times/week) HHD (6-8 hours, 3 times/week)	NR New Zealand	N=9, cross-over RCT HHD of >6 hours, 3 times/week for >6 months; no antihypertensive medications, mean pre-dialysis BP over previous month <160/90 mmHg; excluded diabetes, overt cardiac disease, prior nephrectomy, any recent illness 8 weeks per arm	Age (yr): 48 Gender (% male): 44 Race (%): Caucasian (89), Polynesian (11) **Risk of Bias: High** **Allocation generation/concealment:** unclear **Blinding:** partially (echocardiographer blinded; other outcomes unclear) **Incomplete outcomes:** no **Selective outcome reporting**: no	NR	Quality of life: 1. HHD interfered more with social activities (P < .05) 2. HHD perceived to be more of a burden on family of patient (P = .07) 3. HHD less physical suffering (P < .005)	NR
Controlled Clinical Trials (CCTs)						
Xue 2015[17] HD (3 times/ week) HHD (nocturnal, 5-6 times/week)	1997-2010 (HHD) 2007-2010 (HD) USA	N=63 HHD N=121 HD (matched to HHD patients based on age, gender, race, dialysis vintage, and DM) Inclusion: NR 20 months (censored at change to fistula/graft, transfer to PD, or kidney transplant)	Age (yr): 54 Gender (% male): 58 Race (%): white (57), black (43) **Risk of Bias: High** **Allocation generation/concealment:** N/A **Blinding:** no **Incomplete outcomes:** no **Selective outcome reporting:** no	NR	NR	*First Catheter Only* -Catheter-related sepsis HHD: 10/63 (16%); 1.77/100 PtM HD:14/121 (12%); 2.03/100 PtM (P = .21) HR 0.99 (CI NR) (P = NS) -Median catheter life HHD: 5.6 months HD: 4.6 months (P = .64)

Author, Year Dialysis Modalities	Study Years Country	Sample Size Inclusion Criteria Length of Follow-up	Patient Characteristics Study Risk of Bias	Hospitalization	Quality of Life, Cognition, Depression	Adverse Events
Lindsay 2003[19] Heidenheim 2003[21] London Daily/ Nocturnal Hemodialysis Study HD (3 times/ week, 3.5-4.5 hours) HHD1 (nocturnal 5-6 times/week, 6-8 hours) HHD2 (daily 5-6 times/ week, 1.5-2.5 hours)	1998-2001 Canada	N=46 (22 HD controls, 13 HHD1, 11 HHD2) Age >18, on conventional HD for at least 3 months, expected to survive 1 year Matched controls on age, gender, comorbidity, and original dialysis modality 18 months	Age (yr): 47 Gender (% male): 67 Race (%): NR **Risk of Bias: High** **Allocation generation/concealment:** N/A **Blinding:** no **Incomplete outcomes:** yes – patients were replaced during course of trial **Selective outcome reporting:** no	All-cause hospitalization, admissions per patient-year HD: 0.93 HHD1: 0.95, P = .96 vs HD HHD2: 0.49, P = .23 vs HD	-Quality of Life - RAND SF-36 Physical Component at 18 months HD: 39.9 HHD1: 49.1, P = .25 vs HD HHD2: 42.1, P = .60 vs HD -Cognition - RAND SF-36 Mental Component at 18 months HD: 47.2 HHD1: 52.2, P = .98 vs HD HHD2: 52.4, P = .31 vs HD	-Access complications (annual) 1) Arteriovenous fistula HD: 0.31 HHD1 and HHD2: 0.67 2) Synthetic graft HD: 2.18 HHD1 and HHD2: 1.73 3) Catheter HD: 2.64 HHD1 and HHD2: 2.66 -Access interventions (annual); all P = NS 1) Arteriovenous fistula HD: 0.52 HHD1 and HHD2: 0.18 2) Synthetic graft HD: 2.12 HHD1 and HHD2: 1.58 3) Catheter HD: 3.73 HHD1 and HHD2: 4.51
Quintaliani 2000[25] HD (3 times/week, mostly in-center) HHD (daily, 70% at home)	Final observation Nov 15, 1996 Italy	N=148 (123 HD, 24 HHD) Adults, native arteriovenous fistula functioning for at least 1 month; excluded if prosthetic device, diabetes, collagen disease, malignancy 3.6 years (mean)	Age (yr): 56* Gender (% male): 62* Race (%): NR *HHD patients younger and more likely male **Risk of bias: High** **Allocation generation/concealment:** not applicable **Blinding:** no **Incomplete outcomes:** no **Selective outcome reporting:** no	NR	NR	-Access closures - event rate (per 100 PY) HD: 9.8; HHD: 2.2; Rate difference 7.6/100 PY (3.4, 11.9); RR 4.5 (1.2, 16.9), P < .01 -Access survival (3 year probability) HD: 70%; HHD: 92%; P < .05

Author, Year Dialysis Modalities	Study Years Country	Sample Size Inclusion Criteria Length of Follow-up	Patient Characteristics Study Risk of Bias	Hospitalization	Quality of Life, Cognition, Depression	Adverse Events
Clinical Cohort Studies						
Plantinga 2010[63] CHOICE PD, HD	1995-1998 USA	N=949 incident patients NR Max of 9 years and 2 months	Age (yr): 58 Gender (% male): 54 Race (%): white (67) **Risk of Bias: High** **Selection bias:** adequate **Blinding:** N/A (self-report) **ITT:** unclear **Attrition bias:** inadequate **Selective outcome reporting:** no	NR	-Overall functional support (MOS Social Support Survey); mean (SD) HD: 76.1 (23.1) PD: 80.5 (21.9); P = .002 Significantly higher scores for PD vs HD for emotional support, tangible support, and positive social interaction domains; no difference for affectionate support domain -Social support in highest tertile significantly associated with greater chance of being treated with PD (P = .02) -Modality switching not associated with overall functional social support (Relative Hazard 1.03 [0.57, 1.83]) or any support domain	NR
Noordzij 2006[52] NECOSAD PD, HD	1997-2004 Netherlands	N=1629 incident patients (1043 HD, 586 PD) Age ≥18, dialysis was 1st RRT Max of 7.8 years, min of 5 months (medians: 29 months PD, 28 months HD)	Age (yr): 59* Gender (% male): 61* Race (%): NR *PD patients significantly younger and more likely male **Risk of Bias: Moderate** **Selection bias:** unclear **Blinding:** unclear **ITT:** adequate **Attrition bias:** adequate **Selective outcome reporting:** no	Hospitalized at least once: PD 46%, HD 58%	NR	NR

Author, Year Dialysis Modalities	Study Years Country	Sample Size Inclusion Criteria Length of Follow-up	Patient Characteristics Study Risk of Bias	Hospitalization	Quality of Life, Cognition, Depression	Adverse Events
Jansen 2013[64] NECOSAD-2 PD, HD	Patients still in study in January 2006	N=161 who returned first questionnaire (of 248 approached) Age > 18 years, no previous history of RRT 8 months (second questionnaire sent)	Age (yr): 66 Gender (% male): 65 Race (%): NR **Risk of Bias: High** **Selection bias:** unclear **Blinding:** unclear **ITT:** no **Attrition bias:** inadequate **Selective outcome reporting:** no	NR	-BIPQ Illness consequences: no difference between PD and HD -TEQ Treatment consequences: HD patients perceive more consequences than PD patients (P = .01) -BIPQ Treatment controls the illness: no difference between PD and HD	NR
Thong 2007[65] NECOSAD-2 PD, HD	1998-2002 Netherlands	N=528 incident patients who returned SSL (87%) Age >18 years, no previous history of RRT, survived 1st 3 months of dialysis Max of 6 years, mean of 2.5 years	Age (yr): 59 Gender (% male): 59 Race (%): Caucasian 94 **Risk of Bias: High** **Selection bias:** adequate **Blinding:** unclear **ITT:** unclear **Attrition bias:** unclear **Selective outcome reporting:** no	NR	*Adj RR (per unit increase) for social support on all-cause mortality* Interaction scale: 0.998 (0.982, 1.014) Discrepancy scale (perceiving that not enough social support is received): 1.022 (1.003, 1.042) HD vs PD: effect of social support on mortality was similar; confidence intervals were wider due to smaller number per groups; only daily emotional support component of "Discrepancy" was significant for HD patients after adjustment	NR
Merkus 1999[66] NECOSAD-1 PD, HD	1993-1995 Netherlands	N=228 (119 HD, 109 PD) for Quality of Life analysis 18 months after initiation	Age (yr): 55 Gender (% male): **Risk of Bias: Moderate** **Selection bias:** adequate **Blinding:** unclear **ITT:** adequate **Attrition bias:** adequate **Selective outcome reporting:** no	NR	-Physical QOL (SF-36), adjusted mean difference over time, HD vs PD, ITT: 1.6 (0.04, 3.20), P = .04 -Mental QOL (SF-36), ITT: no treatment effect	NR

Author, Year Dialysis Modalities	Study Years Country	Sample Size Inclusion Criteria Length of Follow-up	Patient Characteristics Study Risk of Bias	Hospitalization	Quality of Life, Cognition, Depression	Adverse Events
Van Diepen 2014[71] NECOSAD PD, HD	1997-2007 Netherlands	N=452 incident patients Age ≥ 18 years, no exclusion criteria Max of 12 years and 6 months	Age (yr): 64* Gender (% male): 65 Race (%): Caucasian (91)* *PD patients younger and less likely Caucasian **Risk of Bias: High** **Selection bias:** unclear **Blinding:** adequate **ITT:** unclear **Attrition bias:** unclear **Selective outcome reporting:** no	NR	NR	-Adj IRR (HD vs PD) *Overall:* Total infections: 1.65 (1.34, 2.03) Dialysis technique-related infection: 4.10 (3.06, 5.58) Non-dialysis technique-related infection: 0.56 (0.40, 0.79) *6-12 months (n=363)* Total: 1.66 (1.05, 2.62) Dialysis-related infection: 3.28 (1.77, 6.09) Non-dialysis-related infection: 0.68 (0.32, 1.45) *24-36 months (n=207)* Total: 3.21 (1.51, 6.87) Dialysis-related infection: 19.34 (5.20, 71.93) Non-dialysis-related infection: 0.71 (0.13, 3.74)
Longitudinal Studies						
Oliver 2012[72] PD, HD	2007-2010 Canada	N=369 incident patients (224 PD, 145 HD) Eligible for PD or HD, ≥4 months pre-dialysis care, patient chose out-patient modality Excluded if lost to follow-up in 1st 6 months of dialysis Follow-up: mean of 1.3 years (0.1-3.6)	Age (yr): 62* Gender (% male): 60 Race (%): NR *HD patients were older **Risk of Bias: Moderate** **Selection bias:** adequate **Blinding:** N/A **ITT:** adequate **Attrition bias:** adequate **Selective outcome reporting:** no	NR	NR	-Access-related invasive interventions required while on dialysis HD 1.4/pt-year PD 1.0/pt-year Rate Ratio (PD vs HD) 0.72 (0.53, 0.96)

Author, Year Dialysis Modalities	Study Years Country	Sample Size Inclusion Criteria Length of Follow-up	Patient Characteristics Study Risk of Bias	Hospitalization	Quality of Life, Cognition, Depression	Adverse Events
Liberek 2009[77] PD, PD after HD	1994-2006 Poland	N=264 incident PD patients (197 initial PD, 67 transfer after ≥ 3 months of HD) (NOTE: transfer due to vascular access problems (64%), heart failure or severe hypotension (21%), preference (15%) Follow-up: median of 20.5 months (range 1-132)	Age (yr): 51 Gender (% male): 53* Race (%): NR *Higher % male in initial PD group **Risk of Bias: Moderate** **Selection bias:** adequate **Blinding:** N/A **ITT:** adequate **Attrition bias:** unclear **Selective outcome reporting:** no	NR	NR	-Patient survival: RR (transfer PD vs initial PD) 1.68 (0.87, 3.22) -Combined patient and technique survival: RR (transfer PD vs initial PD) 1.45 (0.89, 2.37) NOTE: median time on HD before transfer: 18 months (range 3-268)
Aslam 2006[56] PD, HD	1999-2005 USA	N=181 incident patients (119 HD, 62 PD) No previous ESRD therapy Follow-up (medians) HD: 18 months PD: 15 months	Age (yr): 58 Gender (% male): 53 Race (%): white (60)* *PD patients were more likely white **Risk of Bias: Moderate** **Selection bias:** adequate **Blinding:** N/A **ITT:** adequate **Attrition bias:** adequate **Selective outcome reporting:** no	-All admissions for infection per year at risk HD: 0.29 PD: 0.42; P = .02 -Total admissions per year at risk HD: 2.4 PD: 1.4; P < .0001 -More admissions for bacteremia, cellulitis, and pneumonia in HD group; more admissions for peritonitis in PD group (all P < .0001)	NR	-Infections - total per time at risk; median (range) HD: 1 (0-14) PD: 1 (0-10); P = NS -Infection rate per year at risk HD: 0.77 PD: 0.86; P = NS -Higher bacteremia/fungemia infection rate in HD group (overall and in 1st 90 days; P < .001) -Higher peritonitis rate in PD group (overall and in 1st 90 days; P > .001)

Author, Year Dialysis Modalities	Study Years Country	Sample Size Inclusion Criteria Length of Follow-up	Patient Characteristics Study Risk of Bias	Hospitalization	Quality of Life, Cognition, Depression	Adverse Events
Harris 2002[58] PD, HD	1995-1996 UK	N=174 incident and prevalent patients (96 HD, 78 PD) 70 years or older at start of dialysis, 90 days of uninterrupted dialysis, recruited from 4 hospital-based renal units offering PD and HD Excluded if terminal illness with life-expectancy < 6 months, diagnosis of psychosis, cognitively impaired 12 month follow-up	Age (yr): 77 Gender (% male): 66 Race (%): NR **Risk of Bias: Moderate** **Selection bias:** adequate **Blinding:** unclear **ITT:** adequate **Attrition bias:** adequate **Selective outcome reporting:** no	-Events/1 pt-year (N=171) HD 2.0 (66%) PD 1.9 (68%) RR (PD vs HD) 0.97 (0.77, 1.22)	Adjusted difference in scores (PD-HD) -SF-36 PCS Baseline: 1.2 (-2.0, 4.3) 6 months: 2.9 (-0.04, 5.9) 12 months: -0.5 (-3.7, 2.7) -SF-36 MCS Baseline: 2.9 (-0.4, 6.2) 6 months: -1.5 (-4.1, 1.1) 12 months: -0.9 (-4.5, 2.7) -KDQOL symptoms Baseline: 3.5 (0.3, 6.6) 6 months: 2.4 (-0.5, 5.3) 12 months: -1.2 (-4.1, 1.7)	NR

Author, Year Dialysis Modalities	Study Years Country	Sample Size Inclusion Criteria Length of Follow-up	Patient Characteristics Study Risk of Bias	Hospitalization	Quality of Life, Cognition, Depression	Adverse Events
Mittal 2001[57] PD, HD	1996-1998 USA	N=177 (134 HD, 34 PD) Receiving HD or PD for >3 months at study site Mean follow-up: 15.2 months for PD, 14.5 months for HD	Age (yr): 59 Gender (% male): 59 Race (%): Caucasian (59), African-American (31), Hispanic and other (10)* *PD patients less likely Caucasian, more likely African-American **Risk of Bias: High** **Selection bias:** inadequate **Blinding:** inadequate **ITT:** unclear **Attrition bias:** unclear **Selective outcome reporting:** no	-Number of hospitalizations HD: 1.5 (1.9) PD: 0.43 (0.7); P < .01 -Hospital days HD: 12.2 (21.2) PD: 2.39 (4.4); P < .05	-SF-36 *PCS* HD: 36.9 (8.8) PD: 31.8 (7.8); P < .02 *MCS* HD: 48.7 (9.3) PD: 47.1 (10.7); P = NS *Rate of change over time* Non-significant changes for PD and HD (PCS and MCS) -Depression (MCS ≤ 42; %) HD: 25.4 PD: 26.1; P = NS	NR
Bruno 2000[73] PD, HD	1989-1998 Netherlands	N=397 (269 HD, 128 PD) Chronic dialysis (>6 weeks) patients Follow-up (median) HD: 19 months PD: 17 months	*HD patients* Age (yr): 64 (mean) Gender (% male): 62 Race (%): NR *PD patients* Age (yr): 59 (median) Gender (% male): 66 Race (%): NR **Risk of Bias: Moderate** **Selection bias:** adequate **Blinding:** unclear **ITT:** adequate **Attrition bias:** adequate **Selective outcome reporting:** no	NR	NR	Pancreatitis HD: 1/269 (0.4%); 0.0016 events/PY; “uneventful” clinical outcome PD: 7/128 (5.4%); 7 patients had 9 events; 0.037 events/PY or 0.029 patients/PY; 1 patient died (1/7 [14%]), 6 uneventful clinical outcome P < .001 (HD vs PD)

Author, Year Dialysis Modalities	Study Years Country	Sample Size Inclusion Criteria Length of Follow-up	Patient Characteristics Study Risk of Bias	Hospitalization	Quality of Life, Cognition, Depression	Adverse Events
Van Biesen 2000[74] PD, HD	1979-1996 Belgium	N=417 (223 HD, 194 PD) Survived >3 months on initial modality Follow-up: 10 years	Age (yr): 56 Gender (% male): 52 Race (%): NR **Risk of Bias: High** **Selection bias:** inadequate **Blinding:** N/A **ITT:** unclear **Attrition bias:** unclear **Selective outcome reporting:** no	NR	NR	*Reasons for modality switch* -HD to PD: n=35 cardiovascular problems (40%), access problems (25%), personal choice (23%), blood pressure problems (12%) -PD to HD: n=32 peritonitis or exit-site infection (50%), adequacy and/or ultrafiltration problem (25%), social problems (14%), extraperitoneal leakage of dialysis fluid (11%)
Cross-Sectional Studies						
Kalirao 2011[68] PD, HD	NR USA	N=389 (51 PD, 338 HD) English as primary language, age ≥18 (PD) or age ≥55 (HD), no documented history of recent chemical dependency or acute psychoses All testing at least 2 hours from time of last dialysis Follow-up: NA	Age (yr): 69* Gender (% male): 56 Race (%): white (79), African American (13)* *PD patients younger, more likely male, broader race distribution Dialysis duration (months) PD: 23.0 (15.6) HD: 32.8 (32.8) (P = .005) **Risk of Bias: High** **Selection bias:** unclear **Blinding:** unclear **ITT:** unclear **Attrition bias:** unclear **Selective outcome reporting:** no	NR	-Cognitive impairment[a] *None* PD: 26% HD: 13% *Mild* PD: 8% HD: 14% *Moderate* PD: 35% HD: 36% *Severe* PD: 31% HD: 37% -Risk of moderate to severe impairment relative to controls age ≥55 without CKD PD: OR 2.58 (1.02, 6.53) HD: OR 3.16 (1.91, 5.24)	NR

Author, Year Dialysis Modalities	Study Years Country	Sample Size Inclusion Criteria Length of Follow-up	Patient Characteristics Study Risk of Bias	Hospitalization	Quality of Life, Cognition, Depression	Adverse Events
Griva 2010[22] HD, HHD, PD (CAPD, APD)	NR UK	N=145 (HD 52, HHD 25, PD 68) Age ≥ 18, maintained on same dialysis modality for ≥ 3 months, fluent in English, medically stable (no acute medical or psychiatric problems) Follow-up: NA	Age (yr): 50 Gender (% male): 50 Race (%): 64 Duration of treatment HD: 38.9 months; significantly shorter than HHD, significantly longer than either PD modality HHD: 88.4 months PD: 18.6 (21.6 CAPD, 12.9 APD) **Risk of Bias: High** **Selection bias:** inadequate **Blinding:** inadequate **ITT:** unclear **Attrition bias:** unclear **Selective outcome reporting:** no	NR	-TEQ: Significant difference across modalities (P < .01); post hoc significant difference was between PD modalities (P = .01) -BDI (% with score of ≥16 [clinical cutoff for depression]) HD: 42 % (P = NS vs other modalities) HHD: 8% CAPD: 49% (P = .01 vs APD; P = .04 vs HHD) APD: 26% -CDI (% with score of ≥10 [clinical cutoff for depression]) HD: 31% (P = NS vs other modalities) HHD: 12% CAPD: 44% (P = .001 vs APD; P = .005 vs HHD) APD: 22%	NR

Author, Year Dialysis Modalities	Study Years Country	Sample Size Inclusion Criteria Length of Follow-up	Patient Characteristics Study Risk of Bias	Hospitalization	Quality of Life, Cognition, Depression	Adverse Events
Cano 2007[75] PD, HD	NR UK	N=148 (HD 100, PD 48) All HD or PD patients were asked to complete questionnaire Follow-up: NA	*HD Patients* Age (yr): 21-86 (mean NR) Gender (% male): 51 Race (%): NR *PD Patients* Age (yr): 19-87 (mean NR) Gender (% male): 65 Race (%): NR **Risk of Bias: High** **Selection bias:** adequate **Blinding:** unclear **ITT:** inadequate **Attrition bias:** inadequate **Selective outcome reporting:** no	NR	NR	GI Symptoms (Rome II classification) *HD Patients* Abdominal pain: 72/100 (72%)[b,c] Constipation: 33/100 (33%)[b,c] Laxative use: 44/100 (43%)[b,c] Heartburn: 20/100 (20%)[b] Dysphagia: 6/100 (6%)[b] Aerophagia: 11/100 (11%)[c] Vomiting 18/100 (18%)[b,c] IBS: 21/100 (21%)[b,c] *PD Patients* Abdominal pain: 31/48 (65%)[b,c] Laxative use: 38/48 (79%)[b,c] IBS: 16/48 (33%)[b]
Lee 2005[67] PD, HD	2002 UK	N=173 (HD 99, PD 74) Response rates HD: 37% PD: 47% Identified from renal unit database of a hospital Trust Follow-up: NA HD patients completed survey during dialysis appointment	Age (yr): 61 Gender (% male): 57 Race (%): NR **Risk of Bias: High** **Selection bias:** inadequate **Blinding:** N/A (self-report) **ITT:** inadequate **Attrition bias: in**adequate **Selective outcome reporting:** no	NR	-EQ-5D$_{index}$ (1.0=perfect health) HD: 0.44 (0.32) PD: 0.53 (0.34); P = NS -KDQOL (scoring?) PD significantly higher than HD for effects of kidney disease, burden of kidney disease, cognitive function; PD significantly lower than HD for sexual function -SF-36 (100=best health) *PCS:* HD 33.0 (10.4), PD 33.7 (10.8); P = NS *MCS:* HD 44.7 (9.2), PD 47.5 (8.1); P = .03 *Individual domains:* PD significantly higher than HD for emotional well-being and social function	NR

Author, Year Dialysis Modalities	Study Years Country	Sample Size Inclusion Criteria Length of Follow-up	Patient Characteristics Study Risk of Bias	Hospitalization	Quality of Life, Cognition, Depression	Adverse Events
Wight 1998[23] PD, HD, HHD	1995 UK	N=192 (41 HD, 42 HHD, 109 PD) All patients treated at a hospital-affiliated kidney institute Follow-up: NA	Age (yr): mean NR HD: 59% 40-69 years HHD: 69% 40-69 years PD: 63% 40-69 years Gender (% male): 60 Race (%): NR (ethnic minorities approximately 5% of all patients at facility) Duration of treatment HD: 85% ≤ 9 months HHD: 62% ≤ 9 months PD: 94% ≤ 9 months **Risk of Bias: High** **Selection bias:** unclear **Blinding:** N/A **ITT:** inadequate **Attrition bias:** inadequate **Selective outcome reporting:** no	NR	SF-36 (0-100, higher scores = higher quality of life) Physical functioning* HD: 28.3; HHD: 47.1; PD: 40.6 Role physical* HD: 16.7; HHD: 40.9; PD: 20.4 Bodily pain HD: 55.3; HHD: 54.7; PD: 59.0 General health HD: 31.6; HHD: 38.1; PD: 35.1 Vitality HD: 32.0; HHD: 41.7; PD: 35.8 Social functioning* HD: 48.8; HHD: 62.9; PD: 50.0 Role emotional* HD: 29.7; HHD: 65.0; PD: 55.5 Mental health HD: 66.6; HHD 68.8; PD 65.9 *P < .01 for differences across treatments (including hospital HD group data not presented here)	NR

Author, Year Dialysis Modalities	Study Years Country	Sample Size Inclusion Criteria Length of Follow-up	Patient Characteristics Study Risk of Bias	Hospitalization	Quality of Life, Cognition, Depression	Adverse Events
Molzahn 1997[24] PD, HD, HHD	1987-1989 Canada	N=119 (52 HD, 37 HHD, 30 PD) Receiving care at ambulatory care clinic of a major teaching hospital in western Canada Follow-up: NA	Age (yr): 48 Gender (% male): NR Race (%): NR Duration of Treatment (mean) HD: 43.8 months (P = NS vs HHD, P < .05 vs PD) HHD: 37.7 months PD: 24.8 months HD patients assessed during treatment; others before an appointment **Risk of Bias: High** **Selection bias:** unclear **Blinding:** inadequate **ITT:** unclear **Attrition bias:** unclear **Selective outcome reporting:** no	In past year (mean(SD)) HD: 1.68 (1.83) (P = NS vs HHD or PD) HHD: 1.96 (1.73) PD: 1.43 (1.79)	-SASS HD: 5.65 (1.90) (P = NS vs HHD or PD) HHD: 5.68 (2.07) PD: 5.30 (2.04) -IWB HD: 7.04 (2.28) (P < .05 vs HHD or PD) HHD: 8.85 (2.55) PD: 8.84 (3.33) -TTO HD: 0.39 (0.32) (P < .05 vs HHD or PD) HHD: 0.61 (0.29) PD: 0.53 (0.28)	NR

AMT = Abbreviated Mental Test; AT = as treated (analysis); BDI = Beck Depression Inventory; BIPQ = Brief Illness Perception Questionnaire; BMI = body mass index; BP = blood pressure; CAD = coronary artery disease; CAPD = continuous ambulatory peritoneal dialysis; CCPD = continuous cycling peritoneal dialysis; CDI = Cognitive Depression Index; CHF = congestive heart failure; COPD = chronic obstructive pulmonary disease; CVD = cardiovascular disease; DM = diabetes mellitus; eGFR = estimated glomerular filtration rate; ESRD = end stage renal disease; Freq/Ext = more frequent and/or longer duration than conventional; GI = gastrointestinal; GFR = glomerular filtration rate; HD = hemodialysis (in-center); HHD = home hemodialysis; HR = hazard ratio; IBS = irritable bowel syndrome; ITT = intention-to-treat (analysis); IWB = Index of Well-Being; KDQOL = Kidney Disease Quality of Life questionnaire; MCS = Mental Component Summary (SF-36); MOS = Medical Outcomes Study; NA = not applicable; NR = not reported; NS = not statistically significant; PCS = Physical Component Summary (SF-36); PD = peritoneal dialysis; PtM = patient months; PY = person years; QOL = quality of life; RR = relative risk; RRT = renal replacement therapy; SGA = Subjective Global Assessment; SASS = Self-Anchoring Striving Scale; TEQ = Treatment Effects Questionnaire; TTO = Health State Utility/Time Trade-Off technique

[a] Level of cognitive impairment determined from scores relative to age-adjusted means; normal=scores ≤ 1.49 SD below mean on all tests in all 3 domains (memory, language, executive function); mild=scores 1.50-1.99 SD below mean in 1 domain; moderate=scores 1.50-1.99 SD below mean in 2 or more domains or ≥2 SD below mean in 1 domain; severe=scores ≥ 2 SD below mean in 2 or more domains

[b] Symptoms significantly higher compared to hospital outpatient controls

[c] Symptoms significantly higher compared to community controls

Table 5. Study Characteristics and Modality Selection Findings for Key Question 3

Author, Year Country Design	Sample Size Inclusion Criteria	Patient Characteristics Study Risk of Bias	Key Findings
Patient Perspective			
Keating 2014[95] Canada Cohort (retrospective)	N=299 Patients from a multi-disciplinary CKD clinic who had initiated dialysis for a minimum of 30 days, had attended clinic for at least 120 days, received pre-ESRD modality education, had declared an intended modality	Age (yr): 69 Gender (% male): 60 Race (%): Caucasian (85), Afro-Canadian (6), Aboriginal (3), other (6) **Risk of Bias: High** **Selection bias:** adequate **Blinding:** unclear **ITT:** N/A **Attrition bias:** N/A **Selective outcome reporting:** no	-Intended and actual modalities PD: initiated by 91/154 (59%) HHD: initiated by 9/21 (43%) HD: initiated by 84/89 (94%) -*Patient r*easons for not performing PD after intending to initiate PD Preference for hospital based treatment: 37% Lack of space in home: 1.6% -*Medical* reasons for not performing PD after intending to initiate PD Acute start (37%) Abdominal surgeries (8%) Hernia (3.2%) Obesity (2.3%)
Forbes 2013[117] UK Observational (prospective)	N=249 Deemed medically suitable for HHD	Age (yr): 53 (median) Gender (% male): 57 Race (%): white (26), black (33), Indo-Asian (34), other (7) **Risk of Bias: High** **Selection bias:** inadequate **Blinding:** N/A **ITT:** N/A **Attrition bias:** N/A **Selective outcome reporting:** no	-Home visit: 33% of homes did not meet Government's Decent Homes Standard -Hazards to health/well-being: overcrowding (57%), damp/mold growth (33%), inadequate facilities for sanitation and drainage (17%), risk of structural collapse (10%), inadequate domestic hygiene, pests and refuge (8), inadequate facility for storing and preparing food (8), inadequate supply of uncontaminated water (3%) -70% of homes visited were not suitable for either PD or HHD (spatial, health, and safety concerns) -1/249 (0.4%) started HHD, 72/249 (29%) started PD

Author, Year Country Design	Sample Size Inclusion Criteria	Patient Characteristics Study Risk of Bias	Key Findings
Maaroufi 2013[96] France Prospective cohort	N=228 CKD (eGFR <20 ml/min/1.73m^2) or incident HD (<1 month of treatment), 2009-2011, no formal information on ESRD treatment Minimum follow-up: 1 year	Age (yr): 70 Gender (% male): 63 Race (%): NR Patients had at least one information session (more if requested) on principles, advantages, and complications of PD and HD (HHD was not an option in this region; PD was offered to all patients expressing a preference or with contraindications to HD) **Risk of Bias: High** **Selection bias:** inadequate **Blinding:** N/A **ITT:** adequate **Attrition bias:** adequate **Selective outcome reporting:** no	-78% (n=177) were pre-dialysis, 22% (n=51) on HD for <1 month (no significant differences in patient characteristics between groups) **-Information received during pre-dialysis care** PD preference: 82/177 (46%); 45 went to RRT (21 [47%] HD, 21 [47%] PD, 3 [6%] transplant at 1 month) HD preference: 49/177 (28%); 33 went to RRT (32 [97%] HD, 1 [3%] transplant at 1 month) Undecided: 34/177 (19%); patients more often female; 11 went to RRT (9 [82%] HD, 1 [9%] PD, 1 [9%] transplant at 1 month) Reluctant to undergo dialysis: 12/177 (7%); patients older (3 went to RRT, all HD at 1 month) **-Information received during 1st month of HD** PD preference: 14/51 (27%); 12 alive at 3 months (8 [67%] HD, 4 [33%] PD) Stay with HD: 26/51 (51%); 25 alive at 3 months (100% HD) Undecided: 11/51 (22%); 11 alive at 3 months (100% HD) -Excluding “reluctant” patients: PD preference patients were older, had lower BMI, and were more frequently informed pre-dialysis -Reasons for preferring PD: home treatment (54%), autonomy (31%), comfort to travel (5%), employment compatibility (11%) -Reasons for preferring HD: treatment in medical facility (32%), autonomy (37%), socioeconomic criteria (15%), socializing/security (12%), reluctance for intra-abdominal catheter (11%) -Reasons for reluctance: age and comorbidities (75%) only pre-emptive transplantation (8%), behavioral impairment (8%), cultural (8%) -Mismatches between preference and treatment – only for n=29 in PD group; 48% due to medical causes (largely abdominal contraindication), 52% due to other causes (medical center transfer, adverse opinion of family or employer, changed opinion)

Author, Year Country Design	Sample Size Inclusion Criteria	Patient Characteristics Study Risk of Bias	Key Findings
Ribitsch 2013[92] Austria Retrospective cohort	N=227 (70 intervention, 157 standard care) eGFR ≤ 15 mL/min/1.73m^2, anticipated progression to ESRD in following year; excluded patients who started dialysis with central venous catheter (eliminating late referrals and emergency starts)	Age (yr): 56 Gender (% male): 66 Race (%): NR Information on Dialysis (INDIAL) pre-dialysis education program offered to all patients with participation voluntary; 2 days of information and demonstrations (PD and HD) Standard care group did not receive structured education **Risk of Bias: High** **Selection bias:** inadequate **Blinding:** N/A **ITT:** N/A **Attrition bias:** unclear **Selective outcome reporting:** no	-227 patients progressed to dialysis during study period Education group: 46% (32/70) chose HD; 54% (38/70) chose PD Standard care group: 72% (113/157) chose HD; 28% (44/157) chose PD OR (choosing PD with INDIAL vs standard care, age corrected): 3.35 (1.82, 6.14)

Author, Year Country Design	Sample Size Inclusion Criteria	Patient Characteristics Study Risk of Bias	Key Findings
Chanouzas 2012[97] UK Cross-sectional (survey)	N=118 (response rate 49%); HD 82, PD 24, conservative management 12) Patients who had already made a modality choice following standard education program; referred for education with irreversible CKD and deteriorating GFR	Age (yr): 67* Gender (% male): 59 Race (%): Caucasian (79) *PD patients younger than HD patients Education program included home visit (2-4 hours) with educational materials, invitation to visit HD or PD unit, invitation to formal education workshop (1/2 day), plus additional meetings as requested **Risk of Bias: High** **Selection bias:** inadequate (49% response rate) **Blinding:** N/A **ITT:** N/A **Attrition bias:** adequate **Selective outcome reporting:** no	-Patients choosing PD (vs HD, all P < .05): lower comorbidity index score, more likely married, more likely employed or in school, less likely living alone -Patients choosing PD scored the following factors significantly more important than patients choosing HD (all P < .05) Written information on modality Modality fitting with lifestyle Family/home/work circumstances -Patients choosing HD scored “past medical history” significantly more important than patients choosing PD (P = .02)

Author, Year Country Design	Sample Size Inclusion Criteria	Patient Characteristics Study Risk of Bias	Key Findings
Lacson 2011[93] USA CCT	N=20,057 incident patient/TOPs attendees (8/2006-12/2008); subset of 30,217 incident patients (1/2008-12/2008, 3,165 who attended TOPS); 2,800 matched (TOPS/non-TOPS) pairs (age, gender, race, diabetes, geographic area) Attended treatment options program (TOPs) at Fresenius Medical Care, North America facilities	For 30,217 incident patients Age (yr): 63 Gender (% male): 57 Race (%): white (65), black (29), other (5) For 2,800 matched pairs Age (yr): 63 Gender (% male): 57 Race (%): white (76), black (21), other (2) **Risk of Bias: Moderate** **Allocation generation/concealment:** N/A **Blinding:** N/A (database) **Incomplete outcomes:** no **Selective outcome reporting:** no	-Of 20,057 TOPs attendees, modality selections were: in-center (27%), home (24%), transplant (13%), no therapy (0.2%), no choice (35%) -5,567 of these patients started dialysis therapy; 25% began a home dialysis therapy (compared to 3.3% of approximately 75,000 patients who did not attend TOPS during same time period); home-based was predominantly PD -Of 30,217 incident patients, TOPs attendees (n=3,165) were younger (62 vs 63 years, P = .008), more likely white (73% vs 65%, P < .001), larger body surface area ($1.89m^2$ vs $1.87m^2$, P < .01), with fewer comorbid conditions (3.7 vs 3.9, P = .01) -Choice of PD: 25% of TOPs attendees, 3.7% of non-attendees (adjOR 5.13 [3.58, 7.35]) -Of 2,800 matched pairs, 24.0% of TOPs attendees and 4.0% of non-attendees chose PD (adjOR 7.73 [3.26, 18.32]) -90 day survival (adj HR for death, attendees vs non-attendees): 0.61(0.50, 0.74) (similar results in matched analysis) -adjOR for TOPs attendees being on PD at day 90: 4.69 (3.24, 6.79)
Oliver 2010[82] Canada Cohort (prospective)	N=497 incident ESRD patients Written diagnosis of ESRD by nephrologist, received at least 1 dialysis treatment or had initiated outpatient chronic dialysis or had acute or acute-on-chronic renal failure and had received at least 4 weeks of uninterrupted dialysis	Age (yr): 66 Gender (% male): NR Race (%): NR Note: contraindications, barriers to self-care, and availability of support in the home were determined by a multidisciplinary team (nephrologist, pre-dialysis nurse, PD nurse and/or acute care nurse, social worker) **Risk of Bias: Moderate** **Selection bias:** adequate **Blinding:** N/A **ITT:** adequate **Attrition bias:** adequate **Selective outcome reporting:** no	-110/497 (22%) had medical and social <u>contraindications</u> to PD a. Medical: obesity (5%), abdominal scarring (5%), ascites (1%), diverticulitis (1%), abdominal hernia (1%), other conditions (all < 1%) b. Social: residence did not permit PD (3%), work did not permit PD (0.2%) -245/387 (63%) had <u>barriers</u> to self-care; patients with barriers were older, more likely female, lower weight and BMI, more likely to have a cardiovascular condition or cancer, more likely to have started dialysis as an inpatient and at a higher eGFR a. Physical: ↓strength (53%), ↓manual dexterity (43%), ↓vision (33%), ↓hearing (16%), immobility (25%), poor health (14%), poor hygiene (3%) b. Cognitive: language (15%), history of non-compliance (13%), psychiatric condition (8%), dementia/poor memory (8%), other (8%) -Among 245 patients with barriers to self-care PD, family support increased PD eligibility (80% vs 63%,; P = .003; adjOR 3.1 [1.6, 6.1], P = .001) -Among 179 patients offered PD, family support increased choice of PD (57% vs 40%, P = .03; adjOR 2.3 [1.2, 4.7], P = .01) -Among 245 patients with barriers to self-care; family support increased PD utilization (39% vs 23%, P = .009) -Family-assisted PD: 34% of patients with barriers to self-care and family support; 0% of patients with barriers and no family support, and 9% of those with no barriers to self-care

Author, Year Country Design	Sample Size Inclusion Criteria	Patient Characteristics Study Risk of Bias	Key Findings
Rioux 2010[118] Canada Cohort (prospective data collection)	N=236 initiating home dialysis (83 HHD, 153 PD) All patients initiating PD or HHD, 2004-2008	Age (yr): 56 Gender (% male): 62 Race (%): Caucasian (52), Asian (21), black (10), other (18) **Risk of Bias: High** **Selection bias:** adequate **Blinding:** N/A **ITT:** N/A **Attrition bias:** N/A **Selective outcome reporting: no**	(NOTE: facility has a "home dialysis first" policy) -Patient differences (HHD vs PD) a. HHD patients more likely male (70% vs 57%, P = .05) b. HHD patients younger at start of modality (46 years vs 62 years, P < .001) c. HHD patients less likely to have diabetes (24% vs 45%, P = .003) d. HHD patients had longer delay between 1st RRT and HHD (4.8 years) than PD patients (delay between 1st RRT and PD = 0.34 years); P = .002
Zhang 2010[119] Canada Cohort (retrospective data collection)	N=486 attended clinic; 153 started RRT (59 HD, 15 HHD, 79 PD) Attended CKD clinic 2001-2007	Demographic data for N=486 Age (yr): 65 Gender (% male): 61 Race (%): Caucasian (70), Asian (14), black (6), other (10) 11% had medical contraindication for HHD **Risk of Bias: High** **Selection bias:** inadequate **Blinding:** N/A **ITT:** N/A **Attrition bias:** N/A **Selective outcome reporting:** no	-Patient differences; all P < .05 a. HHD patients younger (48 yrs) than HD (62 yrs) or PD (64 yrs) patients b. HHD patients had lower BMI (19) than HD (32) or PD (29) patients c. HHD patients more likely English speaking (100%) than HD (68%) patients d. HHD patients more likely working (73%) than HD (39%) or PD (42%) patients -No difference in eGFR or comorbidity index at initiation -Patients' reasons for NOT choosing HHD: disinterest (25%), lack of social support (24%), inadequate space (5%), communication (5%), inability to perform own dialysis (3%) (NOTE: not all patients provided a reason)

Author, Year Country Design	Sample Size Inclusion Criteria	Patient Characteristics Study Risk of Bias	Key Findings
Cafazzo 2009[120] Canada Cross-sectional survey	N=66 NHHD and 199 eligible HD patients Excluded: medical contraindication to NHHD, life expectancy < 6 months, physical and/or visual impairments limiting ability for HHD, mental or psychiatric diagnoses that prevent independent living	Age (yr): 53 Gender (% male): 57 Race (%): NR **Risk of Bias: High** **Selection bias:** inadequate (21% non-response) **Blinding:** N/A **ITT:** N/A **Attrition bias:** adequate **Selective outcome reporting:** no	-Response rate: 56/66 (85%) NHHD; 153/199 (77%) HD -Patient differences a. NHHD patients were younger (47 years vs 55 years, P = .001) b. No difference in gender (60% vs 56%, P = .49) c. NHHD patients less likely to have diabetes (12.5% vs 31.4%, P = .006) d. NHHD patients had higher physical quality of life (SF-12) scores (41.5 vs 34.7, P < .0001) e. No difference In mental component, perceived ability for self-care, perceived social support, or anxiety -Perceptions of NDDH (all differences P < .05) a. HD patients less likely to be comfortable with self-cannulation b. HD patients less likely to believe they will receive as good care as with HD c. HD patients less likely to believe they would be able to perform NHHD properly d. HD patients more fearful of a catastrophic event
Portolés 2009[76] Spain Prospective cohort	N=489 All incident PD patients (2003-2006) Average follow-up 13.36 months (range 1-36)	Age (yr): 54 Gender (% male): 62 Race (%): NR **Risk of Bias: Low** **Selection bias:** adequate **Blinding:** N/A **ITT:** adequate **Attrition bias:** adequate **Selective outcome reporting:** no	-Hospitalizations: comorbidity index, diabetes, and previous CV event predicted hospital admission -Mortality: 28/489 (5.7%), patients that died were older, had higher comorbidity index values, had diabetes or previous CV event, had higher hospital admission rate -Patients that changed from HD to PD had higher mortality rate (11.5% vs 4.6%, P = .009) -Patients receiving PD through choice has lower mortality than those forced to accept PD for medical reasons (3.5% vs 20.4%, P < .001) and lower peritonitis rate (0.46 per year at risk vs 0.82, P < .05)

Author, Year Country Design	Sample Size Inclusion Criteria	Patient Characteristics Study Risk of Bias	Key Findings
Oliver 2007[83] Canada CCT	N=134 incident patients All pre-dialysis patients who progressed to ESRD, ESRD patients who started dialysis urgently	Age (yr): 73 (median) Gender (% male): 58 Race (%): NR Multidisciplinary team (physician, program coordinator, social work, home dialysis nurse) reviewed for medical and social conditions that could be barriers to PD **Risk of Bias: Moderate** **Allocation generation/concealment:** N/A **Blinding:** inadequate **Incomplete outcomes:** no **Selective outcome reporting:** no	-Control group patients lived in regions without home care support -108/134 (81%) had at least 1 medical or social barrier to PD a. Medical: ↓strength 43%, ↓manual dexterity 37%, ↓vision/blindness 25% immobility 20%, ↓hearing/deafness 17%, others (all 4% or less) b. Mental or psychological: anxiety 25%, decreased cognition (including dementia) 8%, psychiatric condition 7%, history of non-compliance 5% c. Social: living alone and requiring assistance with PD 19%, residence does not permit PD 9%, nursing home does not support PD 7%, others (all 4% or less) -80% of patients living in regions with home care support were eligible for PD (compared to 65% of those living in regions without support, P = .01) -Each condition acting as a barrier reduced odds of being eligible for PD (OR 0.74 per condition, P = .02) -No difference in likelihood of choosing PD based on availability of home care (59% in regions with home care, 58% in regions without home care) -Female patients (adjOR 2.8, P = .03) more likely to choose PD -Patients receiving pre-dialysis care (adjOR 5.0, P = .01) more likely to choose PD (pre-dialysis care defined as at least 4 months of nephrology care before dialysis) -Utilization of PD: 47% in regions with home care support, 37% in regions without home care support (P = .27) -Utilization of PD greater in patients receiving pre-dialysis care (OR 4.0, P = .01) and in females (OR 2.3, P = .04) -Among patients living in region with home care assistance, choosing PD, and consenting to follow-up, mean rate of home care visits per week in 1st year was 4.6 (including 4 self-care patients) or 5.8 in patients who received assistance (maximum allowable visits = 14) -Adverse events in mean follow-up of 449 days per patient (all P = NS) a. Hospitalizations per patient year: Assisted PD 1.4, Other dialysis modalities 1.0 b. Hospital days per patient year: Assisted PD 23.5, Other dialysis modalities 13.1 c. Modality switches per patient year: Assisted PD 0.40*, Other dialysis modalities 0.19 d. Deaths per patient year: Assisted PD 0.12, Other dialysis modalities 0.18 *Included temporary switches, technique survival was 81% at 1 year

Author, Year Country Design	Sample Size Inclusion Criteria	Patient Characteristics Study Risk of Bias	Key Findings
Manns 2005[89] McLaughlin 2008[90] Canada RCT	N=70 (35 per group) Patients with CKD (GFR < 30 mL/min/1.73m^2) who had attended, at a minimum, the standard 3-hour education session; excluded if cognitive dysfunction, non-English speaking unless family member could translate), unable to do ADLs independently, currently on dialysis	Age (yr): 64 Gender (% male): 54 Race (%): NR Randomized to educational intervention (4 written manuals, videos, small group interactive session) or standard care only **Risk of bias: High** **Allocation:** adequate **Blinding:** inadequate **ITT:** no (all patients providing data at time of outcome measurement n=34 in usual care group; n=30 in intervention group at 1st assessment, n=28 at 2nd assessment); **Withdrawals:** 8/70 (11%); all accounted for **Selective outcome reporting:** no	**Manns 2005** -Intention to start self-care dialysis at baseline: 57.1% intervention, 48.6% control (P = .6) -Intention to start self-care dialysis at study completion: 82.1% intervention, 50.0% control (P = .015) -Among patients who were either uncertain or planned to start with in-center HD at baseline: 64.2% of intervention group and 16.7% of control group (P = .01) planned to start self-care at study completion -No interactions -2 factors associated with increased odds of choosing self-care a. intention to choose self-care at the start of the study (OR 41.7 [6.5, 264.3], P < .001) b. being in intervention group (OR 10.2 [2.0, 50.3], P = .004) -Knowledge: intervention group significantly different from control group on 2 of 3 items at study completion -Attitudes: intervention group significantly different from control group on 2 of 5 items at study completion -At mean follow-up of 339 days since enrollment, 12 additional patients started dialysis: 2 intervention group patients died within 1 week of start (modality not reported), 4 of 7 control group patients started with self-care dialysis; 2 of 3 intervention group patients started with self-care dialysis **McLaughlin 2008** -Patient-reported perceived advantages of self-care dialysis categorized as *freedom, lifestyle, and control* -Association of perceived advantages with intended choice of self-care dialysis a. Freedom: adjOR 9.1 (2.0, 41.3), P = .004 b. Lifestyle: adjOR 7.0 (1.6, 29.7), P = .008 c. Control: adjOR 4.3 (0.9, 19.1), P = .058 -Perceiving no advantage of self-care dialysis associated with reduced odds of selecting self-care dialysis (OR 0.06 [0.01, 0.24], P < .001) -Control group: no change in perceptions of advantages of self-care dialysis from baseline to study completion -Intervention group: increased % identifying freedom (P = .01) and control (P = .01) as advantages; decreased % reporting no advantage (P < .001)

Author, Year Country Design	Sample Size Inclusion Criteria	Patient Characteristics Study Risk of Bias	Key Findings
Bass 2004[100] USA Cross-sectional	N=188 Diagnosis of ESRD, began dialysis ≥3 months before interview, spoke English, age ≥18, lived within 1 hour of Baltimore or Boston	Age (yr): NR (34% > 65 yr) Gender (% male): 37 Race (%): African-American (56)* *PD patients less likely African American HD patients interviewed at dialysis facilities; PD patients interviewed at home or at facility HD patients more likely on dialysis ≥5 years and less likely to have had a different previous modality **Risk of Bias: High** **Selection bias:** inadequate **Blinding:** no **ITT:** N/A **Attrition bias:** inadequate **Selective outcome reporting:** no	-Depressed mood (patients with Beck Depression Index score > 9 [mild to moderate depressive mood]) HD: 8/109 (7%); CAPD 3/57 (5%); CCPD 3/22 (14%) -Quality of life (patients with General Health Perceptions score ≥ 70 [median score for general population]; 0 = worst, 100 = best) HD: 38%; CAPD 18%; CCPD 14% (P < .05 across modalities) -Aspects of daily life (patients reporting negative effect of current dialysis modality) a. No differences across modalities for ability to perform daily tasks, ability to control your life, relationships with family and friends, getting the sleep you need, feelings of anxiety, or interest in sex b. Significant difference across modalities for feelings about how you look (HD 29%, CAPD 26%, CCPD 55%) -Time trade-off-based preference values for current treatment vs other modalities a. No differences across modalities in values for current health (0 = death, 1 = perfect health) (HD 0.69, CAPD 0.74, CCPD 0.70) b. HD patients assigned significantly lower values to CAPD, CCPD, and HHD c. CAPD patients assigned significantly lower values to HD and HHD d. CCPD patients assigned significantly lower values to HHD -Approximately 38% of HD patients would switch to CAPD if it increased survival time by 20%; approximately 66% would switch if increase was 100% -Approximately 34% of CAPD patients would switch to HD if it increased survival time by 20%; approximately 70% would switch if increase was 100% -Approximately 30% of CCPD patients would switch to HD if it increased survival time by 20%; approximately 65% would switch if increase was 100%
Rubin 2004[94] CHOICE USA Cross-sectional	N=736 incident dialysis patients from centers offering both HD and PD Initiation of chronic outpatient dialysis in past 3 months, ability to consent, age > 17 years, able to speak English or Spanish	Age (yr): 56* Gender (% male): 56 Race (%): white (69)* *PD patients younger and more likely white **Risk of Bias: High** **Selection bias:** inadequate **Blinding:** surveys returned anonymously **ITT:** N/A **Attrition bias:** inadequate **Selective outcome reporting:** no	-Response rate: 89% (656/736), 521 complete responses, 135 partial responses PD: 85% (185/256) plus 28 partial responses HD: 92% (336/480) plus 107 partial responses -Rating of “Excellent” on amount of information given on choosing HD or PD PD patients: 69% (134/193) HD patients: 26% (99/382) Relative probability (PD vs HD): 2.65 (2.21, 3.02) -Rating of “Excellent” on amount of dialysis information PD patients: 71% (137/193) HD patients: 33% (129/394) Relative probability (PD vs HD): 2.07 (1.78, 2.32)

Author, Year Country Design	Sample Size Inclusion Criteria	Patient Characteristics Study Risk of Bias	Key Findings
McLaughlin 2003[91] Canada Cross-sectional survey	N=223 Attended progressive renal insufficiency clinic (actively promoting self-care dialysis)	Completers of survey: Age (yr): 61 Gender (% male): 60 Race (%): NR **Risk of Bias: Moderate** **Selection bias:** adequate **Blinding:** N/A **ITT:** N/A **Attrition bias:** adequate **Selective outcome reporting:** no	-Response rate 185/223 (85%) (NOTE: if questionnaire wasn't returned, another was sent 2 weeks later until response rate was >80%); 12 questionnaires were excluded (patient could not be identified and/or errors in completion) -Barriers to self-care dialysis (% of patients who agreed or strongly agreed with statement): a. knowledge (highest of 4 reasons): lack of explanation of self-care (60%); lack of understanding (36%) b. attitudes (highest of 13 reasons): fear of social isolation (54%), patient should not be unsupervised (53%), lack of self-efficacy in performing self-care (50%), fear of substandard care (40%) c. skills (highest of 9 reasons): needle phobia (47%), lack of space at home (42%), visual impairment (30%)
Ravani 2003[98] Italy Prospective cohort	N=229 Consecutive patients new to RRT 1999-2002 Compared patients referred ≤3 months before dialysis to those referred >3 months before Among patients referred >3 months before dialysis - compared standard unstructured pre-dialysis clinic to formal multidisciplinary pre-dialysis care	Age (yr): 64 (median 70)* Gender (% male): 62 Race (%): NR *Standard care group was older Patients at study centers were invited to consider PD as 1st choice if no major clinical or psychological contraindications or personal unwillingness **Risk of Bias: Moderate** **Selection bias:** adequate **Blinding:** N/A **ITT:** adequate **Attrition bias:** adequate **Selective outcome reporting:** no	-Participation in modality selection Referral ≤3 months: 53/84 (63%) Referral >3 months:113/145 (78%), P = .015 Standard pre-dialysis care: 44/52 (85%) Multidisciplinary pre-dialysis care: 69/93 (74%), P = .147 (unadjusted analysis) -Choice of PD (vs HD) Referral ≤3 months: 25/84 (30%) Referral >3 months: 70/145 (48%), P = .006 Standard pre-dialysis care: 21/52 (40%) Multidisciplinary pre-dialysis care: 49/93 (53%), P = .155 (unadjusted analysis) -Planned dialysis start Standard pre-dialysis care: 39% Multidisciplinary pre-dialysis care: 91%, P < .001 (unadjusted analysis) Choice of PD higher in those with planned start (56% vs 24%, P < .001)

Author, Year Country Design	Sample Size Inclusion Criteria	Patient Characteristics Study Risk of Bias	Key Findings
Gadallah 2001[99] USA Prospective before/after	N=201 in dialysis program before intervention; N=235 after intervention All patients approaching ESRD in study period Patients invited to visit both HD and PD units and discuss dialysis with current patients, also given booklets and films	Age (yr): NR Gender (% male): NR Race (%): NR Developed comprehensive infrastructure including nephrologist placement of PD catheters, identification and training of family members/ nursing home/ daycare staff to perform PD, increased social support, early ESRD education, provision of in-center intermittent PD for selected patients **Risk of Bias: High** **Selection bias:** inadequate **Blinding:** N/A **ITT:** unknown **Attrition bias:** unknown **Selective outcome reporting:** no	-Significant changes in number of PD patients associated with initiation of PD program element (before, after; P value) a. training nursing home personnel (3, 11; P = .01) b. training daycare center personnel (0, 5; P = .05) c. training family members/providing support (4, 15; P = .03) d. early patient and family education (4, 24; P = .008) e. improving home conditions (1, 14; P = .01) f. in-center intermittent PD program (0, 6; P = .05) g. nephrologists laparoscopic catheter placement (loss to HD due to mechanical catheter failure) (22, 3; P = .005) -Percent of patients choosing PD: 19% before, 76% after (P = .001) -Number of patients in PD program: 33 before, 93 after (P = .001) -Number of patients in HD program: 168 before, 142 after (P = .05) -Percent of dialysis patients at facility on PD *before* intervention: 16% -Percent of dialysis patients at facility on PD *after* intervention: 40%

Author, Year Country Design	Sample Size Inclusion Criteria	Patient Characteristics Study Risk of Bias	Key Findings
Winkelmayer 2001[101] USA Cohort	N=12,557 incident patients (1990-1996); 3014 were eligible (2344 HD, 670 PD) Active in Medicare or Medicaid in New Jersey for at least 12 months prior to initiation; at least 1 health service encounter in each of 2 years prior to RRT; first diagnosis of renal insufficiency >1 year prior to dialysis (exclude new-onset renal disease)	Age (yr): NR (Medicare/Medicaid population - 43% age 65-74, 35% age 75-80) Gender (% male): 56 Race (%): white (74), black (19), other (6) **Risk of Bias: High** **Selection bias:** inadequate **Blinding:** anonymous study numbers **ITT:** N/A **Attrition bias:** adequate **Selective outcome reporting:** no	-Predictors of PD vs HD as initial modality *Race* Black race (vs white) OR 0.56 (0.43, 0.72) Other race (vs white) OR 0.56 (0.38, 0.85) *Socioeconomic Status (SES)* Lower status OR 0.68 (0.56, 0.83) *Age* Age 45-54 (vs 65-74) OR 1.53 (1.01, 2.31) *Gender, renal diagnosis, and timing of referral* – not statistically significant -Determinants of modality switch – incident HD patients *Race* Black race (vs white) OR 0.69 (0.49, 0.97) *Age* Age 75-84 (vs 65-74) OR 0.73 (0.54, 0.99) *Renal Diagnosis* Diabetic nephropathy (vs not specified) OR 1.49 (1.13, 1.96) *Gender, SES, timing of referral* – not statistically significant -Determinants of modality switch – incident PD patients *Timing of referral* Late referral (≤90 days) (vs early referral) OR 1.47 (1.12, 1.93) *Age, gender, race, SES, renal diagnoses* – not statistically significant
Prichard 1996[86] Canada Retrospective observational	N=150 Chronic renal failure, entering ESRD programs 1988-1991; excluded if transplant at onset of ESRD or transplant or death within 6 weeks of dialysis start date	Age (yr): 57 Gender (% male): 54 Race (%): NR After chart review of comorbid and/or social conditions, patients assigned to Group A (n=31 HD recommended), Group B (n=14 PD recommended), Group C (n=31 diabetic patients encouraged to do CAPD), Group D (n=74 patient choice) **Risk of Bias: Moderate** **Selection bias:** adequate **Blinding:** N/A **ITT:** N/A **Attrition bias:** N/A **Selective outcome reporting:** no	-Dialysis modality during study period HD 83/150 (55%) PD 67/150 (45%) -Group A – HD recommended for a. social reasons (social situation inappropriate to support home PD): 20/31 (65%) b. unusable abdomen (ostomies, hernias, obesity, polycystic kidneys, abdominal wall infection): 9/31 (29%) c. awaiting liver transplant: 1/31 (3%) d. age (92 years old): 1/31 (3%) -Group B – PD recommended for a. cardiovascular disease: 10/14 (71%) b. difficult vascular access: 3/14 (21%) c. lived too far away from center: 1/14 (7%) -Group C – PD recommended (diabetic patients) a. 17/31 (55%) chose PD b. 14/31 (45%) chose HD (10 for social reasons, 3 refused CAPD, 1 unsuitable abdomen) -Group D – Free choice a. 37/74 (50%) chose HD (including 15 self-care HD) (7 had previous HD, 4 lifestyle reasons, 11 missed patient education session [9 were late referrals]) b. 37/73 (50%) chose PD c. no gender preference for HD or PD

Author, Year Country Design	Sample Size Inclusion Criteria	Patient Characteristics Study Risk of Bias	Key Findings
Barker-Cummings 1995[102] USA Cohort	N=10,726 incident patients, 1989-1991, African American or white Defined PD as initial modality if patient started PD within 3 months of treatment for ESRD	Age (yr): 57 Gender (% male): 50 Race (%): African American (59), white (41) **Risk of Bias: Moderate** **Selection bias:** adequate **Blinding:** unclear **ITT:** N/A **Attrition bias:** N/A **Selective outcome reporting:** no	*Choice of PD* *Ethnicity* African Americans: 16% (996/6314); White: 30% (1337/4412) OR (African American vs white): 0.43 (0.39, 0.47); AdjOR 0.45 (0.38, 0.52) *Gender* Female: 20% (1052/5409; Male: 24% (1281/5317) OR (male vs female): 1.32 (1.20, 1.44); AdjOR not statistically significant *Age* Relative to age <20, all age groups less likely to choose PD Age 20-29: OR 0.48 (0.34, 0.58); AdjOR 0.47 (0.29, 0.76) Age 40-49: OR 0.34 (0.24, 0.47); AdjOR 0.35 (0.22, 0.55) Age 60-69: OR 0.18 (0.13, 0.25); AdjOR 0.23 (0.15, 0.37) *Functional Status* Mildly impaired (vs normal): OR 0.80 (0.69, 0.92); AdjOR 0.94 (0.84, 1.13) Moderately impaired (vs normal): OR 0.54 (0.46, 0.63); AdjOR 0.80 (0.66, 0.80) Severely impaired (vs normal): OR 0.35 (0.29, 0.43); AdjOR 0.61 (0.48, 0.77) *Other Factors* Education: decreased use of PD with level of education ≤ 12 years Employment: increased use of PD if employed; AdjOR not statistically significant Housing status: decreased use of PD if not a home owner Social support: increased use of PD if living with family (vs alone), decreased use if "other arrangement" (vs alone) Student: increased use of PD if a student; AdjOR not statistically significant
Provider Perspective			
Jayanti 2014[87] International Cross-sectional (Survey)	N=272 health care practitioners who completed an on-line survey (at Nephrology Dialysis Transplantation-Educational (NDT-E) site) Respondents: Europe (61%), Middle East (10%), Asia (9%), North America (8%)	Age: 45-54 (36%); 55-64 (29%); 35-44 (22%) Nephrologists (93%): Hospital-based: 54%; Academic department: 28%; Dialysis unit: 14% **Risk of Bias: High** **Selection bias:** inadequate **Blinding:** N/A **ITT:** N/A **Attrition bias:** N/A **Selective outcome reporting:** no	-56% of respondents had no HHD patients; those who did - median of 6 (range 1-150) -Practitioners from units with a greater number of HHD patients (defined as 6+) were: a. more likely to have a dedicated education team b. more likely to place patients' choice of modality above all other factors c. more likely to offer choice of HHD at all stages of CKD d. more likely to believe evidence supporting extended dialysis schedules -Practitioners from units that had HHD patients a. were more likely to see no financial disadvantage b. were more likely to have belief in current evidence for extended HHD c. had higher expectation of proportion of patients who could do HHD d. did not differ from practitioners from units that did not have HHD patients with regard to view of the choice of therapy that offers the best outcomes, choice of best location for patient management, view of perceived benefits of HHD, or in perceived cost-effective therapy

Author, Year Country Design	Sample Size Inclusion Criteria	Patient Characteristics Study Risk of Bias	Key Findings
Tennankore 2013[88] Canada Cross-sectional (Survey)	N=78 complete surveys (61% response rate) (partial responses from a total of 89) HT, PD, HHD, and pre-dialysis clinic nurses at one health network	Home dialysis (HHD, PD, and pre-dialysis clinic) nurses more likely to have certification in nephrology nursing than HD nurses **Risk of Bias: High** **Selection bias:** adequate **Blinding:** N/A **ITT:** N/A **Attrition bias:** N/A **Selective outcome reporting:** no	-Nurses rankings of group with most influence on patients' choice of modality Physicians (87% by home dialysis nurses; 57% by in-center HD nurses) -Nurses rankings of group with least influence on patients' choice of modality Dialysis nurses (48% by home dialysis nurses; 38% by in-center HD nurses) -Home dialysis nurses thought home dialysis was strongly preferred for patients working or studying part- or full-time and somewhat preferred for patients of poor SES, multiple chronic illnesses, no education beyond high school, age > 70 years, English not primary language, no caregivers or social supports -In-center HD nurses thought in-center HD was strongly preferred for patients with poor SES, multiple chronic illnesses, and no patient caregivers or social supports and somewhat preferred for patients with lo education beyond high school, age > 70 years, English not primary language -Home dialysis nurses thought home dialysis benefited patient quality of life and survival and was lower cost to patients and the healthcare system -In-center HD nurses thought in-center HD was preferred for lower risk of catastrophic events and provided job security for current dialysis nurses -Both groups were "neutral" regarding whether patients were well-informed about all modalities, agreed that patients would benefit from further modality education after starting dialysis, and agreed that they would benefit from further education about dialysis modalities
Morton 2011[81] Australia Prospective observational	N=721 incident CKD Stage 5, July to September 2009; excluded acute kidney injury or return to dialysis from failed transplant	Age (yr): 63 (median=67) Gender (% male): 59 Race (%): NR **Risk of Bias: Low** **Selection bias:** adequate **Blinding:** adequate **ITT:** adequate **Attrition bias:** adequate **Selective outcome reporting:** no	-603/721 (84%) received information about treatment options prior to commencing treatment; 118/721 (16%) did not; 30/721 (4%) unknown -Of 588 dialysis patients (excluding transplant, conservative care, and deceased patients) 17.5% did not receive information about treatment options; increasing time known to a nephrologist (> 3 months vs < 3 months) and treatment at a small renal unit (< 100 patients) significantly associated with higher likelihood of receiving information prior to commencing treatment (both P < .01) -PD information not given because of medical/surgical contraindications (n=30), unsuitable living conditions (n=4), low literacy (n=2), psycho-social contraindications (n=2), patient or family refused (n=3), option not available via service provider (n=2), acute presentation (n=1) -HHD information not given because of medical/surgical contraindications (n=16), unsuitable living conditions (n=18), low literacy (n=2), no social/community support at home (n=10), psycho-social contraindication (n=5), patient or family refused (n=1) -Home-based dialysis in 146/721 (20%); these patients less likely to be known to nephrologist for < 3 months (8% vs 29%, P < .001); more likely to have caregiver with them at information session (80% vs 59%, P < .001); no difference in proportion who received information about treatment options (66% vs 73% of center-based HD)

Author, Year Country Design	Sample Size Inclusion Criteria	Patient Characteristics Study Risk of Bias	Key Findings
Pipkin 2010[80] USA and Canada Survey	N=12 survey respondents (75% response rate) Principal Investigator and Study Coordinator at 8 FHN Nocturnal Trial centers N=87 patients Patients randomized in FHN Nocturnal Trial (nocturnal home HD or in-center HD)	Completers of survey: 6 investigators, 6 study coordinators Age (yr): NR Gender (% male): NR Race/ethnicity (%): NR FHN Nocturnal Trial patients Age (yr): 53 Gender (% male): 66 Race/ethnicity (%): Caucasian (55), African-American (27) **Risk of Bias: High** **Selection bias:** inadequate (75% response rate) **Blinding:** N/A **ITT:** N/A **Attrition bias:** adequate **Selective outcome reporting:** no	-5 most common perceived barriers to HHD by > 66% of respondents: lack of motivation, patients too comfortable in-center, fear of self-cannulation, fear of needles falling out or catheter disconnecting (nocturnal), fear of inability to sleep on machine (nocturnal only) -5 most common perceived barriers to HHD by 33 to 66% of respondents: age 70-79 years, training too long and intense, burden of dialysis/burn out patient/partner (nocturnal only), inadequate dwelling, fear of intradialytic hypotension/hurting self -5 most common perceived incentives by > 66% of respondents: flexible scheduling, flexible prescription, less travel, more liberal diet (nocturnal only), partner encouragement -Home renovation: median cost for all patients $1,329 (range $575 to $4,603); median ranged from $998 to $4,018 across 6 study centers -Training time: mean number of sessions 28 (range 11 to 59) a. training time less for patients with experience in self-care or both self-care and cannulation b. training time not related to tests of cognition, education level, or SF-36 Physical Function subscale c. higher comorbidity score and higher age were related to increased training time required

Author, Year Country Design	Sample Size Inclusion Criteria	Patient Characteristics Study Risk of Bias	Key Findings
Jager 2004[84] (NECOSAD) Netherlands Cohort (prospective)	N=1,347 patients who had survived 1st 3 months and were still on dialysis Age ≥ 18, dialysis was first RRT, long-term dialysis modality is modality at 3 months	Patients Age (yr): 59 Gender (% male): 61 Race: NR Nephrologists completed questionnaire on modality selection (medical, social, or logistic contraindications and most important factor in modality choice) **Risk of Bias: Moderate** **Selection bias:** adequate **Blinding:** N/A **ITT:** N/A **Attrition bias:** adequate **Selective outcome reporting:** no	-864/1347 (64%) made their own modality choice; 448 (52%) chose HD, 416 (48%) chose PD -Choice of HD vs PD (OR > 1 = greater probability to choose HD) Age 40-55 (vs 18-40): OR 1.45 (0.86, 2.44) Age 55-65 (vs 18-40): OR 2.17 (1.27, 3.73) Age 65-70 (vs 18-40): OR 4.51 (2.40, 8.46) Age 70+ (vs 18-40): OR 5.97 (3.44, 10.34) Serum albumin (greater): OR 0.72 (0.55, 0.94) Female: OR 1.44 (1.04, 2.00) Living alone: OR 1.46 (1.01, 2.12) Pre-dialysis care: OR 0.46 (0.30, 0.70) -Technique survival in patients who chose their modality HD: 93% at 12 months, 91% at 24 months PD: 74% at 12 months, 62% at 24 months -483 (36%) had medical, social, or logistic contraindication to either HD (n=97) or PD (n=386) (66 patients with logistic contraindications excluded from subsequent analyses) -Medical contraindications to PD: prior major abdominal surgery (38%), cystic kidneys (7%), poor lung function (6%), IBD (4%), poor cardiac condition (4%), obesity (2%), other (30%) -Social contraindications to PD: incapable of performing exchanges themselves (77%), other (23%) -Medical contraindications to HD: poor cardiac condition (52%), acute start (7%), other (41%) -Social contraindications to HD: other (100%)

Author, Year Country Design	Sample Size Inclusion Criteria	Patient Characteristics Study Risk of Bias	Key Findings
Thamer 2000[85] Cross-sectional (survey with patient scenarios) USA	N=271 (53% response rate) 15% geographically stratified, random sample of all office-based and full-time hospital-based nephrologists in US	Responding nephrologists Age (yr): 46 Gender (% male): 85 Race (%): white (72), Asian (14), black (5), unknown (9) Training in dialysis Mostly HD: 61% HD and PD equally: 35% Mostly PD: 0.4% Unknown: 4% **Risk of Bias: High** **Selection bias:** inadequate (53% response rate) **Blinding:** N/A **ITT:** N/A **Attrition bias:** inadequate **Selective outcome reporting:** no	-More likely to recommend PD for (adj OR, 95% CI) Males: 1.44 (1.15, 1.80) Age 51-65 (vs 30-50): 1.36 (1.05, 1.77) (non-significant for age 65+ vs 30-50) Patients compliant with treatment: 11.80 (9.29, 15.01) Patients with residual renal function (>250 ml/d of urine): 2.14 (1.71, 2.70) Patients with ejection fraction >25%: 2.53 (1.88, 3.41) -Less likely to recommend PD for (adj OR, 95% CI) Weight ≥200 lbs: 0.44 (0.35, 0.55) Diabetic: 0.51 (0.41, 0.64) Living alone: 0.60 (0.48, 0.76) -Race or HIV status did not independently influence recommendation for modality -Conditions not included in patient scenarios (% of respondents recommending HD): IBD (96%), substance abuse (94%), malnutrition (93%), pregnancy (83%), hepatitis (40%), myocardial infarction (33%) -Importance of involvement in modality decision (% rated as extremely or very important): patient (98%), nephrologist (91%), nurses and social workers (70%), family (65%), other clinicians (12%)
Health Care System Factors			
Walker 2010[79] USA Cross-sectional	4,653 dialysis facilities (92.1% of facilities in 2007 ESRD Network Annual Report) Excluded if no match in Medicare's Dialysis Facility Compare (DFC) database or missing other information	NA **Risk of Bias: Low** **Selection bias:** adequate **Blinding:** N/A **ITT:** N/A **Attrition bias:** N/A **Selective outcome reporting:** no	-Mean % of patients on home dialysis (HHD or PD): 7.1% (range 0-100%) -Higher provision of home dialysis associated with: a. larger dialysis facility size (≥ 62 vs 62 patients) b. more years of facility certification (Medicare) c. higher population of working patients in a facility d. percentage of patients between ages 18 and 54 -Lower provision of home dialysis associated with: a. facility in more rural location b. facility in a geographically larger zip code area c. facility in high-population-density zip code d. facility offering a late shift (5 pm or later) e. facility owned by a chain f. facility with higher treatment capacity g. higher percentage of black patients -For-profit status of facility was not significantly associated with use of home dialysis

ADL = activities of daily living; BMI = body mass index; CAPD = continuous ambulatory peritoneal dialysis; CCPD = continuous cycling peritoneal dialysis; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; eGFR = estimated glomerular filtration rate; ESRD = end stage renal disease; FHN = Frequent Hemodialysis Network; HD = hemodialysis (in-center); HHD = home hemodialysis; NA = not applicable; NHHD = nocturnal home hemodialysis; NR = not reported; PD = peritoneal dialysis; RRT = renal replacement therapy

Table 6. Study Characteristics and Technique Survival Findings for Key Question 3

Author, Year Study Design	Study Years Country	Sample Size Inclusion Criteria	Patient Characteristics Study Risk of Bias	Analysis Outcome definition	Length of Follow-up	Key Findings
HHD Technique Survival						
Jayanti 2013[121] Cohort (Prospective)	2004-2011 United Kingdom	N=166 (143 survivors continuing HHD, 24 failures (switch modality) All incident and prevalent HHD patients during study period	Age (yr): 49 Gender (% male): 65 Race (%): Caucasian (86) **Risk of Bias: High** **Selection bias:** adequate **Blinding:** inadequate **ITT:** N/A **Attrition bias:** inadequate **Selective outcome reporting:** no	Cox proportional hazards Technique failure: inability to continue HHD at any point from the commencement of training necessitating a permanent modality switch	4528 patient-months	-Identified 142 survivors (continued HHD) and 24 failures (switched modalities) -Technique survival: 90%, 87%, 82% at 1, 2, & 3 yrs, respectively -Predictors of technique failure (multivariate analysis) Diabetes HR 3.96 (1.66, 9.48) -Patient-reported reasons for modality switch (n=11 [61% response rate]): family dynamics (20%), lack of carer support (17%), lack of confidence with procedure (15%), interference with home life (15%), medical issues including access (12%)
Schachter 2013[122] Cohort (Retrospective)	Initiated HHD training 2003-2011) Canada	N=177 (32 failure, 145 success) “Home-first” RRT policy; only patients with absolute contraindications (dementia, lack of housing) not invited to trial for HHD	Age (yr): 46 Gender (% male): 61 Race (%): Caucasian (55) **Risk of Bias: Moderate** **Selection bias:** adequate **Blinding:** N/A **ITT:** N/A **Attrition bias:** adequate **Selective outcome reporting:** no	Binary logistic regression HHD was nocturnal (6-8 hr), 5-6 nights/wk Failure defined as training failure or technique failure	Minimum of 1 year; 775 patient-years total	-Factors associated with failure (multivariable analysis) ESRD due to diabetes: OR 3.84 (1.43, 10.3) Renting current residence: OR 3.09 (1.25, 7.59) -Most common reasons for *training* failure (n=24): home inappropriate, deterioration in medical status, cannot cope with burden of HHD, non-adherence, failed training tests -Most common reasons for *technique* failure (n=8): deterioration in medical status, cannot cope with burden of HHD, moved residence, inadequate family support, care-giver anxiety, cannot cannulate

Author, Year Study Design	Study Years Country	Sample Size Inclusion Criteria	Patient Characteristics Study Risk of Bias	Analysis Outcome definition	Length of Follow-up	Key Findings
Tennankore 2012[123] (Likely includes some patients from Schachter 2013[122]) Cohort	Completed nocturnal HHD training 2003-2010 Canada	N=152 (105 independent, 47 dependent) Started and completed home nocturnal HD (HNHD) training, pre-dialysis or other RRT before HNHD Characterized as independent or dependent (partial or total) based on need for caregiver assistance	Age (yr): 45* Gender (% male): 61 Race (%): Caucasian (60) *Independent patients younger **Risk of Bias: High** **Selection bias:** inadequate **Blinding:** inadequate **ITT:** N/A **Attrition bias:** inadequate **Selective outcome reporting:** no	Cox proportional hazards adjusted for age, comorbidity, catheter dialysis access, ESRD due to diabetes, gender, RRT vintage, Caucasian race Primary composite outcome: time to all-cause hospitalization, technique failure (permanent change to either PD or in-center HD), or death	Minimum of 6 months; 436 patient-years for primary outcome	-Primary composite outcome - dependent vs independent: HR 1.71 (1.10, 2.66), P = .02 adj HR 1.25 (0.76, 2.04), P = .40 -Hospitalizations (dependent vs independent): adj IRR 1.58 (0.95, 2.65) -Hospital days (dependent vs independent): adj IRR 1.94 (0.78, 4.34) -Home visits by nurses (dependent vs independent): adj IRR 2.03 (1.39, 2.97) -In-center/training facility backup dialysis runs (dependent vs independent): adj IRR 0.92 (0.58, 1.44)
Pauly 2010[124] CAN-SLEEP Collaborative Group Cohort	1994-2006 Canada	N=247 All nocturnal HHD patients from 3 sites 74% performed nocturnal HHD independently, 18% required minimal assistance, 9% were completely dependent	Age (yr): 46 Gender (% male): 61 Race (%): Caucasian (73), black (10), Asian (9), other (8) **Risk of Bias: Moderate** **Selection bias:** adequate **Blinding:** N/A **ITT:** N/A **Attrition bias:** adequate **Selective outcome reporting:** no	Cox proportional hazards adjusted for effect of the treating center Technique failure defined as inability to carry out nocturnal HHD as a result of physical or cognitive incapacity Composite outcome: nocturnal HHD program exits due to death and technique failure	Maximum of 12 years	-Model of adverse program exit (death and technique failure);36 events in 247 patients: Age: HR 1.07 (1.03, 1.10) Diabetes: HR 2.64 (1.21, 5.76) -Predictor of program exit (technique failure only); 10 events in 247 patients: Age (per 1 year increase): HR 1.09 (1.03, 1.16)

Author, Year Study Design	Study Years Country	Sample Size Inclusion Criteria	Patient Characteristics Study Risk of Bias	Analysis Outcome definition	Length of Follow-up	Key Findings
Komenda 2008[125] Cohort (prospective)	2004-2006 Canada	N=105 All patients who began training for HHD (deemed medically and psychosocially stable, speak and understand English, express interest in HHD); 30 months of dialysis (mean) before HHD	Age (yr): 52 Gender (% male): 71 Race (%): Caucasian (58) **Risk of Bias: Moderate** **Selection bias:** adequate **Blinding:** N/A **ITT:** N/A **Attrition bias:** N/A **Selective outcome reporting:** no	Cox proportional hazards for predictors of technique failure (variables of interest: age, gender, ethnicity, training site size, prior dialysis vintage, presence of CVD and DM) Technique failure not defined	1-3 years	-37 patients dropped out of HHD program: transplantation (13); death (14); inadequate social support (2); medical reasons (2); dialysis withdrawal (1); moving (1); inadequate dialysis (2); unspecified (2) -1 year technique survival: 85% -2 year technique survival: 74% -No predictors of technique survival were significant -32% of patients hospitalized with 75 admissions (0.5 per pt-year of HHD) -90% of patients required in-center HD run with 1816 runs (11 per pt-year of HHD)
PD Technique Failure Studies						
Shen 2013[103] US Renal Data System Dialysis Morbidity and Mortality Study Wave 2 (Prospective cohort)	PD initiated in 1996 – 1997 USA	N=1587 Nationally representative cohort of US patients who initiated PD in 1996 to 1997	Age (yr): 56 Gender (% male): 54 Race (%): white 29; African American 22 **Risk of Bias: Not determined (registry study)**	Cox proportional hazards regression, unadjusted and adjusted analyses. Demographic, medical, social, and pre-dialysis health care factors were analyzed as potential correlates of technique failure; these factors were chosen *a priori* Technique failure defined as any switch from PD to HD for ≥ 30 days	3 years	Factors associated with higher rates of technique failure -Black race (vs white): adj HR 1.48 (1.20, 1.82) -Medicaid recipients: adj HR 1.48 (1.17, 1.86) -Retired (vs full-time work): adj HR 1.49 (1.07, 2.08) -Disabled: adj HR 1.38 (1.01, 1.88) -Systolic BP 140-160 mmHg (vs 120-140 mmHg): adj HR 1.24 (1.00, 1.52) Female gender associated with lower rates of technique failure: adj HR 0.78 (0.64, 0.95)

Author, Year Study Design	Study Years Country	Sample Size Inclusion Criteria	Patient Characteristics Study Risk of Bias	Analysis Outcome definition	Length of Follow-up	Key Findings
Lobbedez 2012[104] French Language Peritoneal Dialysis Registry (retrospective cohort)	PD initiated 2002-2010 France	N=9822 (baseline data for 9801; 1056 family-assisted PD, 4230 nurse-assisted PD, 4515 self PD) >18 years, no primary PD failure (PD duration < 2 days), not previously treated with PD	Age (yr): 68 (median) Gender (% male): 57 Race (%): NR **Risk of Bias: Not determined (registry study)**	Cox regression for cause-specific relative hazards Fine & Gray model for subdistribution relative hazards Technique failure defined as cessation of PD due to transfer to HD (transfer lasting > 2 months)	Median PD duration: 16.5 months	-Assisted PD (family or nurse) associated with decreased risk of transfer to HD vs self-care PD: RH 0.85 (0.77, 0.95) -Bivariate analysis Family-assisted vs self-care: RH 0.76 (0.66, 0.87) Nurse-assisted vs self-care: RH 0.67 (0.61, 0.73) -Per year of age: RH 0.99 (0.99, 0.99) -Male gender: RH 1.13 (1.04, 1.23) -Diabetes: RH 1.14 (0.98, 1.33) -HD before PD: RH 1.31 (1.19, 1.46)
Smyth 2012[105] Retrospective	1998-2008 Ireland	N=148 Age ≥ 50, commenced PD as first RRT for ESRD (CrCl ≤ 10 ml/min) Excluded if other indications for RRT (*eg,* CHF 85% performed PD independently (93% of patients 50-69 years vs 63% ≥ 70 years; P = .001)	Age (yr): 63 Gender (% male): 65 Race (%): Caucasian 90; African American 10 **Risk of Bias: High** **Selection bias:** inadequate **Blinding:** unclear **ITT:** unclear **Attrition bias:** unclear **Selective outcome reporting:** no	Tests of means, Chi - square Technique failure defined as permanent transfer to HD	Minimum of 1 year	-Mean survival: 30 months (2-132); P = .68 between age groups -Technique failure: n=55; difference between age groups not significant -No significant predictors of technique failure (age, etiology of ESRD, catheter method, PD complications, comorbidities) -Assisted PD not associated with technique failure (36% of assisted PD patients, 37% of independent PD patients, P = .93) -Independent PD: no difference in technique failure for < 70 years vs > 70 years (P = .13) -Assisted PD: higher technique failure < 70 vs > 70 years (P = .03) -Assisted PD not associated with hospitalizations (0.78/month for assisted PD, 0.51/month for independent PD, P = 0.42)

Author, Year Study Design	Study Years Country	Sample Size Inclusion Criteria	Patient Characteristics Study Risk of Bias	Analysis Outcome definition	Length of Follow-up	Key Findings
Taveras 2012[106] Retrospective	NR (past 22 years) USA	N=235 Initiated PD at ≥ 75 years of age (one facility) 76% performed PD independently	Age (yr): 79 Gender (% male): 51 Race (%): Caucasian 90; African American 10 **Risk of Bias: High** **Selection bias:** inadequate **Blinding:** unclear **ITT:** unclear **Attrition bias:** unclear **Selective outcome reporting:** no	Life-table analysis Univariate analysis for predictors of technique failure	Unclear	-12 month technique survival: 84%; significantly lower for patients 85 and older vs patients 75-84; no differences by gender or race -Reasons for technique failure: psychosocial problems (41%), peritonitis (25%)

Author, Year Study Design	Study Years Country	Sample Size Inclusion Criteria	Patient Characteristics Study Risk of Bias	Analysis Outcome definition	Length of Follow-up	Key Findings
Kolesnyk 2010[107] NECOSAD (prospective cohort)	PD initiated in 1997 – 2007 Netherlands	N=709 >18 years and not previously received RRT	Age (yr): varied per period, 51-59 Gender (% male): varied per period, 50-76 Race (%): NR **Risk of Bias: High** **Selection bias:** unclear **Blinding:** N/A **ITT:** inadequate **Attrition bias:** unclear **Selective outcome reporting:** no	Cox proportional hazards analyses, unadjusted and adjusted analyses Effect of diabetes, (adjusted for age, gender); effect of CVD, (adjusted for age, gender); and influence of residual GFR (rGFR), measured at the start of every follow-up period (adjusted for age, gender, diabetes, CVD Technique survival on PD compared in 4 periods of follow-up: within the 1st 3 months, 3-12 months, 12-24 months, and 24-36 months of treatment Technique failure defined as permanent switch to HD or death on PD	-	Risk factors for PD discontinuation were also those responsible for patient survival: -Age: 1-year increase in age, RR of PD failure of 1.04 (1.003, 1.06) -CVD: 0-3 month group, RR 2.5 1.2, 5.0) then stabilized over next follow-up periods (RR 2 [1.1, 3.5]) -Diabetes: RR of stopping PD after 3 months of treatment increased from 1.8 (1.1, 3.0) during the first year to 2.2 (1.3, 4.0) after second year -rGFR: loss of 1 mL/min rGFR appeared to be a significant predictor of PD failure after 3 months of treatment; within 1st 2 years: RR 1.1 (1.04, 1.25)

Author, Year Study Design	Study Years Country	Sample Size Inclusion Criteria	Patient Characteristics Study Risk of Bias	Analysis Outcome definition	Length of Follow-up	Key Findings
Singh 2010[108] University of Texas Southwestern/DaVita Peritoneal Dialysis Clinic (Retrospective)	First PD catheter placed between 2001 and 2009 USA	N=315 Insertion of a PD catheter at UT Southwestern hospitals during study period	Age (yr): 50 Gender (% male): 57 Race (%): African American 43; white 28;Hispanic 23 Diabetes was the primary etiology of end-stage renal disease (43%) **Risk of Bias: Moderate** **Selection bias:** adequate **Blinding:** N/A **ITT:** N/A **Attrition bias:** adequate **Selective outcome reporting:** no	Kaplan-Meier method. Cox proportional hazard regression model to identify factors independently associated with catheter survival (demographic and clinical characteristics including age, gender, race, body mass index [BMI], primary etiology of ESRD, co-morbidities and prior abdominal surgeries) PD catheter failure was defined as removal of dysfunctional PD catheter due to various catheter-related causes	9 years (median 19 months)	PD catheter-related non-infectious problem (*ie,* intra-luminal/extra-luminal obstruction, catheter malpositioning or migration, omental wrap around catheter, catheter leakage, catheter extrusion) was only independent variable that significantly affected catheter survival time (HR 22.5 [6.7, 75.7]) No significant association between PD catheter survival and other risk factors (*eg,* age, BMI, diabetic status, co-morbidities, previous abdominal surgeries or infections) Overall PD catheter survival rates at 12, 24, and 36 months: 92.9%, 91.9%, and 91.1% respectively
Jaar 2009[109] CHOICE (Prospective cohort)	PD initiated in October 1995 to June 1998 USA	N=262 (197 non-switchers and 65 switchers)	Age (yr): 54 Gender (% male): 57 Race (%): white 81 **Risk of Bias: High** **Selection bias:** unclear **Blinding:** N/A **ITT:** inadequate **Attrition bias:** inadequate **Selective outcome reporting:** no	Cox proportional hazards analyses Adjusted model included age, race, education, employment, distance to dialysis clinic, DM status, BMI, baseline serum creatinine Technique failure defined as switch to HD for ≥30 days	2 years	Risk factors for PD discontinuation -Black race (vs white race): HR 5.01 (1.15, 21.8) -Higher BMI (per 1 kg/m2 increase): HR 1.09 (1.03, 1.16)

Author, Year Study Design	Study Years Country	Sample Size Inclusion Criteria	Patient Characteristics Study Risk of Bias	Analysis Outcome definition	Length of Follow-up	Key Findings
Plantinga 2009[110] EQUAL cohort, prospective (assembled from CHOICE study PD patients)	1995-1998 USA (13 states, 26 clinics)	N=236 incident PD patients Age > 18 years, speak either English or Spanish Divided into 2 groups: patients from facilities with > 50 patients or ≤ 50 patients	Age (yr): 54* Gender (% male): 56 Race (%): white 75 *Patients from larger facilities were older, higher BMI, more late referrals **Risk of Bias: High** **Selection bias:** unclear **Blinding:** N/A **ITT:** inadequate **Attrition bias:** inadequate **Selective outcome reporting:** no	Covariates were confounders (significantly associated with both clinic size and patient outcomes) or previously shown to be associated with patient outcomes Technique failure defined as switch to HD lasting > 30 days	Maximum of 9 years	-Technique failure Clinics ≤ 50 patients: 37.5% Clinics > 50 patients: 9.7% RH 0.13 (0.13, 0.31) -CV events Clinics ≤ 50 patients: 0.22 per pt-year Clinics > 50 patients: 0.12 RH 0.61 (0.38, 0.98) -CV mortality Clinics ≤ 50 patients: 0.09 per pt-year Clinics > 50 patients: 0.05 RH 1.05 (0.46, 2.40) -All-cause mortality Clinics ≤ 50 patients: 0.18 per pt-year Clinics > 50 patients: 0.15 RH 1.35 (0.78, 2.35)
Tonelli 2007[111] Canadian Organ Replacement Registry (CORR) (Random sample of prospectively collected data)	PD initiated between 1990 and 2000 Canada	N=26,775 Random sample of data from the CORR	Age (yr): 62 Gender (% male): 57 Race (%): white 75 Diabetic nephropathy was primary etiology of ESRD (33%) **Risk of Bias: Not determined (registry study)**	Cox proportional hazards analyses Adjusted for age, sex, race, primary cause of kidney failure, comorbidities, smoking status, socioeconomic status, geographic region of residence, and year of dialysis initiation. Technique failure defined as switch to HD for ≥ 90 days	2.5 years	PD technique failure significantly lower for subjects living farther distances from attending nephrologist compared to patients living within 50 km of attending nephrologist >300 km (vs ≤ 50 km) : HR 0.63 (0.50, 0.79) 150.1-300 km (vs ≤ 50 km): HR 0.78 (0.65, 0.94) 50.1-150 km (vs ≤ 50 km): HR 0.86 (0.75, 0.97)

Author, Year Study Design	Study Years Country	Sample Size Inclusion Criteria	Patient Characteristics Study Risk of Bias	Analysis Outcome definition	Length of Follow-up	Key Findings
Mujais 2006[78] Baxter Healthcare (data from four cohorts of US patients tracked in the Baxter Healthcare system)	PD initiated between 2000 and 2003 USA	N=40,869 based on four cohorts of US patients that started PD in 2000, 2001, 2002, and 2003; followed until June 2005	Age (yr): approximately 54 Gender (% male): 57 Race (%): NR Mostly APD (58-64%) and new to dialysis **Risk of Bias: Not determined (registry study)**	Cox regression estimation with adjustments for age, diabetic status, gender, center size, calendar year, patient type (new to dialysis vs transfer from HD), and PD submodality (APD vs CAPD)	Varied between cohorts (2-5 years)	Determinants of technique survival included -Patients new to dialysis (vs transfer from HD): HR 0.79, P<0.0001 -No diabetes (vs with diabetes): HR 0.85, P<0.0001 -Patients from larger centers (vs small center): HR 0.94, P<0.0001 -APD (vs CAPD): HR 0.85, P<0.0001 Temporal profile for adjusted rate of transfer to HD highest in 1st 6 months on PD (relative risk 1.27–1.49, P<0.0001 vs all successive 6 month periods); declined to stable rate afterwards (*ie,* after 1st 6 months)

Author, Year Study Design	Study Years Country	Sample Size Inclusion Criteria	Patient Characteristics Study Risk of Bias	Analysis Outcome definition	Length of Follow-up	Key Findings
McDonald 2003[112] ANZDATA	PD initiated between 1991 and 2002 Australia/New Zealand	N=9440 Patients in the ANZDATA Registry who were ≥15 years of age at the initiation of PD	Age (yr): approximately 60 Gender (% male): 52 Race (%): NR **Risk of Bias: Not determined (registry study)**	Cox regression for multivariate analyses, covariates age, gender, race, type I and type II DM, CAD, peripheral vascular disease, CVD, chronic lung disease, treated HTN, current smoking, country, and size of center at which dialysis was initiated Patients classified as obese (BMI ≥30 kg/m^2), overweight (BMI 25.0 to 29.9 kg/m^2), normal weight (BMI 20 to 24.9 kg/m^2), or underweight (BMI <20 kg/m^2) Technique failure defined as transfer from PD to HD for >1 month	varied	Technique survival rates significantly worse for groups with increased BMI at start of RRT Obese group (versus normal weight group): adj HR 1.16 (1.07, 1.26) Overweight group (versus normal weight group): adj HR 1.15 (1.06, 1.24)
Snyder 2003[113] CMS (Retrospective cohort)	PD initiated in October 1995 to 2000 USA	N=41,197 Age ≥18 years at initiation of dialysis therapy	PD patients only Age (yr): 57 Gender (% male): 53 Race (%): white 67, African American 20 Diabetes was primary etiology of renal disease (47%) **Risk of Bias: Not determined (registry study)**	Logistic regression model, adjusted for incident year, race, gender, age, DM as primary cause of renal failure, employment status, baseline glomerular filtration rate, albumin, hemoglobin, and baseline comorbidities (several), and inability to ambulate or transfer Technique failure defined as switching to HD for ≥ 60 days	3 years	Compared to those with normal BMI, obese subjects (BMI ≥30 kg/m^2) had higher rates of changing to HD in each of the 3 years; HRs 1.28 [CI NR], 1.29 [CI NR], and 1.36 [CI NR], respectively (P < 0.05 for all) Compared to those with a normal BMI, overweight subjects (BMI 25 to 29.9 kg/m^2) had significantly higher rates of changing to HD in years 1 and 2 (HRs 1.07 and 1.11, respectively)

Author, Year Study Design	Study Years Country	Sample Size Inclusion Criteria	Patient Characteristics Study Risk of Bias	Analysis Outcome definition	Length of Follow-up	Key Findings
Jager 1999[114] NECOSAD (prospective cohort study)	PD initiated in 1993 to 1995 Netherlands	N=118 ESRD patients >18 years when starting PD, no prior RRT, survived first 3 months on dialysis	Age (yr): 54 Gender (% male): 64 Race (%): NR 95% were on CAPD **Risk of Bias: High** **Selection bias:** adequate **Blinding:** N/A **ITT:** unclear **Attrition bias:** unclear **Selective outcome reporting:** no	Cox proportional hazards analyses, adjusted for several variables Technique failure defined as transfer from PD to HD	2-4 years	Predictors of technique failure included -Total fluid removal: RR 0.79 (0.68, 0.93) per 500 mL/24 hr -Systolic BP: RR 1.22 (1.05, 1.41) per 10 mm Hg -Peritoneal ultrafiltration, RR 0.73 (0.61, 0.87) per 500 mL/24 hr
Korbet 1999[115] Retrospective	1987-1997 USA	N=233 Entered ESRD program, treated with PD	Age (yr): 52 Gender (% male): 49 Race (%): black (61), white (27), other (12) **Risk of Bias: High** **Selection bias:** inadequate **Blinding:** N/A **ITT:** adequate **Attrition bias:** adequate **Selective outcome reporting:** no	Cox proportional hazard model Technique failure defined as transfer to HD	Minimum of 3 months; median 26 months	-Technique failure at 2 years: 29% (67/233) (39% [55/142] for black patients, 8% [5/62] for white patients; P < .0001)

Author, Year Study Design	Study Years Country	Sample Size Inclusion Criteria	Patient Characteristics Study Risk of Bias	Analysis Outcome definition	Length of Follow-up	Key Findings
Temporal Studies						
Perl 2012[116] Canadian Organ Replacement Registry (CORR) Prospective	PD initiated between 1995 and 2009 Canada	N=13,120 Patients from CORR, CAPD and APD patients	Most were ≥55 years of age, male, and white race Compared with patients who initiated PD between 1995 and 2000, patients in more contemporary cohorts more likely to be older, had a higher frequency of diabetes mellitus as a comorbidity, and had higher BMI; frequency of CAD and PVD lower in more contemporary cohorts **Risk of Bias: Not Determined (Registry Study)**	PD technique failure compared among three incident cohorts of PD patients initiating dialysis during 1995 to 2000, 2001 to 2005, and 2006 to 2009 Marginal structural model with inverse probability of treatment and censoring weighting to examine risk of PD technique failure Prespecified interactions with exposure of interest and risk of all-cause technique failure included age (<65 versus ≥65 years), sex, DM (presence vs absence), any comorbidities (presence vs absence), and being obese versus non-obese (BMI >29.9 kg/m2 versus ≤29.9 kg/m^2) PD technique failure defined as transfer to hemodialysis for ≥90 days	Varied between cohorts (3-5 years)	Initiating PD between 2001 and 2005: -Lower adjusted risk of technique failure (adj HR 0.89 [0.82, 0.98]) compared to 1995 to 2000 group Risk of technique failure similar between 2006 to 2009 group and 1995 to 2000 group (adj HR 0.95 [0.85, 1.06]) Patients >65 years of age had significantly lower risk of technique failure between 2001 and 2005 (adj HR 0.86 [0.75, 0.97]) and between 2006 and 2009 (adj HR 0.80; [0.69, 0.93]) relative to those >65 years of age who initiated PD between 1995 and 2000

APD = ambulatory automated peritoneal dialysis; BMI = body mass index; BP = blood pressure; CAD = coronary artery disease; CAPD = continuous ambulatory peritoneal dialysis; CVD = cardiovascular disease; DM = diabetes mellitus; eGFR = estimated glomerular filtration rate; ESRD = end stage renal disease; GFR = glomerular filtration rate; HD = hemodialysis (in-center); HR = hazard ratio; HTN = hypertension; N/A = not applicable; NR = not reported; PD = peritoneal dialysis; RR = relative risk; RRT = renal replacement therapy

Table 7. Study Characteristics and Cost Findings for Key Question 4

Author, Year Country	Inclusion Criteria	Comparisons Patient Characteristics	Analysis	Key Findings
Klarenbach 2014[126] Cost-utility analysis of data from the Alberta nocturnal home HD Canada	Patients from the Alberta nocturnal home HD RCT	Frequent home nocturnal hemodialysis (FHNHD) compared to conventional HD (in-center 61%; satellite 14%, home 25%) Age (yr): 54 Male (%): 62	Cost-effectiveness of FHNHD (including training and ongoing costs) compared with remaining on existing modality; during each 6 month time period patients could die or receive renal transplant, and patients in the FHNHD arm could experience technique failure and return to conventional HD (all outcomes would be attributed to FHNHD) High-quality administrative data and direct measurement of resource use with microcosting (including patient medication, capital and ongoing costs of a home dialysis training program, and direct elicitation of patient-borne and caregiver costs) Because the FHNT RCT did not show a difference in the risk and duration of hospitalization by modality, these costs were excluded in the reference case but explored in sensitivity analysis; resource use not captured by this cohort (*eg,* cost of transplantation or peritoneal dialysis), obtained from other sources; costs of training and each hemodialysis modality based on study and non-study patients to provide more accurate determination of costs QALYs also determined	Compared to conventional (mostly in-center) HD, FHNHD led to incremental cost savings of -$6700 Canadian dollars (US$5872 in 2014) and an additional 0.38 QALYs over a lifetime horizon Attractiveness of FHNHD varied by technique failure rate, training time, and dialysis modalities from which patients are drawn; these variables should be considered when establishing FHNHD programs Limitations: small sample size and short duration of Alberta NHD RCT

Author, Year Country	Inclusion Criteria	Comparisons Patient Characteristics	Analysis	Key Findings
Chui 2013[134] Alberta Renal Programs Canada	Adult patients; initiated long-term dialysis (PD or in-center HD) therapy July 1999 to December 2003; identified from administrative records from Northern and Southern Alberta Renal Programs	1,378 patients initiated dialysis therapy in Alberta. 165 (12%) patients had at least one modality switch during year 1 Initial Dialysis Modality PD: N=253 Age (yr): 55 (P<0.05 vs HD) Male (%): 57 White race (%): 72 (P<0.05 vs HD) HD : N=1125 Age (yr): 61 Male (%): 58 White race (%): 64	Primary cost outcomes: total cumulative costs at years 1 and 3 Secondary cost outcomes: health care resource utilization cost categories (dialysis costs, inpatient costs, medication costs, and physician fees) Analysis did not include related nonmedical costs (*eg,* costs of lost productivity and informal care)	Compared with HD patients, PD patients and patients who transitioned from HD to PD had significantly lower total health care costs at 1 and 3 years Patients who underwent PD technique failure had costs similar and not in excess of HD patients at 3 years supporting economic rationale for PD-first policy in eligible patients 3-year adjusted total cumulative costs in 2010 Canadian dollars PD: $58,724 ($44,123, $73,325) (US$51,473 in 2014) HD-to-PD: $114,503 ($96,318, $132,688) (US$100,374) HD: $175,996 ($134,787, $217,205) (US$154,340) Adjusted total cumulative costs at 1 year in 2010 Canadian dollars PD: $33,932 ($28,692, $39,172) (US$27,775) HD-to-PD: $63,281 ($55,839, $70,723) (US$55,528) HD: $88,850 ($72,642, $105,058) (US$77986) Limitations: analysis based on perspective of health payer; costs outside healthcare system not measured

Author, Year Country	Inclusion Criteria	Comparisons Patient Characteristics	Analysis	Key Findings
Coentrão 2013[135] Retrospective cost data from patients initiating dialysis at one center Spain	Diagnosis of ESRD, received outpatient chronic dialysis treatment Excluded: previous RRT	Modalities: HD with tunneled cuffed catheter (TCC), HD with arteriovenous fistula (AVF), PD HD-TCC: N=45 Age (yr): 66 (P < .05 vs PD) Male (%): 55 HD-AVF: N=65 Age (yr): 63 (P < .05 vs PD) Male (%): 60 PD: N=42 Age (yr): 55 Male (%): 52	Treatment modality assigned at time of first attempt at dialysis access placement (ITT basis) Annual dialysis access costs evaluated using a mixed costing method Included access surgery, diagnostic imaging, TCC-related interventions, hospitalization, and patient transportation	Costs related to dialysis access at 1 year from time of first dialysis Total Access-related interventions (per pt-year at risk) HD-TCC: 3.67 (Rate Ratio vs PD: 1.43 (1.07, 1.80) HD-AVF: 2.38 (Rate Ratio vs PD: 1.57 (1.25, 1.89) PD: 1.54 Total access-related costs (mean, per pt-year at risk) HD-TCC: €4208.20 (P < .05 vs HD-AVF or PD) HD-AVF: €1555.20 PD: €1171.60 Limitations: selection bias possible in modality selection and time of referral to nephrologist; time at risk after first access attempt varied between groups; small sample size, short follow-up; single center
Komenda 2012[127] Model used was based on data from Australia, Canada, and UK Canada	None, economic model study based on a systematic review of available costing literature	Modalities included in-center HD, conventional HHD, and more frequent HHD including nocturnal HHD (dialysis performed for 6 to 10 h per night for up to 7 nights per week) and short daily HHD(dialysis performed for 2 to 3 h per day for up to 7 days per week)	Standardized model based on a systematic review of available costing literature Cost model was transparent spreadsheet that summarized component costs for each modality Direct medical and well documented direct nonmedical costs associated with dialysis (*eg,* transportation to and from dialysis facilities) included; indirect nonmedical costs (*eg,* lost time from work and unpaid assistance from family members) not included	Conventional HHD and frequent HHD similar in cost to in-center HD in first year (driven primarily by training costs); could be less costly from second year onward, depending on frequency of dialysis Model predicted that conventional HHD may payers between $7,612 (US$6,668 in 2014) and $12,403 (US$10,865) over first year of conventional in-center HD Costs of frequent HHD were higher compared to conventional HHD due to greater consumables and materials usage Limitations: existing costing literature used for modeling yielded inconsistent evidence related to costs of conventional home, frequent home, and in-center HD between and within Australia, Canada, and UK

Author, Year Country	Inclusion Criteria	Comparisons Patient Characteristics	Analysis	Key Findings
Berger 2009[136] Health insurance database (retrospective cohort study) USA	Patients designated PD or HD patients based on first-noted treatment; patients with <6 months of pretreatment data or <12 months of data following initiation of dialysis ("pretreatment" and "follow-up," respectively) were dropped from study sample	PD Group: N=56 Age (yr): 44 (P<0.01 vs HD) Male (%): 52 HD Group: N=407 Age (yr): 55 Male (%): 64 Analysis based on 50 matched pairs PD Group Age (yr): 46 Male (%): 54 HD Group Age (yr): 46 Male (%): 52	PD and HD patients matched using propensity scoring to control for differences in pretreatment characteristics Once matched, cost of healthcare services during 12-month follow-up period examined including: (1) prescription medications, (2) physician office visits, (3) other outpatient visits, (4) emergency department visits, (5) hospitalizations Total reimbursed amount (*ie,* amount paid by insurer plus amount of patient liability) used as proxy for cost	Significantly lower total healthcare costs for PD patients during year following initiation of dialysis Median total per-patient healthcare costs over the 12-month follow-up period HD: $173,507 [IQR $98,706, $335,719] PD: $129,997 [IQR $73,212, $207,578] ($43,510 higher, P=0.03) Median inpatient per-patient healthcare costs HD: $39,851 [IQR $6089, $140,125] PD: $651 [IQR $0, $40,591] (P <0.01) Median outpatient per-patient healthcare costs HD: $73,392 [IQR $24,087, $101,992] PD: $70,642 [IQR $17,652, $96,770] (P=0.53) Limitations: ED visits and hospitalizations higher for HD group despite matching; database contained limited clinical information
Howard 2009[128] ANZDATA Registry Australia	New ESRD patients in Australia 2005 to 2010	NR, analyses based on >14,000 new ESRD patients	Costs reported in 2004 Australian dollars from perspective of central health-care funder and based on best available published data Dynamic population-based Markov model constructed to estimate costs and benefits of proposed changes in RRT modality utilization	Clinical practice changes reduce costs, improve patient quality of life In new ESRD patients -Switching from hospital HD to HHD estimated to produce net saving of $46.6 million Australian$ by 2010 (US$40 million in 2014) -Switching from hospital HD to PD estimated to produce a net saving of $122.1 million Australian$ by 2010 (US$104.8 million) Limitations: analysis did not incorporate indirect costs (eg, lost earnings and productivity, direct out-of-pocket costs to patients and care givers)

Author, Year Country	Inclusion Criteria	Comparisons Patient Characteristics	Analysis	Key Findings
Baboolal 2008[137] Cardiff and Vale NHS Trust and six other hospitals UK	Patients with ESRD receiving APD, CAPD, hospital-based HD, or satellite center-based HD (SHD)	Age and gender not reported Number of patients managed by each unit ranged from 205 to 765; renal dialysis units in study were each supervising 1 to 5 satellite units Number of patients undergoing HD: 158 to 634 per center Number of patients undergoing PD: 46 to 139 per center	All costs, including laboratory costs, estimated from service provider's perspective; also included direct costs, costs of transport, and medication usage Costs associated with access surgery and managing dialysis complications were excluded Dialysis costs estimated by combination of microcosting and top-down approach; if no access to detailed accounts values for Cardiff were applied	Cost of PD (APD or CAPD) lower than hospital-based HD Main costs with PD: solutions and management of anemia Main costs with HD: disposables, nursing, overhead associated with running unit, and management of anemia Mean annual costs in British pounds APD: £21,655 (US$34,702 in 2014) CAPD: £15,570 (US$24,949) HD: £35,023 (US$56,111) SHD: £32,669 (US$52,340) Home-based HD £20 764 (US$33,267) (based on data from only one unit) Limitations: Complete application of microcosting not possible due to confidentiality of financial data and different accounting procedures used by different units; values for overheads may not fully reflect true overhead costs and microcosting approach may have underestimated costs (*eg*. by omitting minor procedures)

Author, Year Country	Inclusion Criteria	Comparisons Patient Characteristics	Analysis	Key Findings
Kontodimopoulos 2008[138] Hellenic Renal Registry Greece	≥18 years old, sufficient knowledge of Greek for self- administration of SF-36 and socio-demographic and disease-related questions, physically and mentally capable of completing the survey with minimal assistance Patients on current treatment method for <1 year excluded (may not have yet stabilized against various technique-related symptoms and/or complications)	PD Group: N=65 Age (yr): 59 Male (%): 51 HD Group: N=642 Age (yr): 58 Male (%): 61	Lifelong QALYs estimated from literature-based expected remaining life years according to age, gender and modality Cost analyses performed from perspective of health system	Promoting PD appeared to be second best step (after transplantation) in improving cost-effectiveness Annual estimated costs per patient in Euros PD: €30,719 (US$38,760 in 2014) HD: €36,247 (US$45,733) Estimated lifelong QALYs PD: 3.94 (3.36, 4.51) HD: 4.37 (4.13, 4.62) Cost per QALY PD: €54,504 (US$68,062) HD; €60,353 (US$ 75,350) Limitations: cost estimates based only on direct medical costs

Author, Year Country	Inclusion Criteria	Comparisons Patient Characteristics	Analysis	Key Findings
Malmström 2008[130] Helsinki University Hospital Finland	Patients attending self-care HD in the Helsinki area by October 2004	Home HD: N=33 Age (yr): 49 (P<0.005 vs satellite HD) Male (%): 76 Self-care satellite HD: N=32 Age (yr): 63 Male (%): 66 Cost data collected from study patients who were on dialysis the whole calendar year 2004 (home HD N=23 and satellite HD N=28)	Cost data: total direct health care costs, travel, and outpatient medication costs Costs of laboratory visits and home installations for home HD were estimated. Remuneration to any assistant included Linear regression analysis used to explore whether weight and diabetes had effect on the different items of costs, when age and group were controlled for	No significant difference in total costs between home HD and satellite HD, costs were less than costs observed for hospital HD in other studies Patient preference should be main decisive factor when choosing between home or satellite HD Total costs per patient in Euros Home HD: €38,477 (€28,512, €56,031) (US$48,026 in 2014) Satellite HD: €39,781 (€25,675, €63,982) Mean difference: €1304 (€6491, €3883) (US$1628) Direct medical costs of dialysis and hospital treatment: higher in home HD than satellite HD (€31,834 vs €27,528, P<0.005) Travel costs lower in home HD (€426 vs €5228, P<0.001) Limitations: HHD patients younger and shorter duration of dialysis than satellite HD patients; all patients fairly young compared to general dialysis patients limiting applicability of results to older/frailer patients

Author, Year Country	Inclusion Criteria	Comparisons Patient Characteristics	Analysis	Key Findings
Gonzalez-Perez 2005[129] United Kingdom	None (clinical and cost data from a systematic review)	None (clinical and cost data from a systematic review)	Markov model to estimate cost-effectiveness over lifetime of 3 different HD modalities Model included direct health service costs and QALYs Sensitivity analyses performed to assess robustness of results Transport costs excluded due to variation across UK	Results supportive of shift from hospital HD to satellite and HHD HHD less costly than in-center (hospital) HD; satellite HD less costly than HHD Total Costs HHD: 5 yrs £47,657 (US$76,270 in 2014), 10 yrs £63,539 (US$101,685) Satellite HD: 5 yrs £46,001 (US$73,617),10 yrs £62,054 (US$99,301) In-center (hospital) HD: 5 yrs £48,254 (US$77,087), 10 yrs £65,131 (US$104,049) Incremental costs per QALY relative to HHD Satellite HD: 5 yrs £6,665 (US$10,648), 10 yrs £3,493 (US$5,581) Hospital HD: NR but home HD more effective and less costly at yrs 5 and 10 Estimated lifelong QALYs HHD: 5 yrs 2.32, 10 yrs 3.45 Satellite HD: 5 yrs 2.085, 10 yrs 3.03 In-center (hospital) HD: 5 yrs 1.69, 10 yrs 2.47 Limitations: data used to populate model were limited; lack of robust data on effectiveness and new dialysis equipment (not included in review)

Author, Year Country	Inclusion Criteria	Comparisons Patient Characteristics	Analysis	Key Findings
Shih 2005[139] Dialysis Morbidity and Mortality Study Wave 2 data, collected by the United States Renal Data System (USRDS), along with the USRDS Core CD and USRDS claims data USA	Patient/insurance data from DMMS Wave 2 (prospective observational database consisting of information on random sample of incident ESRD patients initiating dialysis in 1996 and early 1997)	PD: N=1781 Age (yr): 57 (P<0.001 vs HD) Male (%): 54 White race (%): 70 (P<0.001 vs HD) HD Group: N=1642 Age (yr): 63 Male (%): 52 White race (%): 59	Cost of treatment estimated based on Medicare expenditures over study period of up to 3 years ITT and AT analyses Multivariate analyses to account for the differences between the PD and HD groups	Medicare expenditure perspective: PD more economically advantageous initial dialysis modality Longer time (>1 year) on PD better sustains advantage even if modality switch. Unadjusted average annual Medicare expenditure as first modality in 2004 dollars (ITT) PD: $53,277 ($50,626, $55,927) HD: $72,189 ($67,513, $76,865) (P<0.001) Annual Medicare expenditure as first modality, adjusting for patient characteristics (ITT) PD: $56,807 ($53,205, $60,410) HD: $68,253 ($64,490, $72,016) (P<0.001) Limitations: true costs of caring may be underestimated (costs such as patients' copayments/deductibles and prescription drug costs not included in analysis)

Author, Year Country	Inclusion Criteria	Comparisons Patient Characteristics	Analysis	Key Findings
Kroeker 2003[131] London Daily/Nocturnal Hemodialysis Study Canada	Patients from London Daily/Nocturnal Hemodialysis Study (12-month retrospective chart review)	Home short-daily (quotidian) HD: N=10 Home long nocturnal (quotidian) HD: N=12 Conventional thrice weekly HD: N=22 Conventional HD patients served as matched controls for quotidian HD patients 12-month retrospective chart review allowed each patient to serve as his/her own control	Retrospective analysis of patients' conventional HD costs during 12 months before study entry conducted to measure change in cost after switching to quotidian HD Efforts made to include all costs borne by the public health care system; personal costs (patient travel and costs covered by private insurance [*eg*., home helpers] excluded Each patient generated individual cost and QALY data that were used to generate individual cost per QALY values	Major cost saving in home quotidian HD was reduction in direct nursing time, excluding patient training Treatment supply costs per patient for daily HD and nocturnal HD groups were greater due to increased number of treatments Average costs for consults, hospitalization days, emergency room visits, and lab tests for quotidian HD patients tended to decline after study entry Annual cost per patient in 2001 Canadian dollars Daily HHD: $67,300 (US$59,065 in 2014) Home nocturnal HD: $74,400 (US$65,300) Conventional HD: $72,700 (US$63,808) Total annualized cost per QALY Daily HHD: Can $85,442 (US$ 74,743) Nocturnal HD: Can $120,903 (US$ 105,771) Marginal change of -$15,090 (-US$ 13,201) and -$21,651 (-US$ 18,943), respectively (reflecting both improved quality of life and reduced costs for quotidian HD patients) Limitations: small study not powered to detect statistically significant differences in costs; previous year costing data preceding HD modality assignments indicated variance in morbidity patterns, making it difficult to directly compare study groups

Author, Year Country	Inclusion Criteria	Comparisons Patient Characteristics	Analysis	Key Findings
Lee 2002[132] Southern Alberta Renal Program Canada	Patients from a randomly generated list on dialysis therapy > 6 months 6 months chosen because (1) dialysis modality and permanent vascular access generally established, and (2) goal was to determine cost of ongoing dialysis, rather than costs associated with initiating dialysis therapy	Home/self-care Group: N=9 Age (yr): 56 Male (%): 44 White race (%): 89 PD Group: N=38 Age (yr): 58 Male (%): 50 White race (%): 71 Satellite Group: N=31 Age (yr): 64 Male (%): 61 White race (%): 71 HD (in-center) Group: N=88 Age (yr): 62 Male (%): 56 White race (%): 76	Costs considered: those related to outpatient dialysis care, inpatient care, outpatient non-dialysis care, and physician claims Cost of maintaining dialysis access estimated separately Patients analyzed according to modality with which they started the study	Self-care dialysis (*ie*., home/self-care hemodialysis/PD) costs less compared with in-center HD, largely due to a lower requirement for nursing care Total expenses in 2000 US dollars Home/Self-Care: $29,961 ($21,252, $38,670) PD: $26,959 [$23,500, $30,416] (P<0.001 comparing the four modalities using one-way ANOVA) Satellite: $42,057 ($39,523, $44,592) In-center: $51,252 ($47,680, $54,824) Limitations: enrolled only 50% of eligible patients with limited number of PD and home/self-care patients (reflective of the local distribution); enrolled patients were healthier than non-enrolled; possible selection bias
Sennfält 2002[140] Dialysis departments in southeastern health-care region of Sweden Sweden	Variables used to select eligible patients: age, presence of diabetes, acceptance for transplantation, presence of heart disease (angina pectoris, myocardial infarction, heart failure), type of housing, family situation, and country of birth with respect to ability to understand the Swedish language	136 patients with kidney failure, comprising 68 matched pairs PD Group: N=68 Age (yr): 52 Male (%): NR HD Group: N=68 Age (yr): 53 Male (%): NR	Direct costs for dialysis care, including overhead, obtained from annual accounts for 1998 of respective departments Indirect costs (*eg*. lost working time on the part of patients) estimated by clinical experts	Expected cost per life year and cost per QALY were more favorable for PD as the primary method of treatment for patients eligible for both PD and HD Weighted Total Costs Per Patient Per Month in US dollars PD: $6240 (more activity-related material costs) HD: $8257 (more staff and indirect costs) Expected cost per patient for PD as the primary treatment during first 5 years PD: $201,000 HD: $222,450 Limitations: Lack of consistent cost information in health care (different accounting principles used by participating centers)

Author, Year Country	Inclusion Criteria	Comparisons Patient Characteristics	Analysis	Key Findings
Goeree 1995[133] Regional Nephrology Center in Hamilton, Ontario Canada	ESRD patients treated with different dialysis modalities from 1990 to 1991	Home HD: N=13 CAPD: N=78 Self-care HD: N=31 In-center HD: N=96 No demographic information reported	Fully-allocated hospital costs, professional fees, erythropoietin costs, and patient costs added together to calculated total cost associated (and 95% CI) with each modality Hospital costs: salaries/wage, medical/surgical supplies, drugs/medicines, other department expenses, support department expenses, and overhead expenses Professional fees: all consultations; diagnostic, therapeutic, and surgical services Patient costs: transportation costs, parking and dialysis partner time (home HD) Indirect costs associated with lost productivity for patients were not included in the analysis	Costs varied by modality, lower with home HD and CAPD Major cost driver for CAPD was cost of medical and surgical supplies Major cost drivers for In-center HD and self-care HD were cost of personnel (salaries/ wages) and support department expenses Average cost per patient by modality in 1993 Canadian dollars Home HD: $32,570 ($30,524, $34,613) CAPD: $44,790 ($39,700, $49,879) Self-care HD: $55,593 ($52,425, $58,761]) In-center HD: $88,585 ($81,831, $95,339) Limitations: Small sample sizes

AT = as-treated analysis; CAPD = continuous ambulatory peritoneal dialysis; CI = confidence intervals; ESRD = end-stage renal disease; HD = in-center hemodialysis; HHD = home hemodialysis; ITT = intention-to-treat analysis; PD = peritoneal dialysis; QALY = quality adjusted life years; RCT = randomized controlled trial; RRT = renal replacement therapy